US20040225304A1 - Endovascular splinting devices and methods - Google Patents

Endovascular splinting devices and methods Download PDF

Info

Publication number
US20040225304A1
US20040225304A1 US10/735,269 US73526903A US2004225304A1 US 20040225304 A1 US20040225304 A1 US 20040225304A1 US 73526903 A US73526903 A US 73526903A US 2004225304 A1 US2004225304 A1 US 2004225304A1
Authority
US
United States
Prior art keywords
heart
catheter
tension member
anchor
myocardial tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/735,269
Inventor
Robert Vidlund
Marc Simmon
Todd Mortier
Cyril Schweich
Peter Keith
Richard Schroeder
Jason Kalgreen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edwards Lifesciences LLC
Original Assignee
Myocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myocor Inc filed Critical Myocor Inc
Priority to US10/735,269 priority Critical patent/US20040225304A1/en
Publication of US20040225304A1 publication Critical patent/US20040225304A1/en
Assigned to VENTURE LENDING & LEASING IV, INC. reassignment VENTURE LENDING & LEASING IV, INC. SECURITY AGREEMMENT Assignors: MYOCOR, INC.
Assigned to EDWARDS LIFESCIENCES LLC reassignment EDWARDS LIFESCIENCES LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MYOCOR, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2478Passive devices for improving the function of the heart muscle, i.e. devices for reshaping the external surface of the heart, e.g. bags, strips or bands
    • A61F2/2487Devices within the heart chamber, e.g. splints
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/064Surgical staples, i.e. penetrating the tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/068Surgical staplers, e.g. containing multiple staples or clamps
    • A61B17/0682Surgical staplers, e.g. containing multiple staples or clamps for applying U-shaped staples or clamps, e.g. without a forming anvil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238Type of minimally invasive operation
    • A61B2017/00243Type of minimally invasive operation cardiac
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00292Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery mounted on or guided by flexible, e.g. catheter-like, means
    • A61B2017/003Steerable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00535Surgical instruments, devices or methods, e.g. tourniquets pneumatically or hydraulically operated
    • A61B2017/00557Surgical instruments, devices or methods, e.g. tourniquets pneumatically or hydraulically operated inflatable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831Material properties
    • A61B2017/00902Material properties transparent or translucent
    • A61B2017/00907Material properties transparent or translucent for light
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A61B2017/0404Buttons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A61B2017/0409Instruments for applying suture anchors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A61B2017/0412Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors having anchoring barbs or pins extending outwardly from suture anchor body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A61B2017/0427Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors having anchoring barbs or pins extending outwardly from the anchor body
    • A61B2017/0437Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors having anchoring barbs or pins extending outwardly from the anchor body the barbs being resilient or spring-like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A61B2017/0464Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors for soft tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0469Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
    • A61B2017/048Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery for reducing heart wall tension, e.g. sutures with a pad on each extremity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B2017/0496Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials for tensioning sutures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39Markers, e.g. radio-opaque or breast lesions markers

Definitions

  • the present invention pertains to devices for treating a failing heart and related methods for placing the devices.
  • the invention pertains to splinting devices placed on the heart to reduce the radius of curvature and/or alter the geometry or shape of the heart to thereby reduce wall stress in the heart and improve the heart's pumping performance.
  • the devices and methods of the present invention are directed toward endovascular techniques used to facilitate placement of the splinting devices on the heart.
  • Heart failure is a common outcome in the progression of many forms of heart disease.
  • Heart failure may be considered as the condition in which an abnormality of cardiac function is responsible for the inability of the heart to pump blood at a rate commensurate with the requirements of the metabolizing tissues, or can do so only at an abnormally elevated filling pressure.
  • the process of ventricular dilatation is generally the result of chronic volume overload or specific damage to the myocardium.
  • cardiac output requirements for example, that of an athlete
  • damage to the myocardium or chronic volume overload however, there are increased requirements put on the contracting myocardium to such a level that this compensated state is never achieved and the heart continues to dilate.
  • Mitral regurgitation is a condition whereby blood leaks through the mitral valve due to an improper positioning of the valve structures that causes the valve not to close entirely.
  • Geometric abnormalities resulting from a dilated left ventricle may cause or exacerbate improper functioning of the mitral valve, including mitral valve regurgitation, by altering the normal position and dimension of the valve, particularly the valve annulus.
  • Prior treatments for heart failure associated with such dilatation fall into three general categories. The first being pharmacological, for example, diuretics and ACE inhibitors. The second being assist systems, for example, pumps. Finally, surgical treatments also have been experimented with.
  • diuretics have been used to reduce the workload of the heart by reducing blood volume and preload.
  • Diuretics typically reduce extra cellular fluid which builds in congestive heart failure patients increasing preload conditions.
  • Nitrates, arteriolar vasodilators, angiotensin converting enzyme (ACE) inhibitors have been used to treat heart failure through the reduction of cardiac workload by reducing afterload.
  • Inotropes function to increase cardiac output by increasing the force and speed of cardiac muscle contraction.
  • Assist devices include mechanical pumps. Mechanical pumps reduce the load on the heart by performing all or part of the pumping function normally done by the heart. Currently, mechanical pumps are used to sustain the patient while a donor heart for transplantation becomes available for the patient. There are at least four surgical procedures for treatment of heart failure associated with dilatation: 1) heart transplantation; 2) dynamic cardiomyoplasty; and 3) the Batista partial left ventriculectomy, and 4) the Jatene and Dor procedures for ischemic cardiomyopathy. These procedures are set forth in slightly more detail in U.S. application Ser. No. 09/532,049, filed Mar.
  • a more recent procedure for treating the various forms of heart failure discussed above includes placing devices on the heart to reduce the radius of curvature of the heart and/or alter the cross-sectional shape of the heart to reduce wall stress.
  • the devices are configured to reduce the tension in the heart wall, and thereby reverse, stop or slow the disease process of a failing heart as it reduces the energy consumption of the failing heart, decreases isovolumetric contraction, increases isotonic contraction (sarcomere shortening), which in turn increases stroke volume.
  • the devices reduce wall tension by changing chamber geometry or shape and/or changing the radius of curvature or cross-section of a heart chamber. These changes may occur during the entire cardiac cycle or during only a portion of the cardiac cycle.
  • splints The devices of the present invention which reduce heart wall stress in this way can be referred to generally as “splints.”
  • These splints can be in the form of external devices, as described in U.S. application Ser. No. 09/157,486, filed Sep. 21, 1998, entitled “External Stress Reduction Device and Method,” the entire disclosure of which is incorporated by reference herein, or in the form of transventricular elongate tension members with heart-engaging assemblies, typically in the form of anchor pads, disposed on each end configured to engage substantially opposite portions of the chamber wall, embodiments of which are disclosed in the '049 application incorporated above.
  • An aspect of the present invention pertains to splint devices, and related splinting methods, for endovascular implantation on the heart.
  • the splints of the present invention may be implanted endovascularly through remote vascular access sites.
  • the inventive techniques and devices thus are minimally invasive and less risky to patients.
  • a method for placing a splint assembly transverse a heart chamber comprises providing an elongate member having a first end and a second end and a deployable heart-engaging assembly connected to at least the first end. The method further includes advancing the elongate member through vasculature structure and into the heart chamber such that the first end of the elongate member extends through a first location of a wall surrounding the heart chamber and the second end extends through a second location of the heart chamber wall substantially opposite the first location.
  • a deployable heart-engaging assembly is deployed such that it engages with a first exterior surface portion of the heart chamber wall adjacent the first location.
  • the elongate member is secured with respect to the heart with a second heart-engaging assembly connected to the second end.
  • the second heart-engaging assembly engages with a second exterior surface portion of the heart chamber wall adjacent the second location.
  • Another aspect of the invention includes a splint assembly for treating a heart, comprising an elongate member configured to extend transverse a chamber of the heart and at least one heart-engaging assembly formed at least partially from portions forming the elongate member.
  • the heart-engaging assembly has a collapsed configuration adapted to travel through a heart wall and an expanded configuration adapted to engage the heart wall.
  • Yet another aspect of the invention includes a delivery tool for delivering a transventricular splint assembly to a chamber of the heart, comprising a tubular member having a distal end and a proximal end, the distal end having a curved configuration and the tube defining a lumen configured to carry at least a portion of the splint assembly.
  • the delivery tool further includes at least one support mechanism disposed proximate the distal end of the tubular member, the support mechanism being configured to stabilize the tubular member with respect to a heart wall surrounding the chamber.
  • the tubular member is configured to be advanced through vasculature structure and into the heart chamber.
  • FIG. 1 is a vertical cross-sectional view of the heart showing a delivery catheter inserted endovascularly into the right ventricule according to an aspect of the present invention
  • FIG. 2 is a vertical cross-sectional view of the heart showing a guide wire extending from the catheter of FIG. 1 through the septal wall, across the left ventricular chamber and into the free wall according to an aspect of the present invention
  • FIG. 3 is a vertical cross-sectional view of the heart showing the deliver catheter of FIG. 1 positioned over the guidewire of FIG. 2 with positioning balloons inflated on either side of the free wall according to an aspect of the present invention
  • FIG. 4 is a vertical cross-sectional view of the heart showing the insertion of a tension member into the delivery catheter of FIG. 3 for placement with respect to the left ventricle according to an aspect of the present invention
  • FIG. 5 is a vertical cross-sectional view of the heart showing a deployed fixed anchor on the distal end of the tension member of FIG. 4 after being extended past the distal end of the delivery catheter according to an aspect of the present invention
  • FIG. 6 is a vertical cross-sectional view of the heart showing the removal of the delivery catheter from the tension member of FIG. 5 according to an aspect of the present invention
  • FIG. 7 is a vertical cross-section of the heart showing the delivery of an adjustable anchor to be placed on the tension member of FIG. 6 adjacent the septal wall according to an aspect of the present invention
  • FIG. 8 is a vertical cross-section of the heart showing the securing of the adjustable anchor of FIG. 7 to the tension member to change the shape of the left ventricle according to an aspect of the present invention
  • FIG. 9 is a vertical cross-section of the heart showing a cutting snare inserted into the right ventricle to cut excess tension member length from the splint assembly of FIG. 8 according to an aspect of the present invention
  • FIG. 10 is a vertical cross-section of the heart showing a splint assembly positioned with respect to the left ventricle according to an aspect of the present invention
  • FIG. 11 is a partial side view of the deployable anchor and tension member of FIGS. 5 and 6 according to an aspect of the present invention
  • FIG. 12 is a top view of the anchor of FIG. 11 according to an aspect of the invention.
  • FIG. 13 is a partial perspective view of the deployable anchor and tension member of FIG. 11 prior to a securing band being placed to tighten the filament bundles on the elastic ring portion of the anchor according to an aspect of the invention
  • FIG. 14 is a partial side view of the anchor and tension member of FIG. 11 showing the placement of the securing/tightening band according to an aspect of the present invention
  • FIG. 15 is a close-up, partial side view of the guidewire of FIG. 2 according to an aspect of the present invention.
  • FIG. 16 is a detailed, partial side cross-sectional view of the delivery catheter of FIGS. 1-6 according to an aspect of the present invention
  • FIG. 17 is a vertical cross-sectional view of a heart showing a delivery catheter with two curved catheters inserted endovascularly through the aorta into the left ventricle according to an aspect of the present invention
  • FIG. 18 is a vertical cross-sectional view of a heart showing the curved delivery catheters of FIG. 17 with inflated distal balloons respectively in contact with the free wall and septal wall of the heart and with sharpened wires respectively extending through the free wall and septal wall of the heart according to an aspect of the present invention
  • FIG. 19 is a vertical cross-sectional view of a heart showing a tension member delivered through the curved delivery catheter contacting the free wall of FIG. 18 according to an aspect of the present invention
  • FIG. 20 is a vertical cross-sectional view of a heart showing the curved catheter contacting the free wall of FIG. 18 removed from the patient and the tension member being fed into a proximal end of the curved catheter contacting the septal wall of FIG. 18 according to an aspect of the present invention
  • FIG. 21 is a vertical cross-sectional view of the heart showing the tension member of FIG. 20 being advanced through the curved catheter, through the septal wall, into the right ventricle and out of the heart according to an aspect of the present invention
  • FIG. 22 is a vertical cross-sectional view of the heart showing the tension member of FIG. 21 extended across the left ventricle after the curved delivery catheter of FIG. 21 has been removed according to an aspect of the present invention
  • FIG. 23 is a vertical cross-sectional view of the heart showing a delivery catheter with a curved distal tip inserted into the right ventricle proximate the septal wall for delivering a splint assembly according to an aspect of the present invention
  • FIG. 24 is a vertical cross-sectional view of the heart with a guidewire with inflated balloons on a distal end extending from the delivery catheter of FIG. 23, through the septal wall, and across the left ventricle according to an aspect of the present invention
  • FIG. 25 is a vertical cross-sectional view of the heart showing the guidewire of FIG. 24 with the distal balloon deflated and about to be advanced through the free wall of the left ventricle according to an aspect of the present invention
  • FIG. 26 is a vertical cross-sectional view of the heart showing the guidewire of FIG. 25 advanced through the free wall until the proximal inflated balloon abuts the inside of the free wall and with the distal balloon inflated according to an aspect of the invention;
  • FIG. 27 is a vertical cross-sectional view of the heart showing the guidewire in the position of FIG. 26 with the proximal balloon deflated according to an aspect of the present invention
  • FIG. 28 is a vertical cross-sectional view of the heart showing a splint advancement catheter placed over the guidewire of FIG. 27 according to an aspect of the present invention
  • FIG. 29 is a vertical cross-sectional view of the heart showing the splint advancement catheter of FIG. 28 being removed from a tension member and deployable anchor of the splint according to the present invention
  • FIG. 30 is a vertical cross-sectional view of the heart showing the splint advancement catheter of FIG. 28 entirely removed and the splint assembly deployed across the left ventricle according to an aspect of the present invention
  • FIG. 31 is a partial, detailed cross-sectional view of the splint advancement catheter, tension member and distal anchor of FIG. 28 according to an aspect of the present invention
  • FIG. 32 is a partial side view of a braided tension member according to an aspect of the present invention.
  • FIG. 33 is a partial side view of a braided tension member having a diametrically expandable portion according to an aspect of the present invention.
  • FIG. 34 is a partial perspective view of the tension member of FIG. 33 forming a free wall anchor at the diametrically expandable portion according to an aspect of the present invention
  • FIG. 34 a is a partial perspective view of a spiral-shaped deployable wire used to diametrically expand the tension member of FIG. 33 to form the anchor of FIG. 34 according to an aspect of the present invention
  • FIG. 34 b is a partial perspective view of a spiral-shaped deployable wire used to diametrically expand the tension member to form the anchor having a spiral formed in an opposite direction to the spiral of FIG. 34 a according to another aspect of the present invention
  • FIG. 35 is a partial perspective view of a diametrically expandable tension member forming an anchor portion by using an inflated balloon within the expandable portion of the tension member to cause diametric expansion according to an aspect of the present invention
  • FIG. 36 is a transverse cross-sectional view of the heart showing a preferred placement of a tension member of a splint assembly to treat a mitral valve according to an aspect of the present invention
  • FIG. 37 is a transverse cross-sectional view of the heart showing a splint assembly placed with respect to the heart to treat a mitral valve according to an aspect of the present invention.
  • FIG. 38 is a cross-sectional view of an anchor assembly with an inner surface permitting movement with respect to a tension member in only one direction according to an aspect of the present invention.
  • Each device of the present invention preferably operates passively in that, once placed in the heart, it does not require an active stimulus, either mechanical, electrical, or otherwise, to function. Implanting one or more of these devices alters the shape or geometry of the heart, both locally and globally, and thereby increases the heart's efficiency. That is, the heart experiences an increased pumping efficiency through an alteration in its shape or geometry and concomitant reduction in stress on the heart walls.
  • the devices of the present invention may operate to assist in the apposition of heart valve leaflets to improve valve function.
  • the inventive devices and related methods offer numerous advantages over the existing treatments for various heart conditions, including valve incompetencies.
  • the devices are relatively easy to manufacture and use, and the surgical techniques and tools for implanting the devices of the present invention do not require the invasive procedures of current surgical techniques.
  • the endovascular techniques which will be described do not require performing a sternotomy or removing portions of the heart tissue, nor do they require opening the heart chamber or stopping the heart during operation.
  • Such percutaneous insertion permits the splinting procedures to be performed in a wide variety of laboratories in the hospital.
  • the techniques for implanting the devices of the present invention also are less risky to the patient, both during and after the implantation, and may be performed more quickly than other techniques.
  • the procedures of the invention cause less pain to patients and permit quicker healing.
  • certain endovascular splinting techniques to be described may limit bleeding at access sites, allowing relatively large catheters, cannula, and other similar implantation tools to be inserted in a percutaneous manner.
  • the disclosed inventive devices and related methods involve geometric reshaping of the heart.
  • substantially the entire chamber geometry is altered to return the heart to a more normal state of stress.
  • Models of this geometric reshaping which includes a reduction in radius of curvature of the chamber walls, can be found in U.S. Pat. No. 5,961,440, issued Oct. 5, 1999, entitled “Heart Wall Tension Reduction Apparatus and Method,” and incorporated by reference herein.
  • the heart walls Prior to reshaping the chamber geometry, the heart walls experience high stress due to a combination of both the relatively large increased diameter of the chamber and the thinning of the chamber wall.
  • Geometric reshaping reduces the stress in the walls of the heart chamber to increase the heart's pumping efficiency, as well as to stop further dilatation of the heart.
  • inventive endovascular splinting devices and methods will be used to support an infarcted heart wall to prevent further dilatation, or to treat aneurysms in the heart.
  • the devices and methods of using and implanting the devices could be used to treat heart valves, for example to aid in apposition of the leaflets of a mitral valve or modify the shape of the mitral valve, as described in U.S. application Ser. No. ______, to Richard F. Schroeder et al., filed on the same day as this application, assigned to the same assignee as the present application, and entitled “Methods and Devices for Improving Mitral Valve Function,” and incorporated by reference herein.
  • One of ordinary skill in the art would understand that the use of the devices and methods described herein also could be employed in other chambers and for other valves associated with those chambers.
  • the devices and methods of the invention might be used to reduce stress in the left atrium to treat atrial fibrillation.
  • the left ventricle has been selected for illustrative purposes because a large number of the disorders that the present invention treats occur in the left ventricle.
  • FIGS. 1-10 An embodiment of an endovascular splinting technique according to the present invention is shown in FIGS. 1-10.
  • this splinting technique access to the left ventricle LV and delivery of the splint occurs from within the right ventricle RV.
  • An approach from within the right ventricle is preferred for a number of reasons.
  • the right ventricle is highly accessible through venous structure that leads into the superior vena cava VC, for example from the right or left jugular veins. Since these veins typically are at a relatively low pressure, bleeding at the access sites is limited, and rather large catheters, cannula and the other like surgical tools can be inserted into the veins in a percutaneous manner.
  • this technique permits access to vascular structure without a sternotomy or other open chest surgical access, thereby minimizing trauma to the patient. Additionally, patients are less likely to experience embolic events. Recovery times for the operation also are reduced, due to the minimally invasive nature of such procedures.
  • delivery through the right ventricle allows for straightforward positioning of the splints on the ventricular septal wall SW. Such positioning on the septal wall is preferable because it results in good left ventricle bisection, in a manner believed to have minimal negative impact on mitral valve function, and in some instances, a positive impact on mitral valve function and performance. Moreover, delivery through the right ventricle does not involve the free wall of the right ventricle and also does not restrict outflow of the blood from the heart.
  • a shaped guide device in the form of a delivery catheter 100 is advanced into right ventricle RV from an access site preferably in the left or right jugular vein.
  • Other access sites such as, for example, the left or right subclavian vein also are contemplated.
  • the catheter 100 has a tip portion 101 configured to be adjustably and variably curved through the use of an adjusting pull-wire 104 .
  • the pull-wire 104 attaches to the distal most end of the catheter, has a portion that extends exterior the catheter at the distal end of the catheter, and then extends through the catheter to a proximal end of the catheter where it is controlled.
  • pull wire 104 may be an essentially straight wire that, when pulled (or tensioned), causes tip portion 101 to curve.
  • a pull wire may take the form of a tether, such as described below with reference to the curved catheter having pull wire 405 in FIG. 23.
  • the proximal end of the pull-wire 405 can be pulled and released to thereby cause the distal tip of the catheter to curve and to straighten as desired.
  • the position of the catheter tip can be curved by adjusting the pull-wire and also advanced or rotated, or both, by advancing or rotating the catheter with respect to the right ventricle and septal wall.
  • two anchoring balloons 102 , 103 are disposed near the distal end of catheter 100 .
  • Each balloon 102 , 103 is in fluid communication with a corresponding inflation lumen 102 ′, 103 ′ that extends proximally to an inflating means (not shown).
  • a lumen 101 ′ configured to carry a piercing needle also extends through the length of catheter 100 .
  • delivery catheter 100 additionally defines a lumen 106 ′ for carrying a preformed support wire 106 , which expands upon advancement of support wire 106 relative to catheter 100 .
  • the wire 106 takes on a hoop-like shape which gives mechanical “back up” support to delivery catheter 100 .
  • the support wire 106 also helps to position the catheter 100 within the right ventricle to allow for positioning within the right ventricle RV and with respect to the septal wall SW.
  • the support wire 106 is preferably made from an elastic material, such as a nickel-titanium alloy or the like, and has a preformed shape at or near a distal end of the wire configured to stabilize and position the catheter 100 .
  • the catheter 100 preferably also includes radiographic and echogenic markers (not shown), such as metallic or gas-filled structures, or relatively small balloons filled with a contrast media, to facilitate positioning of the catheter under fluoroscopic and/or ultrasonic guidance, such as transesophageal echo (TEE).
  • TEE transesophageal echo
  • needle 105 is then advanced through the lumen in catheter 100 and out of tip portion 101 , piercing the septal wall SW, and extending across the left ventricle chamber LV.
  • needle 105 is fabricated of a highly elastic material such as, for example, nickel titanium alloy, which will allow the needle to traverse the bend at the tip of the delivery catheter, and then to straighten out for controlled traversing across left ventricle LV.
  • FIG. 15 shows the distal portion of needle 105 in greater detail.
  • needle 105 includes a sharpened tip which may have threads 107 disposed around the outer surface of the tip portion. These threads 107 preferably are flexible such that they can lay substantially flat along the length of needle 105 as the needle traverses through the catheter lumen. Alternatively, the tip may include barbs or other similar structures that aid in anchoring the tip in the heart wall.
  • needle 105 Once needle 105 is across the left ventricle chamber, its position is confirmed by TEE, X-Ray, or other visualization techniques, to assure good bisection and avoidance of key mitral valve and other heart structure.
  • Conventional angiography utilizing a “pigtail” catheter. i.e., a dye injection catheter with a loop shape at the distal end, in the left ventricle LV and angiography catheters in one or both coronary artery ostia may also be used to aid in proper positioning of the associated delivery devices in the LV. It also is important to assure that needle 105 will not penetrate or damage any significant coronary vasculature. To assure this, an angiogram may be performed.
  • the angiographic image is aligned to a position that looks down the axis of the needle in the portion of the needle which traverses the left ventricle LV.
  • This angle will limit parallax to ensure that if the tip of the needle is not coincident with a significant vessel it will not pierce such vessel. Any small variation in the position of the needle tip can be adjusted by gentle manipulation of the delivery catheter.
  • needle 105 has soft threads 107 disposed on the surface of a tip portion of the needle, as shown in FIG. 15. Needle 105 can be advanced into the free wall HW of the left ventricle LV by rotating the needle, essentially causing the tip portion of the needle to be pulled or screwed into the myocardium. Threads 107 also serve to anchor needle 105 and provide support for the further advancement of delivery catheter 100 .
  • delivery catheter 100 is straightened and advanced over needle 105 into left ventricle LV.
  • a tapered tip 101 on delivery catheter 100 enables catheter 100 to penetrate the septal and free walls SW, HW.
  • distal anchoring balloon 103 traverses across the free wall HW, both balloons 102 and 103 are inflated, as shown in FIG. 3, to stabilize catheter 100 with respect to the heart chamber.
  • these balloons 102 , 103 are made of an elastomeric material, such as latex or silicone, for example, to provide a relatively low profile in the non-inflated state.
  • balloons 102 , 103 preferably have a flattened, “pancake” shape. This shape may be particularly important for distal balloon 103 , as it lies in the space between the outside of the myocardium and the pericardial sac.
  • insufflation can occur with the use of a small lumen provided inside needle 105 . Once needle 105 is across the myocardium, the CO 2 can be infused.
  • FIG. 11 shows a preferred structure for fixed anchor mechanism 201 in its fully expanded state after being secured with respect to the heart wall.
  • tension member 200 is comprised of a braided polymer, such as that disclosed in the '049 application incorporated by reference above.
  • a cover of expanded polytetrafluoroethylene (ePTFE) (not shown) preferably covers the majority of the length of tension member 200 .
  • ePTFE expanded polytetrafluoroethylene
  • Each bundle 210 in the braid structure is attached via suturing, adhesive, or other suitable attachment mechanism, to a flexible elastic ring 203 .
  • Ring 203 preferably is comprised of nickel-titanium, or an elastomeric polymer such as silicone or urethane, or other suitable like materials.
  • This attachment of the bundles to the ring is best shown in FIG. 13.
  • the braided structure transitions from a tight woven braid to a region that is primarily unbraided at a position slightly proximal to the ring.
  • flexible elastic ring 203 can be easily deformed into a flattened hoop, without bundles 210 inhibiting this deformation.
  • a stiffening mandrel may be disposed either inside or adjacent the braided portion of the tension member.
  • tension member 200 is advanced until flexible ring 203 fully emerges from the lumen of delivery catheter 100 .
  • anchor mechanism 201 has sufficient strength to serve as an anchor and allows bundles 210 to take on a funnel shape, as shown in FIG. 13.
  • a securing band 204 (FIG. 14) is advanced along the outside of braided tension member 200 , until the bundles tighten into a generally spoke-like configuration, as shown in FIGS. 11 and 12.
  • a flexible pushing tube (not shown), or other suitable mechanism, may be used to advance securing band 204 .
  • Securing band 204 preferably has circumferential ribs 204 ′ on its inner surface that are oriented proximally, as shown in FIG. 14. Ribs 204 ′ allow for the band 204 to be advanced distally, while preventing proximal slipping. Once positioned, the securing band 204 maintains anchor mechanism 201 in a relatively flat profile, as shown in FIG. 11.
  • FIG. 6 shows tension member 200 and fixed anchor 201 in a fully deployed configuration with respect to the heart. After fixed anchor 201 of tension member 200 is deployed, anchor balloons 102 , 103 on delivery catheter 100 are deflated, and the delivery catheter is removed from tension member 200 and out of the heart.
  • a second heart-engaging assembly preferably in the form of an adjustable anchor pad 205 (septal wall anchor) is advanced over tension member 200 using a deployment tool 209 , as shown in FIG. 7.
  • Adjustable anchor pad 205 is similar in many ways to the adjustable pad assembly and deployment mechanism disclosed in the '049 application incorporated above, as will be explained.
  • pad 205 preferably has an oval, as opposed to circular, configuration. Such an oval configuration facilitates introduction of the pad into the access site in the vasculature.
  • a through hole 205 ′ extending through this pad is angled relative to the pad surface, to allow pad 205 to be oriented in a more parallel fashion to the tension member 200 as it is advanced along the tension member 200 , as shown in FIG. 7.
  • Adjustable pad 205 is advanced using deployment tool 209 over tension member 200 in essentially a “monorail” fashion, allowing anchor pad 205 to be oriented substantially adjacent and parallel to tension member 200 as tension member 200 slides through throughhole 205 ′.
  • a tightening device 206 preferably in the form of a tube, is advanced over the outside of the tension member until the distal end of the tightening device 206 engages the adjustable pad 205 .
  • Manipulation of the tightening device 206 relative to tension member 200 positions adjustable pad 205 and tension member 200 into a position so as to alter the shape of the left ventricle LV.
  • adjustable pad 205 is deployed by manipulation of the deployment tool 209 , in a manner similar to the technique disclosed in the '049 application. That is, the deployment tool 209 includes an actuator wire that is pre-engaged with an engagement collar (not shown) in adjustable pad assembly 205 such that when the actuator wire is pulled, the engagement collar travels through various channels disposed within the adjustable anchor pad 205 .
  • the engagement collar causes securement members, preferably in the form of pins or staples, such as staple 218 shown in FIG. 10, to move within the pad to engage with the braided tension member structure running through the pad.
  • FIG. 9 shows adjustable pad 205 secured onto tension member 200 adjacent septal wall SW within right ventricle RV after the tightening device 206 and the deployment tool 209 have been removed.
  • a trimming catheter 207 containing a wire in a snare-like loop 208 is advanced along the excess length of tension member 200 to a position proximate the secured adjustable pad 205 .
  • the wire forming snare-like loop 208 can be heated such that upon retraction of snare loop 208 within the lumen of catheter 207 , the excess length of tension member 200 is thermally severed and can be removed.
  • the wire loop may also have a sharpened edge along its inside periphery to cut tension member 200 as loop 208 is retracted into catheter 207 .
  • Other suitable cutting mechanisms may be used and are contemplated as within the scope of the invention.
  • FIGS. 10 and 37 show fully deployed splints 220 , 1000 in position with respect to the left ventricle LV of the heart.
  • additional splints may be positioned as needed or desired in the left ventricle LV or other chambers of the heart, including near the mitral valve to help improve valve function, as disclosed in the “Methods and Devices for Improving Valve Function” application filed on the same day as this application and incorporated by reference above.
  • three splints are positioned in a spaced, approximately parallel relationship from positions on the ventricular septum SW to positions on the ventricular free wall HW.
  • the splints are oriented perpendicular to the long axis of the left ventricle, as shown in FIGS. 10 and 37.
  • the access site in the vasculature is closed by conventional means, such as sutures and the like.
  • splints can be positioned across the left ventricle via an endovascular route leading directly into the left ventricle rather than through the right ventricle.
  • the access site is located in one of the femoral arteries, in a manner similar to many cardiology procedures, for example.
  • this route requires advancing delivery tools retrograde across the aortic valve, this delivery route permits the delivery catheter to be placed in approximately the middle of, rather than outside, the left ventricle, thus yielding a more symmetrical approach.
  • the ability to position the splint to achieve a good bisection of the left ventricle therefore may be enhanced since the bisection may be easier to visualize prior to implanting the splints.
  • the direct left ventricle delivery approach uses a guide device, preferably in the form of a delivery catheter, of a different structure than that used in the right ventricle delivery approach.
  • a delivery catheter 300 for the left ventricle delivery approach is positioned in the left ventricle LV from the aorta A, with access through the femoral artery.
  • Delivery catheter 300 includes a main catheter 301 and two curved catheters 302 , 303 extending from main catheter 301 and configured to curve in substantially opposite directions to one another.
  • Main catheter 301 defines two side-by-side lumens (not shown) extending along the length of the catheter.
  • Each curved catheter 302 , 303 is disposed inside a respective lumen of catheter 300 and is capable of moving relative to main catheter 300 within the lumen.
  • Curved catheters 302 , 303 each have two anchoring balloons disposed near their distal ends and lumens in fluid communication with each balloon to facilitate inflation, in a manner similar to that described with respect to the right ventricle delivery catheter shown in FIG. 16.
  • Curved catheters 302 , 303 are independently manipulable, both in axial translation and in rotation relative to the main catheter.
  • curved catheters 302 , 303 can have the form of the adjustably curvable catheters discussed with reference to FIGS. 1 and 23. That is, it is contemplated that a pull-wire could be used to independently and adjustably curve the end portions of each catheter, thereby allowing for more control over the curve of the tip portion of each catheter.
  • curved catheters 302 , 303 are advanced with their respective distal anchoring balloons 304 , 305 inflated.
  • Distal balloons 304 , 305 serve to act as protective bumpers on the curved catheters so as to avoid damaging various heart structures as the catheters traverse the ventricle.
  • the curvature of catheters 302 , 303 causes the tips of the catheters to deflect laterally until the distal balloons 304 , 305 of each catheter 302 , 303 contact the inside surface of the left ventricle LV, at the septal wall SW and free wall HW, respectively.
  • the curved catheters press against each other to form a self-supporting structure which remains in place during the beating of the heart.
  • sharpened wires 306 , 307 similar to the one described above in the right ventricle delivery method and shown in detail in FIG. 15, are advanced into the myocardium, as shown in FIG. 18.
  • catheters 302 , 303 are manipulated under ultrasonic and/or fluoroscopic guidance until the tips of the curved catheters are in a desired position on the free wall and septal wall for splint attachment. This permits a good bisection of the left ventricle LV and the avoidance of significant coronary structure.
  • a “pigtail” catheter may also be used to help visualization and positioning of the devices, preferably with a diagnostic catheter in the coronary ostia.
  • sharpened wires 306 , 307 also have soft, preferably polymeric, threads 306 ′, 307 ′ disposed on their surfaces around their distal ends, to allow for screwing into the myocardium.
  • Curved catheters 302 , 303 then are advanced with both anchor balloons deflated over wires 306 , 307 , similar to the step described above in the right ventricle approach. After catheters 302 , 303 have been advanced across the ventricular walls SW, HW at the appropriate positions, both balloons on each of curved catheters 302 , 303 are inflated to keep the catheters securely positioned and stabilized with respect to the chamber walls, as shown in FIG. 19.
  • a tension member 200 with a first heart-engaging assembly, preferably in the form of a deployable fixed anchor pad mechanism 201 (free wall anchor), on its distal end, similar to the tension member and deployable fixed pad mechanism discussed with respect to the right ventricle delivery method, is inserted into curved catheter 303 engaging the free wall HW, as shown in FIGS. 19 and 20.
  • Fixed pad 201 deploys in a manner similar to that of the right ventricle delivery approach. After fixed pad 201 is deployed, curved catheter 303 is removed, as shown in FIG. 20. The free end of tension member 200 opposite to the end on which fixed pad 201 is secured is inserted into the proximal end of curved catheter 302 that is engaged with septal wall SW.
  • Tension member 200 is then advanced through the lumen of catheter 302 until it extends out of the distal end of the catheter and into right ventricle RV.
  • a conventional snare 315 for example with a wire loop on its distal end, may be positioned in the right ventricle through an access site, preferably in a jugular vein, for example.
  • snare 315 captures tension member 200 and pulls tension member 200 out of right ventricle RV and out of the patient's body.
  • FIG. 21 shows tension member 200 after the free end has been snared and pulled out of the jugular vein access site.
  • Tension member 200 preferably is long enough to allow for the withdrawal of catheter 303 that engages the free wall HW, the re-advancement of tension member 200 into catheter 302 that engages the septal wall SW, and the withdrawal of tension member 200 out of the right ventricle RV and the access site. Additionally, the proximal loop extending out the femoral access site (shown in FIG. 20) must still have enough length for the second catheter to be withdrawn.
  • FIG. 22 shows tension member 200 after curved catheter 302 has been fully removed.
  • tension member 200 is in a configuration similar to that shown in FIG. 7, and the technique described with reference to the right ventricle approach above to deliver and secure a second heart-engaging assembly, preferably in the form of an adjustable anchor pad (septal wall anchor), onto tension member 200 adjacent the septal wall SW to finish the splint deployment across the left ventricle LV can be used.
  • a second heart-engaging assembly preferably in the form of an adjustable anchor pad (septal wall anchor) onto tension member 200 adjacent the septal wall SW to finish the splint deployment across the left ventricle LV
  • the left ventricle delivery method and right ventricle delivery method differ only up to the point of delivery of the adjustable pad, and after that the steps may be the same.
  • FIGS. 23-30 illustrate yet another embodiment of a method for delivering and implanting a splint across the left ventricle from a free wall HW to a septal wall SW.
  • the method shown in these figures is similar in many respects to the right ventricle delivery technique described above. However, the method to be described differs from the previously discussed right ventricle approach in that the splint is advanced across the left ventricle LV over a small hollow guidewire or needle of the type shown in FIGS. 24-27. Additionally, an alternative free wall deployable anchor structure is described.
  • a guide device again preferably in the form of a delivery catheter 400 , is positioned in the right ventricle RV from an access point, such as, preferably the right jugular vein, for example.
  • Delivery catheter 400 has a similar structure as delivery catheter 100 used in the right ventricle delivery technique described above. However, delivery catheter 400 does not advance into and across the left ventricle LV, as did delivery catheter 100 .
  • Catheter 400 has a curved distal tip portion 400 ′.
  • a tether, or pull-wire, 405 connected to distal tip portion 400 ′ is configured to adjust the angle or curvature of the tip portion 400 ′.
  • Tether 405 runs inside a lumen 420 disposed adjacent catheter 400 , or, alternatively, within catheter 400 . Pulling proximally on tether 405 causes tip portion 400 ′ to deflect laterally.
  • Delivery catheter 400 also includes a pre-formed support wire 410 configured to extend via advancement of the support wire from another lumen 421 disposed adjacent catheter 400 on a side substantially opposite to the side lumen 420 is.
  • Support wire 410 not only assists to maintain the placement of tip portion 400 ′ of delivery catheter 400 within right ventricle RV in the appropriate position, but also assists in positioning the tip portion 400 ′ near the center of right ventricle RV relative to the anterior and posterior ends of the right ventricle, as a result of the shape and size of the support wire.
  • Alternative shapes of the pre-formed support wire also are contemplated which would facilitate tip positioning and support in other desired positions within right ventricle RV.
  • a hollow sharpened metallic guidewire, or needle, 402 is advanced through a central lumen 422 of delivery catheter 400 , across the ventricular septum SW, and across the left ventricular chamber LV to free wall HW, as shown in FIG. 24.
  • a combination of fluoroscopic and ultrasonic imaging are performed to assist in the guidance and confirmation of positioning for this delivery technique.
  • Appropriate radiographic or other suitable visible markers are positioned on the devices to facilitate this imaging, as described above.
  • Hollow guidewire 402 has a sharpened tip 402 ′ and defines a central lumen plugged near tip 402 ′.
  • the material used to make guidewire 402 preferably includes a superelastic nickel titanium alloy, or other similar like material.
  • Two elastomeric balloons, a distal balloon 403 and a proximal balloon 404 are secured near the distal end of guidewire 402 slightly proximal to sharpened tip 402 ′.
  • Distal balloon 403 is in flow communication with central lumen 422 of guidewire 402 .
  • Proximal balloon 404 is in fluid communication with an additional tube (not shown) positioned inside hollow guidewire 402 . In this manner, each balloon 403 , 404 can be independently inflated and deflated as required.
  • Balloons 403 , 404 preferably are in a deflated condition as they are advanced across septal wall SW and then are inflated during advancement across the left ventricle LV. Inflating the balloons during advancement across the left ventricle LV may assist in visualizing the advancement path of the guidewire. To assist in such visualization, preferably the balloons are inflated with a radiographic contrast agent. The ability to visualize the advancement path of guidewire 402 may prevent damage to various cardiac structure as well as assist in ensuring proper positioning of the guidewire on the free wall HW.
  • distal balloon 403 As guidewire tip 402 ′ approaches free wall HW, distal balloon 403 is deflated, as shown in FIG. 25, and the wire is further advanced into the free wall. Proximal balloon 404 acts as a stop to limit advancement of guidewire 402 through free wall HW. This may eliminate or minimize any damage to tissue outside free wall HW of left ventricle LV. Once fully advanced, distal balloon 403 is re-inflated to secure the position of guidewire 402 across the left ventricular chamber, as shown in FIG. 26. It is preferred that the distance between balloons 403 , 404 approximates the thickness of the heart wall.
  • Proximal balloon 404 is then deflated, as shown in FIG. 27, and a splint advancement catheter 406 carrying the tension member 500 and fixed deployable anchor 502 is advanced over guidewire 402 , as shown in FIG. 28.
  • a splint advancement catheter 406 carrying the tension member 500 and fixed deployable anchor 502 is advanced over guidewire 402 , as shown in FIG. 28.
  • catheter 406 defines a lumen 406 ′ through which braided tension member 500 is configured to extend.
  • Tension member 500 is secured within a distal adhesive portion 502 ′ of a deployable anchor 502 .
  • This adhesive portion preferably is made of a high strength adhesive such as epoxy, or the like and is also configured to slide through lumen 406 ′.
  • a lumen 509 extends through fixed deployable anchor 502 adjacent to tension member braid 500 . This lumen also is formed simultaneously within adhesive portion 502 ′ of anchor 502 . Lumen 509 and lumen 406 ′ both pass over the outside of guidewire 402 (not shown) as advancement catheter 406 carrying tension member 500 with deployable fixed anchor 502 on one end is advanced across the left ventricle LV and through the free wall HW.
  • Anchor 502 preferably is in the form of an elastic or super-elastic metallic tube including a plurality of pre-formed tabs 508 extending proximally from adhesive tube portion 502 ′.
  • the tabs 508 may be formed by several longitudinally-oriented cuts along a portion of the length of the tube.
  • tabs 508 are prevented from flaring outward by the sheath defining lumen 406 ′ of splint advancement catheter 406 , as shown in FIG. 31.
  • tabs 508 Upon retraction of the sheath of splint advancement catheter 406 , tabs 508 are able to expand radially outwardly to their pre-formed shape, thus defining distal anchor 502 .
  • a separate push tube 520 for pushing on anchor 502 as the catheter 406 is retracted from the tension member and fixed anchor assembly also is shown in FIG. 31.
  • Push tube 520 is configured to pass over the outside of guidewire 402 within lumen 406 ′ adjacent tension member 500 to engage with the adhesive portion 502 ′ of anchor 502 .
  • the deployable fixed anchor may have a structure similar to that described above with reference to the right ventricle and left ventricle delivery techniques.
  • the deployable anchor configurations described in connection with FIGS. 29-31 may be used in conjunction with other delivery techniques described above.
  • the deployable anchor structures described in connection with the previous splint embodiments can be utilized in conjunction with this embodiment.
  • Elongate tension member 500 preferably is similar to that described above in connection with the right ventricle delivery method and comprises a braid of high strength polymer fibers, preferably Spectra or other suitable like ultra-high molecular weight polyethylene.
  • Tension member 500 may also include a covering along its full length made of a thin expanded polytetrafluoroethylene. Alternatively, only the region of tension member 500 which is disposed inside the ventricular chamber could include a covering.
  • Tension member 500 is thus advanced into position by sliding splint advancement catheter 406 carrying tension member 500 and anchor 502 over guidewire 402 . That is, guidewire 402 will be placed within lumen 509 of anchor 502 and then within lumen 406 ′ of the catheter 406 . The lumen 406 ′ and the lumen 509 will move relative to guidewire 402 to advance catheter 406 , tension member 500 , and anchor 502 in the configuration shown in FIG. 31 until deployable anchor 502 protrudes beyond the myocardium of free wall HW. Once tension member 500 and anchor 502 are positioned appropriately with respect to the left ventricle and free wall HW, that is, when anchor 502 retained within the catheter 406 protrudes beyond the free wall HW as shown in FIG.
  • catheter 406 is retracted off tabs 508 . This retraction of catheter 406 enables tabs 508 to expand radially outward from the remainder of deployable anchor 502 .
  • Push tube 520 is used to maintain the position of the tension member 500 during the catheter's retraction to overcome any friction between catheter 406 and tabs 508 . After anchor 502 is deployed, both catheter 406 and push tube 520 are removed from guidewire 402 and then guidewire 402 also is removed.
  • the proximal anchor may have a similar structure as the distal fixed deployable anchor or may be separately slidable and adjustable on the tension member (such as the adjustable anchor shown in FIGS. 7-10). The proximal anchor also may be pre-attached at an appropriate position on the tension member to provide the desired amount of ventricular shape change.
  • a one way “ratchet” or friction surface may be disposed on the inner surface of the tubular portion of the anchor to prevent its displacement in one direction.
  • the inner surface of the tubular portion of the anchor can be in the form of rings or flared protrusions 380 that are angled with respect to the longitudinal axis of a tension member 385 as it is inserted into an anchor 388 .
  • the angled rings or protrusions 380 are configured so as to permit movement of the anchor with respect to the tension member in one direction but prevent movement in the opposite direction.
  • the rings or protrusions would permit movement in the direction of the solid arrow, but prevent movement in the direction of the dotted arrow by essentially digging into the tension member surface.
  • a tightening device such as that described and shown in FIG. 8 may be utilized to advance the deployed anchor into position.
  • the anchor may be initially positioned such that when the sheath of the splint advancement catheter is further withdrawn, the proximal anchor also would deploy within the right ventricle RV adjacent to the septal wall SW.
  • the tightening device could then be used to advance the position of the proximal anchor to a desired position against the septal wall SW, as shown in FIG. 30.
  • the delivery catheter itself could be used to advance the deployed proximal anchor to the desired position. Once the proximal anchor is positioned to its appropriate location, any excess tension member length extending beyond the proximal anchor may be severed in a manner similar to that described above in connection with FIG. 9.
  • proximal anchor In the alternative case where proximal anchor is pre-attached at a specified distance from the distal anchor, the left ventricle should be deformed prior to the pad deployment.
  • the delivery catheter can act as a temporary proximal anchor, while the tension member and distal anchor are pulled proximally.
  • the proximal anchor may be deployed upon further retraction of the sheath of the splint advancement catheter.
  • the distance between the distal and proximal anchors will be selected prior to delivery such that a desired shape change of the heart chamber may be obtained, since the adjustability of the shape change will be limited by the fixed position of the proximal anchor on the tension member.
  • the delivery catheter may then be removed and excess tension member severed, again as described with reference to FIG. 9.
  • FIGS. 23-30 While the splint delivery methods and devices just described in connection with FIGS. 23-30 were in the context of a right ventricle approach, it is also contemplated to utilize the delivery devices and methods in a direct left ventricle approach as well. In a direct left ventricle approach, two delivery catheters simultaneously could be utilized to position a splint from within the left ventricle in manners similar to those described with reference to FIGS. 17-22.
  • FIGS. 32-35 Other embodiments of a deployable, fixed heart-engaging assembly, or anchor, also are contemplated as within the scope of the present invention and are shown in FIGS. 32-35.
  • a preferred tension member used in the various embodiments of the present invention is described in the '049 application, incorporated by reference above, and is formed of several multifilament bundles of a high strength polymer. These bundles are braided together in a relatively tight configuration. Certain combinations of bundle size, number of bundles, and pick count, described in more detail in the '049 application, result in a braid with several preferred properties as also described in the '049 application, incorporated by reference above.
  • One property that may result from such a braid construction includes a relatively stable braid diameter that does not deform to a great extent if subjected to axial compression or internal radially-outward directed forces.
  • a braid formed with a lower pick count has a greater diametric expandability when subjected to such forces.
  • a braid woven of the same material and having approximately 16 to approximately 64 bundles and approximately 2 to approximately 15 picks per inch may more readily expand in diameter, upon the application of a radial force directed outwardly from within the braid.
  • This expandable property of a braid can be utilized in the formation of yet another alternative deployable anchor structure.
  • FIG. 32 is a relatively simplified schematic illustrating a tension member 50 formed of a braid of relatively low pick count in its natural (i.e., non-stressed) as-braided condition.
  • the braid is uniformly relatively small in outer diameter D 1 .
  • the diameter D 1 of the braid remains relatively small.
  • FIG. 33 illustrates the same braided tension member 50 as in FIG. 32, but shows the braid with a local application of an outward radially directed force from within the braid. Since the braid pick count is relatively low, the braid has the capacity to expand at the point of application of the radial force to a diameter D 2 , which is several times its original diameter D 1 .
  • FIG. 34 shows a tension member 340 having a braid configuration such as that shown in FIGS. 32 and 33 utilized for an integral expandable distal anchor 342 of tension member 340 . At least a portion of the tension member 340 is woven at a relatively low pick count to allow for that portion to form into the expandable distal anchor 342 . Alternatively, the entire tension member 340 can be uniformly woven at the relatively low pick count.
  • Several methods for creating an outward radial force from within the braid to form anchor 342 are contemplated. These methods include using an elastic or shape memory wire disposed inside the braid of tension member 340 during placement across the ventricular wall HW. A preferred wire 345 is shown in FIG. 34 a .
  • Wire 345 preferably has a natural shape in the form of a disc-shaped spiral.
  • the spiral will have a straightened configuration.
  • the spiral shape of wire 34 may be re-established, thereby forcing the braided portion surrounding it to expand in diameter into a disc-like shape, as shown in FIG. 34.
  • the wire may either be pre-loaded into the tension member or may be advanced into the tension member once the tension member has been positioned with respect to the heart wall and the catheter has been retracted enough to expose a portion of the tension member that is outside the heart wall HW.
  • the force of the catheter on the wire keeps the wire in its straightened configuration.
  • the smaller diameter portion of the spiral forms first, and as more of the wire is advanced through the tension member beyond the catheter, the spiral grows in diameter until the full spiral is re-established.
  • the large diameter portion of the spiral may form first, as the wire 345 ′ is advanced.
  • a thin membrane preferably made of an elastic material for example, is disposed along the inside of the braid in the area where the spiral portion of wire 345 is positioned.
  • wire 345 preferably will remain together with the braid of tension member 340 even after diametric expansion in order provide the anchoring rigidity needed to secure the splint in place on the heart.
  • the spiral portion of wire 345 may carry a significant portion of the load of anchor 342 .
  • the expanded braid forming anchor 342 would become ingrown with scar tissue, and therefore a relatively large portion of the chronic mechanical loading may be carried by the filaments of the braid.
  • filaments of ultra-high molecular weight polyethylene has been shown to produce a tension member and anchor having high strength and high fatigue resistance.
  • a portion of the wire that does not form the spiral may be removed, for example by torquing the wire and breaking it at a location slightly proximal to the spiral.
  • the distal most region of the braid preferably is either fused or banded. This will prevent expansibility in those regions. Alternatively, those regions of the braided tension member could be woven with a higher pick count.
  • An alternative device for causing expansion of an expandable braid portion of a tension member 540 includes an inflatable balloon disposed inside braided tension member at the expandable portion forming the anchor, as shown in FIG. 35.
  • Inflatable balloon 545 can be positioned in the desired location within tension member 540 either before advancement of the tension member across the ventricular wall, or after, as shown in FIG. 35.
  • balloon 545 is formed of an elastomeric material such as silicone or urethane, or the like, and has a disc-like shape upon expansion.
  • a lumen 543 connecting the interior of balloon 545 to an inflation device (not shown) may extend along the inside of braided tension member 540 .
  • the material used to expand balloon 545 includes a curable material such as RTV silicone, epoxy, urethane, or the like. Similar to the spiral anchor embodiment discussed above, the cured material forming the balloon may carry a significant load initially, but upon ingrowth of the expanded braided region of the tension member, the filaments of the braid would be the primary chronic load carrying members.
  • an expandable anchor would utilize an anchor similar to the expandable tab anchor described above with reference to FIGS. 29-31.
  • that anchor would be merely temporary, and could be designed to be relatively small and low profile, for easy delivery, but may not have the adequate strength and durability to be a permanent chronic anchor.
  • a permanent anchor similar to the adjustable pad anchor assembly described in the '049 application incorporated above could be delivered as a replacement to that temporary anchor.
  • a small surgical incision may be made between the ribs adjacent the free wall HW of the left ventricle LV, thus creating an access port to deliver the permanent anchor.
  • a trocar may be positioned in that same location.
  • a snare device positioned within the port or trocar can be used to grab the temporary anchor and tension member and pull the anchor off of the tension member and outside of the patient.
  • An adjustable anchor pad as described in the '049 application and similar to the description of FIGS. 7 and 8 above then may be attached to the braid outside of the patient, using the staple methodology described previously with reference to FIG. 8 and the '049 application.
  • the anchor can then be pulled back into position by retracting the other end of the tension member via the length of the tension member that remains outside the jugular vein.
  • the septal wall anchor in this case preferably would be in the form of the solid anchor and delivered in the manner described above in conjunction with FIGS. 7-10. Overall, this procedure would be a combination endovascular and “minimally invasive” surgical operation.
  • both anchor pads would be of a solid type construction.
  • An alternative proximal anchor also may utilize the expandable capability of a relatively low pick count braid, in a manner similar to that described above for the distal, or free wall, anchor.
  • the entire braid of the tension member preferably includes the relatively low pick count permitting diametric expansion.
  • the tension member and distal anchor could be delivered using any of the approaches described herein, but preferably one of the right ventricle approach methods. After the distal, or free wall, anchor is delivered, the proper ventricle shape change can be induced using a tightening device in the form of a simple tube, such as the one described above, but without the anchor shown in FIG. 8.
  • a balloon or spiral wire type of expander device as described in connection with the distal anchors shown in FIGS.
  • a balloon type expansion device may also include a detachable inflation tube, such that when the balloon is inflated with a curable material, the inflation tube can be removed prior to the excess tension member length being severed. It is also contemplated that such an expandable proximal anchor can be secured to the end of the tension member at a location adjacent to an exterior surface of a heart wall other than the septal wall, such as a wall surrounding the right ventricle, for example.
  • the methods described above to place the splint assemblies with respect to the heart can be repeated for any desired number of splint assemblies to achieve a particular configuration.
  • the length of the tension members extending between the free wall and septal wall anchors also can be optimally determined based upon the size and condition of the patient's heart. It should also be noted that although the left ventricle has been referred to here for illustrative purposes, the apparatus and methods of this invention can be used to splint multiple chambers of a patient's heart, including the right ventricle or either atrium, or can be used to aid the function of valves, such as the mitral valve.
  • An example of a preferred position of a splint assembly 1000 improves mitral valve function, as well as reducing stress in the left ventricular walls.
  • the valve function is improved by aiding in the apposition of valve leaflets when positioned as shown in FIG. 37.
  • three splints are placed in a coplanar fashion, bisecting the left ventricle LV of the heart.
  • the superior-most splint 1000 is placed at approximately the level of the heads of the papillary muscles PM, and the additional two splints (not shown in FIG. 37) are placed inferiorly toward the apex.
  • the preferred orientation shown in FIG. 37 both bisects the left ventricle LV and avoids key structures such as coronary vessels and the like.
  • the splints according to this orientation also extend through the septum SW and enter a portion of the right ventricle RV.
  • heart-engaging assemblies 1002 , 1003 will be positioned adjacent an exterior surface of a free wall HW surrounding the left ventricle LV and adjacent an exterior surface of the septal wall SW within the right ventricle RV.
  • Further details regarding splinting devices and methods for treating heart valves can be found in the application entitled “Methods and Devices for Improving Mitral Valve Function,” to Richard F. Schroeder et al., filed on a date even herewith and incorporated by reference above. Although any of the delivery methods described above could be used to implant the splint device in this manner, FIG.
  • FIG. 36 shows a short axis cross-section of a heart and a preferred endovascular technique wherein the elongate tension member 1001 having a deployable fixed anchor 1002 on its distal end is delivered through the right ventricle RV and then into the left ventricle LV.
  • the alignments of the splints with respect to the heart that are described above are illustrative only and may be shifted or rotated about a vertical axis generally disposed through the left ventricle and still avoid the major coronary vessels and papillary muscles.
  • inventive devices and methods can be implanted to treat a heart having aneurysms or infarcted regions similar to those described in prior U.S. application Ser. No. 09/422,328 discussed earlier herein and incorporated above.
  • the various components of the splint assembly to be implanted in the heart should be made of biocompatible material that can remain in the human body indefinitely. Any surface engaging portions of the heart should be atraumatic in order to avoid tissue damage and preferably formed of a material promoting tissue ingrowth to stabilize the anchor pad with respect to the surfaces of the heart.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Prostheses (AREA)
  • Surgical Instruments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method for placing a splint assembly transverse a heart chamber includes providing an elongate member having a first end and a second end and a deployable heart-engaging assembly connected to at least the first end. The method includes advancing the elongate member through vasculature structure and into the heart chamber such that the first end of the elongate member extends through a first location of a wall surrounding the heart chamber and the second end extends through a second location of the heart chamber wall substantially opposite the first location. A deployable heart-engaging assembly is deployed such that it engages with a first exterior surface portion of the heart chamber wall adjacent the first location. The elongate member is secured with respect to the heart with a second heart-engaging assembly connected to the second end. The second heart-engaging assembly engages with a second exterior surface portion of the heart chamber wall adjacent the second location. A splint assembly includes an expandable heart-engaging assembly formed partially from portions forming the elongate member of the splint assembly. A delivery tool includes a tubular member configured to be advanced through vasculature structure and has a curved distal end.

Description

  • This application is a continuation of U.S. patent application Ser. No. 10/410,279 filed Apr. 10, 2003, now pending, which is a continuation of 09/679,550 filed Oct. 6, 2000, now U.S. Pat. No. 6,616,684, issued Sep. 9, 2003.[0001]
  • FIELD OF THE INVENTION
  • The present invention pertains to devices for treating a failing heart and related methods for placing the devices. In particular, the invention pertains to splinting devices placed on the heart to reduce the radius of curvature and/or alter the geometry or shape of the heart to thereby reduce wall stress in the heart and improve the heart's pumping performance. The devices and methods of the present invention are directed toward endovascular techniques used to facilitate placement of the splinting devices on the heart. [0002]
  • BACKGROUND OF THE INVENTION
  • Heart failure is a common outcome in the progression of many forms of heart disease. Heart failure may be considered as the condition in which an abnormality of cardiac function is responsible for the inability of the heart to pump blood at a rate commensurate with the requirements of the metabolizing tissues, or can do so only at an abnormally elevated filling pressure. There are many specific disease processes that can lead to heart failure. Typically these processes result in dilatation of the left ventricular chamber. Etiologies that can lead to this form of failure include idiopathic, valvular, viral, and ischemic cardiomyopathies, including ventricular aneurysms. [0003]
  • The process of ventricular dilatation is generally the result of chronic volume overload or specific damage to the myocardium. In a normal heart that is exposed to long term increased cardiac output requirements, for example, that of an athlete, there is an adaptive process of slight ventricular dilation and muscle myocyte hypertrophy. In this way, the heart fully compensates for the increased cardiac output requirements. With damage to the myocardium or chronic volume overload, however, there are increased requirements put on the contracting myocardium to such a level that this compensated state is never achieved and the heart continues to dilate. [0004]
  • One problem with a large dilated left ventricle is that there is a significant increase in wall tension and/or stress both during diastolic filling and during systolic contraction. In a normal heart, the adaptation of muscle hypertrophy (thickening) and ventricular dilatation maintain a fairly constant wall tension for systolic contraction. However, in a failing heart, the ongoing dilatation is greater than the hypertrophy and the result is a rising wall tension requirement for systolic contraction. This is felt to be an ongoing insult to the muscle myocyte resulting in further muscle damage. The increase in wall stress also occurs during diastolic filling. Additionally, because of the lack of cardiac output, a rise in ventricular filling pressure generally results from several physiologic mechanisms. Moreover, in diastole there is both a diameter increase and a pressure increase over normal, both contributing to higher wall stress levels. The increase in diastolic wall stress is felt to be the primary contributor to ongoing dilatation of the chamber. [0005]
  • Mitral regurgitation is a condition whereby blood leaks through the mitral valve due to an improper positioning of the valve structures that causes the valve not to close entirely. Geometric abnormalities resulting from a dilated left ventricle may cause or exacerbate improper functioning of the mitral valve, including mitral valve regurgitation, by altering the normal position and dimension of the valve, particularly the valve annulus. [0006]
  • Prior treatments for heart failure associated with such dilatation fall into three general categories. The first being pharmacological, for example, diuretics and ACE inhibitors. The second being assist systems, for example, pumps. Finally, surgical treatments also have been experimented with. [0007]
  • With respect to pharmacological treatments, diuretics have been used to reduce the workload of the heart by reducing blood volume and preload. Diuretics typically reduce extra cellular fluid which builds in congestive heart failure patients increasing preload conditions. Nitrates, arteriolar vasodilators, angiotensin converting enzyme (ACE) inhibitors have been used to treat heart failure through the reduction of cardiac workload by reducing afterload. Inotropes function to increase cardiac output by increasing the force and speed of cardiac muscle contraction. These drug therapies offer some beneficial effects but do not stop the progression of the disease. [0008]
  • Assist devices include mechanical pumps. Mechanical pumps reduce the load on the heart by performing all or part of the pumping function normally done by the heart. Currently, mechanical pumps are used to sustain the patient while a donor heart for transplantation becomes available for the patient. There are at least four surgical procedures for treatment of heart failure associated with dilatation: 1) heart transplantation; 2) dynamic cardiomyoplasty; and 3) the Batista partial left ventriculectomy, and 4) the Jatene and Dor procedures for ischemic cardiomyopathy. These procedures are set forth in slightly more detail in U.S. application Ser. No. 09/532,049, filed Mar. 21, 2000, entitled “Splint Assembly for Improving Cardiac Function in Hearts, and Method for Implanting the Splint Assembly,” the entire disclosure of which is hereby incorporated by reference herein. Hereinafter, this application will be referred to as “the '049 application.”[0009]
  • SUMMARY OF THE INVENTION
  • Due to the drawbacks and limitations of the previous devices and techniques for treating a failing heart, including such a heart having dilated, infarcted, and/or aneurysmal tissue, there exists a need for alternative methods and devices that are less invasive and pose less risk to the patient, both after and during placement, and are likely to possess more clinical utility. [0010]
  • Thus, a more recent procedure for treating the various forms of heart failure discussed above includes placing devices on the heart to reduce the radius of curvature of the heart and/or alter the cross-sectional shape of the heart to reduce wall stress. The devices are configured to reduce the tension in the heart wall, and thereby reverse, stop or slow the disease process of a failing heart as it reduces the energy consumption of the failing heart, decreases isovolumetric contraction, increases isotonic contraction (sarcomere shortening), which in turn increases stroke volume. The devices reduce wall tension by changing chamber geometry or shape and/or changing the radius of curvature or cross-section of a heart chamber. These changes may occur during the entire cardiac cycle or during only a portion of the cardiac cycle. The devices of the present invention which reduce heart wall stress in this way can be referred to generally as “splints.” These splints can be in the form of external devices, as described in U.S. application Ser. No. 09/157,486, filed Sep. 21, 1998, entitled “External Stress Reduction Device and Method,” the entire disclosure of which is incorporated by reference herein, or in the form of transventricular elongate tension members with heart-engaging assemblies, typically in the form of anchor pads, disposed on each end configured to engage substantially opposite portions of the chamber wall, embodiments of which are disclosed in the '049 application incorporated above. [0011]
  • An aspect of the present invention pertains to splint devices, and related splinting methods, for endovascular implantation on the heart. The splints of the present invention may be implanted endovascularly through remote vascular access sites. The inventive techniques and devices thus are minimally invasive and less risky to patients. [0012]
  • The advantages and purpose of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages and purpose of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. [0013]
  • According to an aspect of the invention, a method for placing a splint assembly transverse a heart chamber comprises providing an elongate member having a first end and a second end and a deployable heart-engaging assembly connected to at least the first end. The method further includes advancing the elongate member through vasculature structure and into the heart chamber such that the first end of the elongate member extends through a first location of a wall surrounding the heart chamber and the second end extends through a second location of the heart chamber wall substantially opposite the first location. A deployable heart-engaging assembly is deployed such that it engages with a first exterior surface portion of the heart chamber wall adjacent the first location. The elongate member is secured with respect to the heart with a second heart-engaging assembly connected to the second end. The second heart-engaging assembly engages with a second exterior surface portion of the heart chamber wall adjacent the second location. [0014]
  • Another aspect of the invention includes a splint assembly for treating a heart, comprising an elongate member configured to extend transverse a chamber of the heart and at least one heart-engaging assembly formed at least partially from portions forming the elongate member. The heart-engaging assembly has a collapsed configuration adapted to travel through a heart wall and an expanded configuration adapted to engage the heart wall. [0015]
  • Yet another aspect of the invention includes a delivery tool for delivering a transventricular splint assembly to a chamber of the heart, comprising a tubular member having a distal end and a proximal end, the distal end having a curved configuration and the tube defining a lumen configured to carry at least a portion of the splint assembly. The delivery tool further includes at least one support mechanism disposed proximate the distal end of the tubular member, the support mechanism being configured to stabilize the tubular member with respect to a heart wall surrounding the chamber. The tubular member is configured to be advanced through vasculature structure and into the heart chamber.[0016]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and together with the description, serve to explain the principles of the invention. In the drawings, [0017]
  • FIG. 1 is a vertical cross-sectional view of the heart showing a delivery catheter inserted endovascularly into the right ventricule according to an aspect of the present invention; [0018]
  • FIG. 2 is a vertical cross-sectional view of the heart showing a guide wire extending from the catheter of FIG. 1 through the septal wall, across the left ventricular chamber and into the free wall according to an aspect of the present invention; [0019]
  • FIG. 3 is a vertical cross-sectional view of the heart showing the deliver catheter of FIG. 1 positioned over the guidewire of FIG. 2 with positioning balloons inflated on either side of the free wall according to an aspect of the present invention; [0020]
  • FIG. 4 is a vertical cross-sectional view of the heart showing the insertion of a tension member into the delivery catheter of FIG. 3 for placement with respect to the left ventricle according to an aspect of the present invention; [0021]
  • FIG. 5 is a vertical cross-sectional view of the heart showing a deployed fixed anchor on the distal end of the tension member of FIG. 4 after being extended past the distal end of the delivery catheter according to an aspect of the present invention; [0022]
  • FIG. 6 is a vertical cross-sectional view of the heart showing the removal of the delivery catheter from the tension member of FIG. 5 according to an aspect of the present invention; [0023]
  • FIG. 7 is a vertical cross-section of the heart showing the delivery of an adjustable anchor to be placed on the tension member of FIG. 6 adjacent the septal wall according to an aspect of the present invention; [0024]
  • FIG. 8 is a vertical cross-section of the heart showing the securing of the adjustable anchor of FIG. 7 to the tension member to change the shape of the left ventricle according to an aspect of the present invention; [0025]
  • FIG. 9 is a vertical cross-section of the heart showing a cutting snare inserted into the right ventricle to cut excess tension member length from the splint assembly of FIG. 8 according to an aspect of the present invention; [0026]
  • FIG. 10 is a vertical cross-section of the heart showing a splint assembly positioned with respect to the left ventricle according to an aspect of the present invention; [0027]
  • FIG. 11 is a partial side view of the deployable anchor and tension member of FIGS. 5 and 6 according to an aspect of the present invention; [0028]
  • FIG. 12 is a top view of the anchor of FIG. 11 according to an aspect of the invention; [0029]
  • FIG. 13 is a partial perspective view of the deployable anchor and tension member of FIG. 11 prior to a securing band being placed to tighten the filament bundles on the elastic ring portion of the anchor according to an aspect of the invention; [0030]
  • FIG. 14 is a partial side view of the anchor and tension member of FIG. 11 showing the placement of the securing/tightening band according to an aspect of the present invention; [0031]
  • FIG. 15 is a close-up, partial side view of the guidewire of FIG. 2 according to an aspect of the present invention; [0032]
  • FIG. 16 is a detailed, partial side cross-sectional view of the delivery catheter of FIGS. 1-6 according to an aspect of the present invention; [0033]
  • FIG. 17 is a vertical cross-sectional view of a heart showing a delivery catheter with two curved catheters inserted endovascularly through the aorta into the left ventricle according to an aspect of the present invention; [0034]
  • FIG. 18 is a vertical cross-sectional view of a heart showing the curved delivery catheters of FIG. 17 with inflated distal balloons respectively in contact with the free wall and septal wall of the heart and with sharpened wires respectively extending through the free wall and septal wall of the heart according to an aspect of the present invention; [0035]
  • FIG. 19 is a vertical cross-sectional view of a heart showing a tension member delivered through the curved delivery catheter contacting the free wall of FIG. 18 according to an aspect of the present invention; [0036]
  • FIG. 20 is a vertical cross-sectional view of a heart showing the curved catheter contacting the free wall of FIG. 18 removed from the patient and the tension member being fed into a proximal end of the curved catheter contacting the septal wall of FIG. 18 according to an aspect of the present invention; [0037]
  • FIG. 21 is a vertical cross-sectional view of the heart showing the tension member of FIG. 20 being advanced through the curved catheter, through the septal wall, into the right ventricle and out of the heart according to an aspect of the present invention; [0038]
  • FIG. 22 is a vertical cross-sectional view of the heart showing the tension member of FIG. 21 extended across the left ventricle after the curved delivery catheter of FIG. 21 has been removed according to an aspect of the present invention; [0039]
  • FIG. 23 is a vertical cross-sectional view of the heart showing a delivery catheter with a curved distal tip inserted into the right ventricle proximate the septal wall for delivering a splint assembly according to an aspect of the present invention; [0040]
  • FIG. 24 is a vertical cross-sectional view of the heart with a guidewire with inflated balloons on a distal end extending from the delivery catheter of FIG. 23, through the septal wall, and across the left ventricle according to an aspect of the present invention; [0041]
  • FIG. 25 is a vertical cross-sectional view of the heart showing the guidewire of FIG. 24 with the distal balloon deflated and about to be advanced through the free wall of the left ventricle according to an aspect of the present invention; [0042]
  • FIG. 26 is a vertical cross-sectional view of the heart showing the guidewire of FIG. 25 advanced through the free wall until the proximal inflated balloon abuts the inside of the free wall and with the distal balloon inflated according to an aspect of the invention; [0043]
  • FIG. 27 is a vertical cross-sectional view of the heart showing the guidewire in the position of FIG. 26 with the proximal balloon deflated according to an aspect of the present invention; [0044]
  • FIG. 28 is a vertical cross-sectional view of the heart showing a splint advancement catheter placed over the guidewire of FIG. 27 according to an aspect of the present invention; [0045]
  • FIG. 29 is a vertical cross-sectional view of the heart showing the splint advancement catheter of FIG. 28 being removed from a tension member and deployable anchor of the splint according to the present invention; [0046]
  • FIG. 30 is a vertical cross-sectional view of the heart showing the splint advancement catheter of FIG. 28 entirely removed and the splint assembly deployed across the left ventricle according to an aspect of the present invention; [0047]
  • FIG. 31 is a partial, detailed cross-sectional view of the splint advancement catheter, tension member and distal anchor of FIG. 28 according to an aspect of the present invention; [0048]
  • FIG. 32 is a partial side view of a braided tension member according to an aspect of the present invention; [0049]
  • FIG. 33 is a partial side view of a braided tension member having a diametrically expandable portion according to an aspect of the present invention; [0050]
  • FIG. 34 is a partial perspective view of the tension member of FIG. 33 forming a free wall anchor at the diametrically expandable portion according to an aspect of the present invention; [0051]
  • FIG. 34[0052] a is a partial perspective view of a spiral-shaped deployable wire used to diametrically expand the tension member of FIG. 33 to form the anchor of FIG. 34 according to an aspect of the present invention;
  • FIG. 34[0053] b is a partial perspective view of a spiral-shaped deployable wire used to diametrically expand the tension member to form the anchor having a spiral formed in an opposite direction to the spiral of FIG. 34a according to another aspect of the present invention;
  • FIG. 35 is a partial perspective view of a diametrically expandable tension member forming an anchor portion by using an inflated balloon within the expandable portion of the tension member to cause diametric expansion according to an aspect of the present invention; [0054]
  • FIG. 36 is a transverse cross-sectional view of the heart showing a preferred placement of a tension member of a splint assembly to treat a mitral valve according to an aspect of the present invention; [0055]
  • FIG. 37 is a transverse cross-sectional view of the heart showing a splint assembly placed with respect to the heart to treat a mitral valve according to an aspect of the present invention; and [0056]
  • FIG. 38 is a cross-sectional view of an anchor assembly with an inner surface permitting movement with respect to a tension member in only one direction according to an aspect of the present invention.[0057]
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The various aspects of the invention to be discussed herein generally pertain to devices and methods for treating heart conditions, including, for example, dilatation, valve incompetencies, including mitral valve leakage, and other similar heart failure conditions. Each device of the present invention preferably operates passively in that, once placed in the heart, it does not require an active stimulus, either mechanical, electrical, or otherwise, to function. Implanting one or more of these devices alters the shape or geometry of the heart, both locally and globally, and thereby increases the heart's efficiency. That is, the heart experiences an increased pumping efficiency through an alteration in its shape or geometry and concomitant reduction in stress on the heart walls. In addition, the devices of the present invention may operate to assist in the apposition of heart valve leaflets to improve valve function. [0058]
  • The inventive devices and related methods offer numerous advantages over the existing treatments for various heart conditions, including valve incompetencies. The devices are relatively easy to manufacture and use, and the surgical techniques and tools for implanting the devices of the present invention do not require the invasive procedures of current surgical techniques. For instance, the endovascular techniques which will be described do not require performing a sternotomy or removing portions of the heart tissue, nor do they require opening the heart chamber or stopping the heart during operation. Such percutaneous insertion permits the splinting procedures to be performed in a wide variety of laboratories in the hospital. For these reasons, the techniques for implanting the devices of the present invention also are less risky to the patient, both during and after the implantation, and may be performed more quickly than other techniques. For instance, the procedures of the invention cause less pain to patients and permit quicker healing. In addition, certain endovascular splinting techniques to be described may limit bleeding at access sites, allowing relatively large catheters, cannula, and other similar implantation tools to be inserted in a percutaneous manner. [0059]
  • The disclosed inventive devices and related methods involve geometric reshaping of the heart. In certain aspects of the inventive devices and related methods, substantially the entire chamber geometry is altered to return the heart to a more normal state of stress. Models of this geometric reshaping, which includes a reduction in radius of curvature of the chamber walls, can be found in U.S. Pat. No. 5,961,440, issued Oct. 5, 1999, entitled “Heart Wall Tension Reduction Apparatus and Method,” and incorporated by reference herein. Prior to reshaping the chamber geometry, the heart walls experience high stress due to a combination of both the relatively large increased diameter of the chamber and the thinning of the chamber wall. Filling pressures and systolic pressures are typically high as well, further increasing wall stress. Geometric reshaping according to the present invention reduces the stress in the walls of the heart chamber to increase the heart's pumping efficiency, as well as to stop further dilatation of the heart. [0060]
  • It also is contemplated that the inventive endovascular splinting devices and methods will be used to support an infarcted heart wall to prevent further dilatation, or to treat aneurysms in the heart. U.S. application Ser. No. 09/422,328, filed on Oct. 21, 1999, entitled “Methods and Devices for Improving Cardiac Function in Hearts,” which is assigned to the same assignee as the present application and is incorporated by reference herein, discusses this form of heart failure in more detail. Moreover, it is contemplated that the devices and methods of using and implanting the devices could be used to treat heart valves, for example to aid in apposition of the leaflets of a mitral valve or modify the shape of the mitral valve, as described in U.S. application Ser. No. ______, to Richard F. Schroeder et al., filed on the same day as this application, assigned to the same assignee as the present application, and entitled “Methods and Devices for Improving Mitral Valve Function,” and incorporated by reference herein. One of ordinary skill in the art would understand that the use of the devices and methods described herein also could be employed in other chambers and for other valves associated with those chambers. For example, the devices and methods of the invention might be used to reduce stress in the left atrium to treat atrial fibrillation. The left ventricle has been selected for illustrative purposes because a large number of the disorders that the present invention treats occur in the left ventricle. [0061]
  • Reference will now be made in detail to the present preferred embodiments of the invention, examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts. [0062]
  • An embodiment of an endovascular splinting technique according to the present invention is shown in FIGS. 1-10. In this splinting technique, access to the left ventricle LV and delivery of the splint occurs from within the right ventricle RV. An approach from within the right ventricle is preferred for a number of reasons. First, the right ventricle is highly accessible through venous structure that leads into the superior vena cava VC, for example from the right or left jugular veins. Since these veins typically are at a relatively low pressure, bleeding at the access sites is limited, and rather large catheters, cannula and the other like surgical tools can be inserted into the veins in a percutaneous manner. Furthermore, this technique permits access to vascular structure without a sternotomy or other open chest surgical access, thereby minimizing trauma to the patient. Additionally, patients are less likely to experience embolic events. Recovery times for the operation also are reduced, due to the minimally invasive nature of such procedures. [0063]
  • Second, delivery through the right ventricle allows for straightforward positioning of the splints on the ventricular septal wall SW. Such positioning on the septal wall is preferable because it results in good left ventricle bisection, in a manner believed to have minimal negative impact on mitral valve function, and in some instances, a positive impact on mitral valve function and performance. Moreover, delivery through the right ventricle does not involve the free wall of the right ventricle and also does not restrict outflow of the blood from the heart. [0064]
  • According to the right ventricle delivery technique shown in FIGS. 1-10, a shaped guide device in the form of a [0065] delivery catheter 100 is advanced into right ventricle RV from an access site preferably in the left or right jugular vein. Other access sites, such as, for example, the left or right subclavian vein also are contemplated. As shown in FIG. 1, the catheter 100 has a tip portion 101 configured to be adjustably and variably curved through the use of an adjusting pull-wire 104. The pull-wire 104 attaches to the distal most end of the catheter, has a portion that extends exterior the catheter at the distal end of the catheter, and then extends through the catheter to a proximal end of the catheter where it is controlled. As shown in FIGS. 1 and 2, pull wire 104 may be an essentially straight wire that, when pulled (or tensioned), causes tip portion 101 to curve. In another embodiment, a pull wire may take the form of a tether, such as described below with reference to the curved catheter having pull wire 405 in FIG. 23. Also in that embodiment, the proximal end of the pull-wire 405 can be pulled and released to thereby cause the distal tip of the catheter to curve and to straighten as desired. Thus, the position of the catheter tip can be curved by adjusting the pull-wire and also advanced or rotated, or both, by advancing or rotating the catheter with respect to the right ventricle and septal wall.
  • Additionally, as shown best in FIG. 16, two anchoring [0066] balloons 102, 103 are disposed near the distal end of catheter 100. Each balloon 102, 103 is in fluid communication with a corresponding inflation lumen 102′, 103′ that extends proximally to an inflating means (not shown). A lumen 101′ configured to carry a piercing needle also extends through the length of catheter 100. In a preferred embodiment, delivery catheter 100 additionally defines a lumen 106′ for carrying a preformed support wire 106, which expands upon advancement of support wire 106 relative to catheter 100. The wire 106 takes on a hoop-like shape which gives mechanical “back up” support to delivery catheter 100. The support wire 106 also helps to position the catheter 100 within the right ventricle to allow for positioning within the right ventricle RV and with respect to the septal wall SW. The support wire 106 is preferably made from an elastic material, such as a nickel-titanium alloy or the like, and has a preformed shape at or near a distal end of the wire configured to stabilize and position the catheter 100. The catheter 100 preferably also includes radiographic and echogenic markers (not shown), such as metallic or gas-filled structures, or relatively small balloons filled with a contrast media, to facilitate positioning of the catheter under fluoroscopic and/or ultrasonic guidance, such as transesophageal echo (TEE).
  • Once [0067] catheter 100 is manipulated to a desired position on the ventricular septum SW, the support wire 106 is advanced to stabilize the tip position, as shown in FIG. 1. A sharpened needle, or guidewire, 105 is then advanced through the lumen in catheter 100 and out of tip portion 101, piercing the septal wall SW, and extending across the left ventricle chamber LV. Preferably, needle 105 is fabricated of a highly elastic material such as, for example, nickel titanium alloy, which will allow the needle to traverse the bend at the tip of the delivery catheter, and then to straighten out for controlled traversing across left ventricle LV. FIG. 15 shows the distal portion of needle 105 in greater detail. As can be seen from this figure, needle 105 includes a sharpened tip which may have threads 107 disposed around the outer surface of the tip portion. These threads 107 preferably are flexible such that they can lay substantially flat along the length of needle 105 as the needle traverses through the catheter lumen. Alternatively, the tip may include barbs or other similar structures that aid in anchoring the tip in the heart wall.
  • Once [0068] needle 105 is across the left ventricle chamber, its position is confirmed by TEE, X-Ray, or other visualization techniques, to assure good bisection and avoidance of key mitral valve and other heart structure. Conventional angiography utilizing a “pigtail” catheter. i.e., a dye injection catheter with a loop shape at the distal end, in the left ventricle LV and angiography catheters in one or both coronary artery ostia may also be used to aid in proper positioning of the associated delivery devices in the LV. It also is important to assure that needle 105 will not penetrate or damage any significant coronary vasculature. To assure this, an angiogram may be performed. Preferably, the angiographic image is aligned to a position that looks down the axis of the needle in the portion of the needle which traverses the left ventricle LV. This angle will limit parallax to ensure that if the tip of the needle is not coincident with a significant vessel it will not pierce such vessel. Any small variation in the position of the needle tip can be adjusted by gentle manipulation of the delivery catheter.
  • As mentioned above, preferably needle [0069] 105 has soft threads 107 disposed on the surface of a tip portion of the needle, as shown in FIG. 15. Needle 105 can be advanced into the free wall HW of the left ventricle LV by rotating the needle, essentially causing the tip portion of the needle to be pulled or screwed into the myocardium. Threads 107 also serve to anchor needle 105 and provide support for the further advancement of delivery catheter 100.
  • Next, [0070] delivery catheter 100 is straightened and advanced over needle 105 into left ventricle LV. A tapered tip 101 on delivery catheter 100 enables catheter 100 to penetrate the septal and free walls SW, HW. Once distal anchoring balloon 103 traverses across the free wall HW, both balloons 102 and 103 are inflated, as shown in FIG. 3, to stabilize catheter 100 with respect to the heart chamber. Preferably, these balloons 102, 103 are made of an elastomeric material, such as latex or silicone, for example, to provide a relatively low profile in the non-inflated state. Thus, once inflated with, for example, air or other fluid, including a radiographic contrast agent, balloons 102, 103 preferably have a flattened, “pancake” shape. This shape may be particularly important for distal balloon 103, as it lies in the space between the outside of the myocardium and the pericardial sac. To further guard against damage to the pericardium or lungs, it is possible to insufflate the space between the myocardium and the pericardial sac with CO2. Insufflation can occur with the use of a small lumen provided inside needle 105. Once needle 105 is across the myocardium, the CO2 can be infused.
  • As [0071] delivery catheter 100 is advanced over the distal end of needle 105, flexible threads 107 become collapsed and needle 105 can be removed from catheter 100. After removing needle 105, an elongate tension member 200 with a heart-engaging assembly, preferably in the form of a collapsible fixed anchor mechanism 201 (free wall anchor), on its distal end can be inserted into the lumen of catheter 100. Tension member 200 is advanced until it begins to emerge from the tip portion 101 of delivery catheter 100, as shown in FIG. 4.
  • FIG. 11 shows a preferred structure for fixed [0072] anchor mechanism 201 in its fully expanded state after being secured with respect to the heart wall. As shown, tension member 200 is comprised of a braided polymer, such as that disclosed in the '049 application incorporated by reference above. A cover of expanded polytetrafluoroethylene (ePTFE) (not shown) preferably covers the majority of the length of tension member 200. Each bundle 210 in the braid structure is attached via suturing, adhesive, or other suitable attachment mechanism, to a flexible elastic ring 203. Ring 203 preferably is comprised of nickel-titanium, or an elastomeric polymer such as silicone or urethane, or other suitable like materials. This attachment of the bundles to the ring is best shown in FIG. 13. In order to facilitate bundles 210 of the braid to be attached to ring 203, the braided structure transitions from a tight woven braid to a region that is primarily unbraided at a position slightly proximal to the ring.
  • In this configuration, flexible [0073] elastic ring 203 can be easily deformed into a flattened hoop, without bundles 210 inhibiting this deformation. This is the configuration that tension member 200 has as it is advanced through the lumen of delivery catheter 100. To allow tension member 200 to be pushed through catheter 100, a stiffening mandrel may be disposed either inside or adjacent the braided portion of the tension member.
  • As shown in FIG. 5, [0074] tension member 200 is advanced until flexible ring 203 fully emerges from the lumen of delivery catheter 100. As such, anchor mechanism 201 has sufficient strength to serve as an anchor and allows bundles 210 to take on a funnel shape, as shown in FIG. 13. To tighten fiber bundles 210, a securing band 204 (FIG. 14) is advanced along the outside of braided tension member 200, until the bundles tighten into a generally spoke-like configuration, as shown in FIGS. 11 and 12. A flexible pushing tube (not shown), or other suitable mechanism, may be used to advance securing band 204. Securing band 204 preferably has circumferential ribs 204′ on its inner surface that are oriented proximally, as shown in FIG. 14. Ribs 204′ allow for the band 204 to be advanced distally, while preventing proximal slipping. Once positioned, the securing band 204 maintains anchor mechanism 201 in a relatively flat profile, as shown in FIG. 11.
  • FIG. 6 shows [0075] tension member 200 and fixed anchor 201 in a fully deployed configuration with respect to the heart. After fixed anchor 201 of tension member 200 is deployed, anchor balloons 102, 103 on delivery catheter 100 are deflated, and the delivery catheter is removed from tension member 200 and out of the heart.
  • After removing [0076] delivery catheter 100, a second heart-engaging assembly, preferably in the form of an adjustable anchor pad 205 (septal wall anchor) is advanced over tension member 200 using a deployment tool 209, as shown in FIG. 7. Adjustable anchor pad 205 is similar in many ways to the adjustable pad assembly and deployment mechanism disclosed in the '049 application incorporated above, as will be explained. Thus, there preferably is an actuatable staple mechanism within the pad structure for securing pad 205 to braided tension member 200. In accordance with the present invention, however, pad 205 preferably has an oval, as opposed to circular, configuration. Such an oval configuration facilitates introduction of the pad into the access site in the vasculature. Moreover, a through hole 205′ extending through this pad is angled relative to the pad surface, to allow pad 205 to be oriented in a more parallel fashion to the tension member 200 as it is advanced along the tension member 200, as shown in FIG. 7.
  • [0077] Adjustable pad 205 is advanced using deployment tool 209 over tension member 200 in essentially a “monorail” fashion, allowing anchor pad 205 to be oriented substantially adjacent and parallel to tension member 200 as tension member 200 slides through throughhole 205′. Once located at the septal wall SW, a tightening device 206, preferably in the form of a tube, is advanced over the outside of the tension member until the distal end of the tightening device 206 engages the adjustable pad 205. Manipulation of the tightening device 206 relative to tension member 200 positions adjustable pad 205 and tension member 200 into a position so as to alter the shape of the left ventricle LV.
  • Once a desired amount of shape change is achieved, [0078] adjustable pad 205 is deployed by manipulation of the deployment tool 209, in a manner similar to the technique disclosed in the '049 application. That is, the deployment tool 209 includes an actuator wire that is pre-engaged with an engagement collar (not shown) in adjustable pad assembly 205 such that when the actuator wire is pulled, the engagement collar travels through various channels disposed within the adjustable anchor pad 205. The engagement collar causes securement members, preferably in the form of pins or staples, such as staple 218 shown in FIG. 10, to move within the pad to engage with the braided tension member structure running through the pad. A more detailed description of the tightening of the splint assembly and the securing of the adjustable pad on the tension member can be found in the '049 application incorporated herein by reference.
  • FIG. 9 shows [0079] adjustable pad 205 secured onto tension member 200 adjacent septal wall SW within right ventricle RV after the tightening device 206 and the deployment tool 209 have been removed. A trimming catheter 207 containing a wire in a snare-like loop 208 is advanced along the excess length of tension member 200 to a position proximate the secured adjustable pad 205. Preferably, the wire forming snare-like loop 208 can be heated such that upon retraction of snare loop 208 within the lumen of catheter 207, the excess length of tension member 200 is thermally severed and can be removed. The wire loop may also have a sharpened edge along its inside periphery to cut tension member 200 as loop 208 is retracted into catheter 207. Other suitable cutting mechanisms may be used and are contemplated as within the scope of the invention.
  • FIGS. 10 and 37 show fully deployed [0080] splints 220, 1000 in position with respect to the left ventricle LV of the heart. Following the steps discussed above, additional splints may be positioned as needed or desired in the left ventricle LV or other chambers of the heart, including near the mitral valve to help improve valve function, as disclosed in the “Methods and Devices for Improving Valve Function” application filed on the same day as this application and incorporated by reference above. In a preferred method, three splints are positioned in a spaced, approximately parallel relationship from positions on the ventricular septum SW to positions on the ventricular free wall HW. Preferably, the splints are oriented perpendicular to the long axis of the left ventricle, as shown in FIGS. 10 and 37. Once all the desired splints are positioned, the access site in the vasculature is closed by conventional means, such as sutures and the like.
  • In another embodiment of the invention, splints can be positioned across the left ventricle via an endovascular route leading directly into the left ventricle rather than through the right ventricle. Using this approach, preferably the access site is located in one of the femoral arteries, in a manner similar to many cardiology procedures, for example. Although this route requires advancing delivery tools retrograde across the aortic valve, this delivery route permits the delivery catheter to be placed in approximately the middle of, rather than outside, the left ventricle, thus yielding a more symmetrical approach. The ability to position the splint to achieve a good bisection of the left ventricle therefore may be enhanced since the bisection may be easier to visualize prior to implanting the splints. Furthermore, it may be possible to stabilize the delivery system using walls on both sides of the left ventricle, thus requiring fewer additional support mechanisms. [0081]
  • The direct left ventricle delivery approach uses a guide device, preferably in the form of a delivery catheter, of a different structure than that used in the right ventricle delivery approach. As shown in FIG. 17, a [0082] delivery catheter 300 for the left ventricle delivery approach is positioned in the left ventricle LV from the aorta A, with access through the femoral artery. Delivery catheter 300 includes a main catheter 301 and two curved catheters 302, 303 extending from main catheter 301 and configured to curve in substantially opposite directions to one another. Main catheter 301 defines two side-by-side lumens (not shown) extending along the length of the catheter. Each curved catheter 302, 303 is disposed inside a respective lumen of catheter 300 and is capable of moving relative to main catheter 300 within the lumen. Curved catheters 302, 303 each have two anchoring balloons disposed near their distal ends and lumens in fluid communication with each balloon to facilitate inflation, in a manner similar to that described with respect to the right ventricle delivery catheter shown in FIG. 16. Curved catheters 302, 303 are independently manipulable, both in axial translation and in rotation relative to the main catheter. Moreover, it is contemplated that curved catheters 302, 303 can have the form of the adjustably curvable catheters discussed with reference to FIGS. 1 and 23. That is, it is contemplated that a pull-wire could be used to independently and adjustably curve the end portions of each catheter, thereby allowing for more control over the curve of the tip portion of each catheter.
  • Once the distal tip of [0083] main catheter 301 resides in the left ventricle LV, curved catheters 302, 303 are advanced with their respective distal anchoring balloons 304, 305 inflated. Distal balloons 304, 305 serve to act as protective bumpers on the curved catheters so as to avoid damaging various heart structures as the catheters traverse the ventricle. The curvature of catheters 302, 303 causes the tips of the catheters to deflect laterally until the distal balloons 304, 305 of each catheter 302, 303 contact the inside surface of the left ventricle LV, at the septal wall SW and free wall HW, respectively. Once positioned, the curved catheters press against each other to form a self-supporting structure which remains in place during the beating of the heart. Once distal balloons 304, 305 contact the walls, sharpened wires 306, 307, similar to the one described above in the right ventricle delivery method and shown in detail in FIG. 15, are advanced into the myocardium, as shown in FIG. 18. As with the right ventricle delivery method, catheters 302, 303 are manipulated under ultrasonic and/or fluoroscopic guidance until the tips of the curved catheters are in a desired position on the free wall and septal wall for splint attachment. This permits a good bisection of the left ventricle LV and the avoidance of significant coronary structure. As discussed above, a “pigtail” catheter may also be used to help visualization and positioning of the devices, preferably with a diagnostic catheter in the coronary ostia. As with the wire used for the right ventricle approach, sharpened wires 306, 307 also have soft, preferably polymeric, threads 306′, 307′ disposed on their surfaces around their distal ends, to allow for screwing into the myocardium.
  • [0084] Curved catheters 302, 303 then are advanced with both anchor balloons deflated over wires 306, 307, similar to the step described above in the right ventricle approach. After catheters 302, 303 have been advanced across the ventricular walls SW, HW at the appropriate positions, both balloons on each of curved catheters 302, 303 are inflated to keep the catheters securely positioned and stabilized with respect to the chamber walls, as shown in FIG. 19.
  • A [0085] tension member 200, with a first heart-engaging assembly, preferably in the form of a deployable fixed anchor pad mechanism 201 (free wall anchor), on its distal end, similar to the tension member and deployable fixed pad mechanism discussed with respect to the right ventricle delivery method, is inserted into curved catheter 303 engaging the free wall HW, as shown in FIGS. 19 and 20. Fixed pad 201 deploys in a manner similar to that of the right ventricle delivery approach. After fixed pad 201 is deployed, curved catheter 303 is removed, as shown in FIG. 20. The free end of tension member 200 opposite to the end on which fixed pad 201 is secured is inserted into the proximal end of curved catheter 302 that is engaged with septal wall SW. Tension member 200 is then advanced through the lumen of catheter 302 until it extends out of the distal end of the catheter and into right ventricle RV. A conventional snare 315, for example with a wire loop on its distal end, may be positioned in the right ventricle through an access site, preferably in a jugular vein, for example. As the free end of tension member 200 emerges from curved catheter 302 and into right ventricle RV, snare 315 captures tension member 200 and pulls tension member 200 out of right ventricle RV and out of the patient's body.
  • FIG. 21 shows [0086] tension member 200 after the free end has been snared and pulled out of the jugular vein access site. Tension member 200 preferably is long enough to allow for the withdrawal of catheter 303 that engages the free wall HW, the re-advancement of tension member 200 into catheter 302 that engages the septal wall SW, and the withdrawal of tension member 200 out of the right ventricle RV and the access site. Additionally, the proximal loop extending out the femoral access site (shown in FIG. 20) must still have enough length for the second catheter to be withdrawn. As second catheter 302 is withdrawn out of the femoral access site and over tension member 200 secured to the free heart wall, it preferably is removed from the tension member by skiving the length of the catheter down the lumen containing the tension member. FIG. 22 shows tension member 200 after curved catheter 302 has been fully removed.
  • At this point, [0087] tension member 200 is in a configuration similar to that shown in FIG. 7, and the technique described with reference to the right ventricle approach above to deliver and secure a second heart-engaging assembly, preferably in the form of an adjustable anchor pad (septal wall anchor), onto tension member 200 adjacent the septal wall SW to finish the splint deployment across the left ventricle LV can be used. Thus, the left ventricle delivery method and right ventricle delivery method differ only up to the point of delivery of the adjustable pad, and after that the steps may be the same.
  • FIGS. 23-30 illustrate yet another embodiment of a method for delivering and implanting a splint across the left ventricle from a free wall HW to a septal wall SW. The method shown in these figures is similar in many respects to the right ventricle delivery technique described above. However, the method to be described differs from the previously discussed right ventricle approach in that the splint is advanced across the left ventricle LV over a small hollow guidewire or needle of the type shown in FIGS. 24-27. Additionally, an alternative free wall deployable anchor structure is described. [0088]
  • In FIG. 23, a guide device, again preferably in the form of a [0089] delivery catheter 400, is positioned in the right ventricle RV from an access point, such as, preferably the right jugular vein, for example. Delivery catheter 400 has a similar structure as delivery catheter 100 used in the right ventricle delivery technique described above. However, delivery catheter 400 does not advance into and across the left ventricle LV, as did delivery catheter 100. Catheter 400 has a curved distal tip portion 400′. A tether, or pull-wire, 405 connected to distal tip portion 400′ is configured to adjust the angle or curvature of the tip portion 400′. Tether 405 runs inside a lumen 420 disposed adjacent catheter 400, or, alternatively, within catheter 400. Pulling proximally on tether 405 causes tip portion 400′ to deflect laterally. Delivery catheter 400 also includes a pre-formed support wire 410 configured to extend via advancement of the support wire from another lumen 421 disposed adjacent catheter 400 on a side substantially opposite to the side lumen 420 is. Support wire 410 not only assists to maintain the placement of tip portion 400′ of delivery catheter 400 within right ventricle RV in the appropriate position, but also assists in positioning the tip portion 400′ near the center of right ventricle RV relative to the anterior and posterior ends of the right ventricle, as a result of the shape and size of the support wire. Alternative shapes of the pre-formed support wire also are contemplated which would facilitate tip positioning and support in other desired positions within right ventricle RV.
  • After [0090] tip portion 400′ of delivery catheter 300 is positioned and oriented in the desired location with respect to septal wall SW, a hollow sharpened metallic guidewire, or needle, 402 is advanced through a central lumen 422 of delivery catheter 400, across the ventricular septum SW, and across the left ventricular chamber LV to free wall HW, as shown in FIG. 24. As with the methods described above, a combination of fluoroscopic and ultrasonic imaging are performed to assist in the guidance and confirmation of positioning for this delivery technique. Appropriate radiographic or other suitable visible markers are positioned on the devices to facilitate this imaging, as described above.
  • [0091] Hollow guidewire 402 has a sharpened tip 402′ and defines a central lumen plugged near tip 402′. The material used to make guidewire 402 preferably includes a superelastic nickel titanium alloy, or other similar like material. Two elastomeric balloons, a distal balloon 403 and a proximal balloon 404, are secured near the distal end of guidewire 402 slightly proximal to sharpened tip 402′. Distal balloon 403 is in flow communication with central lumen 422 of guidewire 402. Proximal balloon 404 is in fluid communication with an additional tube (not shown) positioned inside hollow guidewire 402. In this manner, each balloon 403, 404 can be independently inflated and deflated as required.
  • Balloons [0092] 403, 404 preferably are in a deflated condition as they are advanced across septal wall SW and then are inflated during advancement across the left ventricle LV. Inflating the balloons during advancement across the left ventricle LV may assist in visualizing the advancement path of the guidewire. To assist in such visualization, preferably the balloons are inflated with a radiographic contrast agent. The ability to visualize the advancement path of guidewire 402 may prevent damage to various cardiac structure as well as assist in ensuring proper positioning of the guidewire on the free wall HW.
  • As [0093] guidewire tip 402′ approaches free wall HW, distal balloon 403 is deflated, as shown in FIG. 25, and the wire is further advanced into the free wall. Proximal balloon 404 acts as a stop to limit advancement of guidewire 402 through free wall HW. This may eliminate or minimize any damage to tissue outside free wall HW of left ventricle LV. Once fully advanced, distal balloon 403 is re-inflated to secure the position of guidewire 402 across the left ventricular chamber, as shown in FIG. 26. It is preferred that the distance between balloons 403, 404 approximates the thickness of the heart wall.
  • [0094] Proximal balloon 404 is then deflated, as shown in FIG. 27, and a splint advancement catheter 406 carrying the tension member 500 and fixed deployable anchor 502 is advanced over guidewire 402, as shown in FIG. 28. The structure of splint advancement catheter 406 with respect to the delivery of the tension member 500 and deployable anchor 502 will now be described in more detail with reference to FIG. 31. As shown, catheter 406 defines a lumen 406′ through which braided tension member 500 is configured to extend. Tension member 500 is secured within a distal adhesive portion 502′ of a deployable anchor 502. This adhesive portion preferably is made of a high strength adhesive such as epoxy, or the like and is also configured to slide through lumen 406′. A lumen 509 extends through fixed deployable anchor 502 adjacent to tension member braid 500. This lumen also is formed simultaneously within adhesive portion 502′ of anchor 502. Lumen 509 and lumen 406′ both pass over the outside of guidewire 402 (not shown) as advancement catheter 406 carrying tension member 500 with deployable fixed anchor 502 on one end is advanced across the left ventricle LV and through the free wall HW. Anchor 502 preferably is in the form of an elastic or super-elastic metallic tube including a plurality of pre-formed tabs 508 extending proximally from adhesive tube portion 502′. The tabs 508 may be formed by several longitudinally-oriented cuts along a portion of the length of the tube. During advancement of tension member 500, tabs 508 are prevented from flaring outward by the sheath defining lumen 406′ of splint advancement catheter 406, as shown in FIG. 31. Upon retraction of the sheath of splint advancement catheter 406, tabs 508 are able to expand radially outwardly to their pre-formed shape, thus defining distal anchor 502. A separate push tube 520 for pushing on anchor 502 as the catheter 406 is retracted from the tension member and fixed anchor assembly also is shown in FIG. 31. Push tube 520 is configured to pass over the outside of guidewire 402 within lumen 406adjacent tension member 500 to engage with the adhesive portion 502′ of anchor 502.
  • Aside from the configurations described above with reference to FIG. 31, the deployable fixed anchor may have a structure similar to that described above with reference to the right ventricle and left ventricle delivery techniques. Similarly, the deployable anchor configurations described in connection with FIGS. 29-31 may be used in conjunction with other delivery techniques described above. Also, the deployable anchor structures described in connection with the previous splint embodiments can be utilized in conjunction with this embodiment. [0095]
  • [0096] Elongate tension member 500 preferably is similar to that described above in connection with the right ventricle delivery method and comprises a braid of high strength polymer fibers, preferably Spectra or other suitable like ultra-high molecular weight polyethylene. Tension member 500 may also include a covering along its full length made of a thin expanded polytetrafluoroethylene. Alternatively, only the region of tension member 500 which is disposed inside the ventricular chamber could include a covering.
  • [0097] Tension member 500 is thus advanced into position by sliding splint advancement catheter 406 carrying tension member 500 and anchor 502 over guidewire 402. That is, guidewire 402 will be placed within lumen 509 of anchor 502 and then within lumen 406′ of the catheter 406. The lumen 406′ and the lumen 509 will move relative to guidewire 402 to advance catheter 406, tension member 500, and anchor 502 in the configuration shown in FIG. 31 until deployable anchor 502 protrudes beyond the myocardium of free wall HW. Once tension member 500 and anchor 502 are positioned appropriately with respect to the left ventricle and free wall HW, that is, when anchor 502 retained within the catheter 406 protrudes beyond the free wall HW as shown in FIG. 28, catheter 406 is retracted off tabs 508. This retraction of catheter 406 enables tabs 508 to expand radially outward from the remainder of deployable anchor 502. Push tube 520 is used to maintain the position of the tension member 500 during the catheter's retraction to overcome any friction between catheter 406 and tabs 508. After anchor 502 is deployed, both catheter 406 and push tube 520 are removed from guidewire 402 and then guidewire 402 also is removed.
  • At this point in the splint delivery technique of FIGS. 23-30, that is, after the deployable fixed distal anchor has been positioned on free wall HW, similar steps as described in connection with both the right ventricle and left ventricle methods above may be followed for the deployment of a second, adjustable anchor pad and for tightening and securing of tension member with respect to the left ventricle. An alternative embodiment of an adjustable anchor to tighten and secure the tension member also may be used in connection with this splint delivery technique, as well as with the other techniques described above. In this alternative embodiment, the proximal anchor may have a similar structure as the distal fixed deployable anchor or may be separately slidable and adjustable on the tension member (such as the adjustable anchor shown in FIGS. 7-10). The proximal anchor also may be pre-attached at an appropriate position on the tension member to provide the desired amount of ventricular shape change. [0098]
  • In the case where the proximal anchor is slidable on the tension member, a one way “ratchet” or friction surface may be disposed on the inner surface of the tubular portion of the anchor to prevent its displacement in one direction. For example, as shown in FIG. 38, the inner surface of the tubular portion of the anchor can be in the form of rings or flared [0099] protrusions 380 that are angled with respect to the longitudinal axis of a tension member 385 as it is inserted into an anchor 388. The angled rings or protrusions 380 are configured so as to permit movement of the anchor with respect to the tension member in one direction but prevent movement in the opposite direction. As illustrated in FIG. 38, the rings or protrusions would permit movement in the direction of the solid arrow, but prevent movement in the direction of the dotted arrow by essentially digging into the tension member surface.
  • A tightening device such as that described and shown in FIG. 8 may be utilized to advance the deployed anchor into position. In this case, the anchor may be initially positioned such that when the sheath of the splint advancement catheter is further withdrawn, the proximal anchor also would deploy within the right ventricle RV adjacent to the septal wall SW. The tightening device could then be used to advance the position of the proximal anchor to a desired position against the septal wall SW, as shown in FIG. 30. Alternatively, the delivery catheter itself could be used to advance the deployed proximal anchor to the desired position. Once the proximal anchor is positioned to its appropriate location, any excess tension member length extending beyond the proximal anchor may be severed in a manner similar to that described above in connection with FIG. 9. [0100]
  • In the alternative case where proximal anchor is pre-attached at a specified distance from the distal anchor, the left ventricle should be deformed prior to the pad deployment. The delivery catheter can act as a temporary proximal anchor, while the tension member and distal anchor are pulled proximally. Once the proper shape change of the left ventricle is attained, the proximal anchor may be deployed upon further retraction of the sheath of the splint advancement catheter. In this embodiment, preferably the distance between the distal and proximal anchors will be selected prior to delivery such that a desired shape change of the heart chamber may be obtained, since the adjustability of the shape change will be limited by the fixed position of the proximal anchor on the tension member. The delivery catheter may then be removed and excess tension member severed, again as described with reference to FIG. 9. [0101]
  • While the splint delivery methods and devices just described in connection with FIGS. 23-30 were in the context of a right ventricle approach, it is also contemplated to utilize the delivery devices and methods in a direct left ventricle approach as well. In a direct left ventricle approach, two delivery catheters simultaneously could be utilized to position a splint from within the left ventricle in manners similar to those described with reference to FIGS. 17-22. [0102]
  • Other embodiments of a deployable, fixed heart-engaging assembly, or anchor, also are contemplated as within the scope of the present invention and are shown in FIGS. 32-35. A preferred tension member used in the various embodiments of the present invention is described in the '049 application, incorporated by reference above, and is formed of several multifilament bundles of a high strength polymer. These bundles are braided together in a relatively tight configuration. Certain combinations of bundle size, number of bundles, and pick count, described in more detail in the '049 application, result in a braid with several preferred properties as also described in the '049 application, incorporated by reference above. One property that may result from such a braid construction includes a relatively stable braid diameter that does not deform to a great extent if subjected to axial compression or internal radially-outward directed forces. However, a braid formed with a lower pick count has a greater diametric expandability when subjected to such forces. For example, a braid woven of the same material and having approximately 16 to approximately 64 bundles and approximately 2 to approximately 15 picks per inch may more readily expand in diameter, upon the application of a radial force directed outwardly from within the braid. This expandable property of a braid can be utilized in the formation of yet another alternative deployable anchor structure. [0103]
  • For example, FIG. 32 is a relatively simplified schematic illustrating a [0104] tension member 50 formed of a braid of relatively low pick count in its natural (i.e., non-stressed) as-braided condition. The braid is uniformly relatively small in outer diameter D1. When the braid is under tension, and absent any other deforming forces, the diameter D1 of the braid remains relatively small. FIG. 33 illustrates the same braided tension member 50 as in FIG. 32, but shows the braid with a local application of an outward radially directed force from within the braid. Since the braid pick count is relatively low, the braid has the capacity to expand at the point of application of the radial force to a diameter D2, which is several times its original diameter D1.
  • FIG. 34 shows a [0105] tension member 340 having a braid configuration such as that shown in FIGS. 32 and 33 utilized for an integral expandable distal anchor 342 of tension member 340. At least a portion of the tension member 340 is woven at a relatively low pick count to allow for that portion to form into the expandable distal anchor 342. Alternatively, the entire tension member 340 can be uniformly woven at the relatively low pick count. Several methods for creating an outward radial force from within the braid to form anchor 342 are contemplated. These methods include using an elastic or shape memory wire disposed inside the braid of tension member 340 during placement across the ventricular wall HW. A preferred wire 345 is shown in FIG. 34a. Note that it is contemplated that the direction of spiral of the wire can be opposite to that shown in FIG. 34a, as shown in FIG. 34b. Wire 345 preferably has a natural shape in the form of a disc-shaped spiral. When tension member 340 is delivered using a splint advancement catheter of the types described above, the spiral will have a straightened configuration. Upon removal of the of the splint advancement catheter from the portion of the tension member 340 which will form the distal anchor 342, however, the spiral shape of wire 34 may be re-established, thereby forcing the braided portion surrounding it to expand in diameter into a disc-like shape, as shown in FIG. 34. The wire may either be pre-loaded into the tension member or may be advanced into the tension member once the tension member has been positioned with respect to the heart wall and the catheter has been retracted enough to expose a portion of the tension member that is outside the heart wall HW. The force of the catheter on the wire keeps the wire in its straightened configuration. The smaller diameter portion of the spiral forms first, and as more of the wire is advanced through the tension member beyond the catheter, the spiral grows in diameter until the full spiral is re-established. Alternatively, as shown in FIG. 34b, the large diameter portion of the spiral may form first, as the wire 345′ is advanced. To help prevent wire 345 from penetrating through the interstices of the braid of tension member 340, a thin membrane, preferably made of an elastic material for example, is disposed along the inside of the braid in the area where the spiral portion of wire 345 is positioned.
  • In this embodiment, [0106] wire 345, particularly in the spiral region, preferably will remain together with the braid of tension member 340 even after diametric expansion in order provide the anchoring rigidity needed to secure the splint in place on the heart. Initially, the spiral portion of wire 345 may carry a significant portion of the load of anchor 342. However, it is anticipated that over time, the expanded braid forming anchor 342 would become ingrown with scar tissue, and therefore a relatively large portion of the chronic mechanical loading may be carried by the filaments of the braid. Using filaments of ultra-high molecular weight polyethylene has been shown to produce a tension member and anchor having high strength and high fatigue resistance. A portion of the wire that does not form the spiral may be removed, for example by torquing the wire and breaking it at a location slightly proximal to the spiral.
  • To prevent any of the braided portion distal of the expanded region from “creeping” back over the spiral region, the distal most region of the braid preferably is either fused or banded. This will prevent expansibility in those regions. Alternatively, those regions of the braided tension member could be woven with a higher pick count. [0107]
  • An alternative device for causing expansion of an expandable braid portion of a [0108] tension member 540 includes an inflatable balloon disposed inside braided tension member at the expandable portion forming the anchor, as shown in FIG. 35. Inflatable balloon 545 can be positioned in the desired location within tension member 540 either before advancement of the tension member across the ventricular wall, or after, as shown in FIG. 35. Preferably, balloon 545 is formed of an elastomeric material such as silicone or urethane, or the like, and has a disc-like shape upon expansion. A lumen 543 connecting the interior of balloon 545 to an inflation device (not shown) may extend along the inside of braided tension member 540. In a preferred embodiment, the material used to expand balloon 545, and thus the region of the braided tension member 540 forming distal, deployable anchor 542, includes a curable material such as RTV silicone, epoxy, urethane, or the like. Similar to the spiral anchor embodiment discussed above, the cured material forming the balloon may carry a significant load initially, but upon ingrowth of the expanded braided region of the tension member, the filaments of the braid would be the primary chronic load carrying members.
  • One of ordinary skill in the art would recognize that the alternative distal anchors described above could be utilized in conjunction with any of the delivery techniques of the present invention and could be used as either the free wall anchor or septal wall anchor with modifications as necessary. [0109]
  • Another alternative embodiment for an expandable anchor would utilize an anchor similar to the expandable tab anchor described above with reference to FIGS. 29-31. However, in this embodiment, that anchor would be merely temporary, and could be designed to be relatively small and low profile, for easy delivery, but may not have the adequate strength and durability to be a permanent chronic anchor. In this case, a permanent anchor, similar to the adjustable pad anchor assembly described in the '049 application incorporated above could be delivered as a replacement to that temporary anchor. Once the temporary anchor is positioned, as shown in FIG. 29, a small surgical incision may be made between the ribs adjacent the free wall HW of the left ventricle LV, thus creating an access port to deliver the permanent anchor. Alternatively, a trocar may be positioned in that same location. A snare device positioned within the port or trocar can be used to grab the temporary anchor and tension member and pull the anchor off of the tension member and outside of the patient. An adjustable anchor pad as described in the '049 application and similar to the description of FIGS. 7 and 8 above then may be attached to the braid outside of the patient, using the staple methodology described previously with reference to FIG. 8 and the '049 application. The anchor can then be pulled back into position by retracting the other end of the tension member via the length of the tension member that remains outside the jugular vein. The septal wall anchor in this case preferably would be in the form of the solid anchor and delivered in the manner described above in conjunction with FIGS. 7-10. Overall, this procedure would be a combination endovascular and “minimally invasive” surgical operation. In this embodiment, preferably both anchor pads would be of a solid type construction. [0110]
  • An alternative proximal anchor also may utilize the expandable capability of a relatively low pick count braid, in a manner similar to that described above for the distal, or free wall, anchor. In this embodiment, the entire braid of the tension member preferably includes the relatively low pick count permitting diametric expansion. The tension member and distal anchor could be delivered using any of the approaches described herein, but preferably one of the right ventricle approach methods. After the distal, or free wall, anchor is delivered, the proper ventricle shape change can be induced using a tightening device in the form of a simple tube, such as the one described above, but without the anchor shown in FIG. 8. A balloon or spiral wire type of expander device as described in connection with the distal anchors shown in FIGS. 34, 34[0111] a, and 35, may be positioned in the proper location and caused to expand a portion of the braid external to the septal wall. If a balloon type expansion device is used, it may also include a detachable inflation tube, such that when the balloon is inflated with a curable material, the inflation tube can be removed prior to the excess tension member length being severed. It is also contemplated that such an expandable proximal anchor can be secured to the end of the tension member at a location adjacent to an exterior surface of a heart wall other than the septal wall, such as a wall surrounding the right ventricle, for example.
  • The methods described above to place the splint assemblies with respect to the heart can be repeated for any desired number of splint assemblies to achieve a particular configuration. The length of the tension members extending between the free wall and septal wall anchors also can be optimally determined based upon the size and condition of the patient's heart. It should also be noted that although the left ventricle has been referred to here for illustrative purposes, the apparatus and methods of this invention can be used to splint multiple chambers of a patient's heart, including the right ventricle or either atrium, or can be used to aid the function of valves, such as the mitral valve. An example of a preferred position of a [0112] splint assembly 1000 improves mitral valve function, as well as reducing stress in the left ventricular walls. The valve function is improved by aiding in the apposition of valve leaflets when positioned as shown in FIG. 37. Preferably, three splints are placed in a coplanar fashion, bisecting the left ventricle LV of the heart. The superior-most splint 1000 is placed at approximately the level of the heads of the papillary muscles PM, and the additional two splints (not shown in FIG. 37) are placed inferiorly toward the apex. The preferred orientation shown in FIG. 37 both bisects the left ventricle LV and avoids key structures such as coronary vessels and the like. The splints according to this orientation also extend through the septum SW and enter a portion of the right ventricle RV. In the preferred placement, as with those described above, heart-engaging assemblies 1002, 1003 will be positioned adjacent an exterior surface of a free wall HW surrounding the left ventricle LV and adjacent an exterior surface of the septal wall SW within the right ventricle RV. Further details regarding splinting devices and methods for treating heart valves can be found in the application entitled “Methods and Devices for Improving Mitral Valve Function,” to Richard F. Schroeder et al., filed on a date even herewith and incorporated by reference above. Although any of the delivery methods described above could be used to implant the splint device in this manner, FIG. 36 shows a short axis cross-section of a heart and a preferred endovascular technique wherein the elongate tension member 1001 having a deployable fixed anchor 1002 on its distal end is delivered through the right ventricle RV and then into the left ventricle LV.
  • Furthermore, the alignments of the splints with respect to the heart that are described above are illustrative only and may be shifted or rotated about a vertical axis generally disposed through the left ventricle and still avoid the major coronary vessels and papillary muscles. In addition, the inventive devices and methods can be implanted to treat a heart having aneurysms or infarcted regions similar to those described in prior U.S. application Ser. No. 09/422,328 discussed earlier herein and incorporated above. [0113]
  • The various components of the splint assembly to be implanted in the heart should be made of biocompatible material that can remain in the human body indefinitely. Any surface engaging portions of the heart should be atraumatic in order to avoid tissue damage and preferably formed of a material promoting tissue ingrowth to stabilize the anchor pad with respect to the surfaces of the heart. [0114]
  • It will be understood that this disclosure, in many respects, is only illustrative. Changes may be made in details, particularly in matters of shape, size, material, number and arrangement of parts without exceeding the scope of the invention. Accordingly, the scope of the invention is as defined in the language of the appended claims. [0115]
  • Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims. [0116]

Claims (33)

What is claimed is:
1. A method for direct localized therapeutic treatment of myocardial tissue in heart having a pathological condition comprising the steps of:
a. identifying a target region of the myocardium;
b. applying material directly and substantially only to at least a portion of the myocardial tissue of the target region substantially identified in step (a) to physically modify the mechanical properties of said tissue.
2. The method of claim 1 wherein the modified mechanical properties include an increase in systolic performance.
3. The method of claim 1 wherein the modified mechanical properties include substantially no decrease in global diastolic performance.
4. The method of claim 1, wherein the material applied is passive.
5. The method of claim 1, wherein said target region includes a myocardial infarct.
6. The method of claim 1, wherein said target region at least in part underlies the papillary muscles associated with a cardiac valve.
7. The method of claim 6, wherein said cardiac valve is the mitral valve.
8. The method of claim 1, wherein said material applied to the myocardial tissue is a device.
9. The method of claim 1, wherein said material applied to the myocardial tissue comprises a polymer.
10. The method of claim 1, wherein said material applied to the myocardial tissue comprises a bioactive agent.
11. The method of claim 1, wherein said applying step includes employing a catheter.
12. The method of claim 12, wherein said catheter is employed percutaneously.
13. The method of claim 1, wherein said applying step is preceded by performing a mini-thoracotomy.
14. The method of claim 1, wherein said applying step includes applying material intramyocardially.
15. A method for direct localized therapeutic treatment of myocardial tissue in heart having a pathological condition comprising the steps of:
a. identifying a target region of the myocardium;
b. advancing an element across the septum of the heart to deliver material; and
c. applying said material directly and substantially only to at least a portion of the myocardial tissue of the target region substantially identified in step (a) to physically modify the mechanical properties of said tissue.
16. The method of claim 15 wherein the modified mechanical properties include an increase in systolic performance.
17. The method of claim 16 wherein the modified mechanical properties include substantially no decrease in global diastolic performance.
18. The method of claim 15 wherein the material applied is passive.
19. The method of claim 15, wherein said target region includes a myocardial infarct.
20. The method of claim 15 wherein said target region at least in part underlies the papillary muscles associated with a cardiac valve.
21. The method of claim 20 wherein said cardiac valve is the mitral valve.
22. The method of claim 15 wherein said material applied to the myocardial tissue is a device.
23. The method of claim 15 wherein said material applied to the myocardial tissue comprises a polymer.
24. The method of claim 15, wherein said material applied to the myocardial tissue comprises a bioactive agent.
25. The method of claim 15, wherein said applying step includes employing a catheter.
26. The method of claim 25, wherein said catheter is employed percutaneously.
27. The method of claim 15 wherein said applying step is preceded by performing a mini-thoracotomy.
28. The method of claim 15 wherein said applying step includes applying material intramyocardially.
29. The method of claim 15, further comprising the step of performing an additional therapeutic or diagnostic procedure either before or after said applying step employing access to the heart gained during said advancing step.
30. The method of claim 29, wherein said additional therapeutic or diagnostic procedure is one or more procedures selected from the set consisting of pressure monitoring, angiography, ablation, placement of pacing leads, electrophysiology mapping, and placement of LVAD cannulae.
31. The method of claim 15, wherein said advancing step comprises advancing an element across the atrial septum of the heart.
32. The method of claim 15, wherein said advancing step comprises advancing an element across the ventricular septum of the heart.
33. The method of claim 15, wherein said advancing step comprises advancing an element across both the atrial and ventricular septa of the heart.
US10/735,269 2000-10-06 2003-12-12 Endovascular splinting devices and methods Abandoned US20040225304A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/735,269 US20040225304A1 (en) 2000-10-06 2003-12-12 Endovascular splinting devices and methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/679,550 US6616684B1 (en) 2000-10-06 2000-10-06 Endovascular splinting devices and methods
US10/410,279 US20030181928A1 (en) 2000-10-06 2003-04-10 Endovascular splinting devices and methods
US10/735,269 US20040225304A1 (en) 2000-10-06 2003-12-12 Endovascular splinting devices and methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/410,279 Continuation US20030181928A1 (en) 2000-10-06 2003-04-10 Endovascular splinting devices and methods

Publications (1)

Publication Number Publication Date
US20040225304A1 true US20040225304A1 (en) 2004-11-11

Family

ID=24727366

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/679,550 Expired - Lifetime US6616684B1 (en) 2000-10-06 2000-10-06 Endovascular splinting devices and methods
US10/410,279 Abandoned US20030181928A1 (en) 2000-10-06 2003-04-10 Endovascular splinting devices and methods
US10/735,269 Abandoned US20040225304A1 (en) 2000-10-06 2003-12-12 Endovascular splinting devices and methods
US11/543,892 Abandoned US20070055303A1 (en) 2000-10-06 2006-10-06 Endovascular splinting devices and methods

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/679,550 Expired - Lifetime US6616684B1 (en) 2000-10-06 2000-10-06 Endovascular splinting devices and methods
US10/410,279 Abandoned US20030181928A1 (en) 2000-10-06 2003-04-10 Endovascular splinting devices and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/543,892 Abandoned US20070055303A1 (en) 2000-10-06 2006-10-06 Endovascular splinting devices and methods

Country Status (6)

Country Link
US (4) US6616684B1 (en)
EP (3) EP1322259B1 (en)
AT (1) ATE326921T1 (en)
AU (1) AU2001294921A1 (en)
DE (1) DE60119944T2 (en)
WO (1) WO2002030335A2 (en)

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040260317A1 (en) * 2003-06-20 2004-12-23 Elliot Bloom Tensioning device, system, and method for treating mitral valve regurgitation
US20050288613A1 (en) * 2004-06-25 2005-12-29 Cardiac Pacemakers, Inc. Endocardial splint and method therefor
US20060089711A1 (en) * 2004-10-27 2006-04-27 Medtronic Vascular, Inc. Multifilament anchor for reducing a compass of a lumen or structure in mammalian body
US20060106403A1 (en) * 2004-11-15 2006-05-18 Laurent Schaller Catheter-based tissue remodeling devices and methods
US20060167494A1 (en) * 2005-01-21 2006-07-27 Loubert Suddaby Aneurysm repair method and apparatus
US20070025009A1 (en) * 2005-07-29 2007-02-01 Fuji Photo Film Co., Ltd. Magnetic recorder
US20070049971A1 (en) * 2005-06-09 2007-03-01 Sing-Fatt Chin Method and apparatus for closing off a portion of a heart ventricle
US20070066863A1 (en) * 2005-08-31 2007-03-22 Medtronic Vascular, Inc. Device for treating mitral valve regurgitation
US20070073274A1 (en) * 2005-08-19 2007-03-29 Sing-Fatt Chin Method and device for treating dysfunctional cardiac tissue
US20070203391A1 (en) * 2006-02-24 2007-08-30 Medtronic Vascular, Inc. System for Treating Mitral Valve Regurgitation
US20070265658A1 (en) * 2006-05-12 2007-11-15 Aga Medical Corporation Anchoring and tethering system
US20080097148A1 (en) * 2004-10-13 2008-04-24 Chf Technologies, Inc. Method and device for percutaneous left ventricular reconstruction
US20080243144A1 (en) * 2006-10-04 2008-10-02 Michael Laufer Methods and systems for manipulating tissue
US20080294251A1 (en) * 2006-09-28 2008-11-27 Bioventrix (A Chf Technologies' Company) Location, time, and/or pressure determining devices, systems, and methods for deployment of lesion-excluding heart implants for treatment of cardiac heart failure and other disease states
US20090093670A1 (en) * 2007-10-03 2009-04-09 Bioventrix (A Chf Technologies, Inc.) Treating Dysfunctional Cardiac Tissue
US20100016655A1 (en) * 2008-07-21 2010-01-21 Bio Ventrix (a CHF Technologies, Inc. Cardiac Anchor Structures, Methods, and Systems for Treatment of Congestive Heart Failure and Other Conditions
US20110160750A1 (en) * 2005-08-19 2011-06-30 BioVentrix (a CHF Technologies Company) Steerable Lesion Excluding Heart Implants For Congestive Heart Failure
US8092363B2 (en) 2007-09-05 2012-01-10 Mardil, Inc. Heart band with fillable chambers to modify heart valve function
US8092367B2 (en) 2001-09-07 2012-01-10 Mardil, Inc. Method for external stabilization of the base of the heart
US20120172931A1 (en) * 2009-06-21 2012-07-05 Aesthetics Point Ltd. implanted medical device useful for cosmetic surgery
US8333777B2 (en) 2005-04-22 2012-12-18 Benvenue Medical, Inc. Catheter-based tissue remodeling devices and methods
US20130090672A1 (en) * 2011-09-30 2013-04-11 Bioventrix, Inc. Cardiac implant migration inhibiting systems
US8465500B2 (en) 2005-01-21 2013-06-18 Mayo Foundation For Medical Education And Research Thorascopic heart valve repair method and apparatus
US8636639B2 (en) 2006-09-28 2014-01-28 Bioventrix, Inc. Signal transmitting and lesion excluding heart implants for pacing, defibrillating, and/or sensing of heart beat
US8758393B2 (en) 2007-10-18 2014-06-24 Neochord, Inc. Minimally invasive repair of a valve leaflet in a beating heart
USD717954S1 (en) 2013-10-14 2014-11-18 Mardil, Inc. Heart treatment device
US9044221B2 (en) 2010-12-29 2015-06-02 Neochord, Inc. Exchangeable system for minimally invasive beating heart repair of heart valve leaflets
WO2016059638A1 (en) * 2014-10-14 2016-04-21 Transseptal Solutions Ltd. Fossa ovalis penetration
US9370425B2 (en) 2012-10-12 2016-06-21 Mardil, Inc. Cardiac treatment system and method
US9545265B2 (en) 2013-04-15 2017-01-17 Transseptal Solutions Ltd. Fossa ovalis penetration using balloons
US9668674B2 (en) 2015-03-03 2017-06-06 Transseptal Solutions Ltd. Measurement of appendage openings
EP3060172A4 (en) * 2013-10-23 2017-07-05 LC Therapeutics, Inc. Percutaneous or minimally invasive cardiac valve repair system and methods of using the same
US9700351B2 (en) 2013-04-15 2017-07-11 Transseptal Solutions Ltd. Fossa ovalis penetration
US9706982B2 (en) 2015-03-03 2017-07-18 Transseptal Solutions Ltd. Treatment of appendage openings
US9737403B2 (en) 2006-03-03 2017-08-22 Mardil, Inc. Self-adjusting attachment structure for a cardiac support device
US9788858B2 (en) 2013-04-15 2017-10-17 Transseptal Solutions Ltd. Fossa ovalis penetration using probing elements
US10206779B2 (en) 2015-09-10 2019-02-19 Bioventrix, Inc. Systems and methods for deploying a cardiac anchor
US10314498B2 (en) 2013-05-24 2019-06-11 Bioventrix, Inc. Cardiac tissue penetrating devices, methods, and systems for treatment of congestive heart failure and other conditions
US10398503B2 (en) 2015-10-14 2019-09-03 Transseptal Soulutions Ltd. Fossa ovalis penetration
US10441266B2 (en) 2017-03-01 2019-10-15 4Tech Inc. Post-implantation tension adjustment in cardiac implants
US10575953B2 (en) 2013-08-30 2020-03-03 Bioventrix, Inc. Heart anchor positioning devices, methods, and systems for treatment of congestive heart failure and other conditions
US10588613B2 (en) 2013-08-30 2020-03-17 Bioventrix, Inc. Cardiac tissue anchoring devices, methods, and systems for treatment of congestive heart failure and other conditions
US10588620B2 (en) 2018-03-23 2020-03-17 Neochord, Inc. Device for suture attachment for minimally invasive heart valve repair
US10682229B2 (en) 2017-02-08 2020-06-16 4Tech Inc. Post-implantation tensioning in cardiac implants
US10695178B2 (en) 2011-06-01 2020-06-30 Neochord, Inc. Minimally invasive repair of heart valve leaflets
US10765517B2 (en) 2015-10-01 2020-09-08 Neochord, Inc. Ringless web for repair of heart valves
US10966709B2 (en) 2018-09-07 2021-04-06 Neochord, Inc. Device for suture attachment for minimally invasive heart valve repair
US11058538B2 (en) 2016-03-10 2021-07-13 Charles Somers Living Trust Synthetic chord for cardiac valve repair applications
US11173030B2 (en) 2018-05-09 2021-11-16 Neochord, Inc. Suture length adjustment for minimally invasive heart valve repair
US11253360B2 (en) 2018-05-09 2022-02-22 Neochord, Inc. Low profile tissue anchor for minimally invasive heart valve repair
US11376126B2 (en) 2019-04-16 2022-07-05 Neochord, Inc. Transverse helical cardiac anchor for minimally invasive heart valve repair
US11478353B2 (en) 2016-01-29 2022-10-25 Bioventrix, Inc. Percutaneous arterial access to position trans-myocardial implant devices and methods
US11589989B2 (en) 2017-03-31 2023-02-28 Neochord, Inc. Minimally invasive heart valve repair in a beating heart
US12121292B2 (en) 2022-04-13 2024-10-22 Transseptal Solutions Ltd. Interatrial septum penetration

Families Citing this family (270)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030216761A1 (en) * 1990-03-27 2003-11-20 Samuel Shiber Guidewire system
US6776754B1 (en) * 2000-10-04 2004-08-17 Wilk Patent Development Corporation Method for closing off lower portion of heart ventricle
US7883539B2 (en) 1997-01-02 2011-02-08 Edwards Lifesciences Llc Heart wall tension reduction apparatus and method
US6050936A (en) 1997-01-02 2000-04-18 Myocor, Inc. Heart wall tension reduction apparatus
FR2768324B1 (en) 1997-09-12 1999-12-10 Jacques Seguin SURGICAL INSTRUMENT FOR PERCUTANEOUSLY FIXING TWO AREAS OF SOFT TISSUE, NORMALLY MUTUALLY REMOTE, TO ONE ANOTHER
US6332893B1 (en) 1997-12-17 2001-12-25 Myocor, Inc. Valve to myocardium tension members device and method
US7491232B2 (en) 1998-09-18 2009-02-17 Aptus Endosystems, Inc. Catheter-based fastener implantation apparatus and methods with implantation force resolution
US6260552B1 (en) * 1998-07-29 2001-07-17 Myocor, Inc. Transventricular implant tools and devices
US20040044350A1 (en) 1999-04-09 2004-03-04 Evalve, Inc. Steerable access sheath and methods of use
US7811296B2 (en) 1999-04-09 2010-10-12 Evalve, Inc. Fixation devices for variation in engagement of tissue
US7226467B2 (en) 1999-04-09 2007-06-05 Evalve, Inc. Fixation device delivery catheter, systems and methods of use
WO2000060995A2 (en) 1999-04-09 2000-10-19 Evalve, Inc. Methods and apparatus for cardiac valve repair
US8216256B2 (en) 1999-04-09 2012-07-10 Evalve, Inc. Detachment mechanism for implantable fixation devices
US10327743B2 (en) 1999-04-09 2019-06-25 Evalve, Inc. Device and methods for endoscopic annuloplasty
US6752813B2 (en) 1999-04-09 2004-06-22 Evalve, Inc. Methods and devices for capturing and fixing leaflets in valve repair
US6626899B2 (en) * 1999-06-25 2003-09-30 Nidus Medical, Llc Apparatus and methods for treating tissue
US20040122456A1 (en) * 2002-12-11 2004-06-24 Saadat Vahid C. Methods and apparatus for gastric reduction
US8257428B2 (en) * 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US8246671B2 (en) 1999-08-09 2012-08-21 Cardiokinetix, Inc. Retrievable cardiac devices
US8377114B2 (en) 1999-08-09 2013-02-19 Cardiokinetix, Inc. Sealing and filling ventricular partitioning devices to improve cardiac function
US8323341B2 (en) 2007-09-07 2012-12-04 Intrinsic Therapeutics, Inc. Impaction grafting for vertebral fusion
WO2009033100A1 (en) 2007-09-07 2009-03-12 Intrinsic Therapeutics, Inc. Bone anchoring systems
US7972337B2 (en) 2005-12-28 2011-07-05 Intrinsic Therapeutics, Inc. Devices and methods for bone anchoring
EP1624832A4 (en) 1999-08-18 2008-12-24 Intrinsic Therapeutics Inc Devices and method for augmenting a vertebral disc nucleus
US7717961B2 (en) 1999-08-18 2010-05-18 Intrinsic Therapeutics, Inc. Apparatus delivery in an intervertebral disc
WO2002054978A2 (en) 1999-08-18 2002-07-18 Intrinsic Orthopedics Inc Devices and method for nucleus pulposus augmentation and retention
US7998213B2 (en) 1999-08-18 2011-08-16 Intrinsic Therapeutics, Inc. Intervertebral disc herniation repair
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
US7862500B2 (en) 2002-08-01 2011-01-04 Cardiokinetix, Inc. Multiple partitioning devices for heart treatment
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US7691144B2 (en) 2003-10-01 2010-04-06 Mvrx, Inc. Devices, systems, and methods for reshaping a heart valve annulus
US20050228422A1 (en) * 2002-11-26 2005-10-13 Ample Medical, Inc. Devices, systems, and methods for reshaping a heart valve annulus, including the use of magnetic tools
WO2004030570A2 (en) * 2002-10-01 2004-04-15 Ample Medical, Inc. Devices for retaining native heart valve leaflet
US20060106278A1 (en) * 2004-05-14 2006-05-18 Ample Medical, Inc. Devices, systems, and methods for reshaping a heart valve annulus, including the use of an adjustable bridge implant system
US20060106279A1 (en) 2004-05-14 2006-05-18 Ample Medical, Inc. Devices, systems, and methods for reshaping a heart valve annulus, including the use of a bridge implant having an adjustable bridge stop
US8956407B2 (en) * 2000-09-20 2015-02-17 Mvrx, Inc. Methods for reshaping a heart valve annulus using a tensioning implant
US20080091264A1 (en) 2002-11-26 2008-04-17 Ample Medical, Inc. Devices, systems, and methods for reshaping a heart valve annulus, including the use of magnetic tools
US20090287179A1 (en) * 2003-10-01 2009-11-19 Ample Medical, Inc. Devices, systems, and methods for reshaping a heart valve annulus, including the use of magnetic tools
WO2004030569A2 (en) * 2002-10-01 2004-04-15 Ample Medical, Inc. Devices, systems, and methods for reshaping a heart valve annulus
US8784482B2 (en) * 2000-09-20 2014-07-22 Mvrx, Inc. Method of reshaping a heart valve annulus using an intravascular device
US6723038B1 (en) 2000-10-06 2004-04-20 Myocor, Inc. Methods and devices for improving mitral valve function
CN100333704C (en) 2001-10-01 2007-08-29 安普尔医药公司 Methods and devices for heart valve treatments
US6575971B2 (en) 2001-11-15 2003-06-10 Quantum Cor, Inc. Cardiac valve leaflet stapler device and methods thereof
US20060292206A1 (en) 2001-11-26 2006-12-28 Kim Steven W Devices and methods for treatment of vascular aneurysms
CA2464048C (en) 2001-11-28 2010-06-15 Lee Bolduc Endovascular aneurysm repair system
US8231639B2 (en) 2001-11-28 2012-07-31 Aptus Endosystems, Inc. Systems and methods for attaching a prosthesis within a body lumen or hollow organ
US20070073389A1 (en) 2001-11-28 2007-03-29 Aptus Endosystems, Inc. Endovascular aneurysm devices, systems, and methods
US9320503B2 (en) 2001-11-28 2016-04-26 Medtronic Vascular, Inc. Devices, system, and methods for guiding an operative tool into an interior body region
US20050177180A1 (en) * 2001-11-28 2005-08-11 Aptus Endosystems, Inc. Devices, systems, and methods for supporting tissue and/or structures within a hollow body organ
US6814743B2 (en) 2001-12-26 2004-11-09 Origin Medsystems, Inc. Temporary seal and method for facilitating anastomosis
US6764510B2 (en) 2002-01-09 2004-07-20 Myocor, Inc. Devices and methods for heart valve treatment
US20030139819A1 (en) * 2002-01-18 2003-07-24 Beer Nicholas De Method and apparatus for closing septal defects
US7048754B2 (en) 2002-03-01 2006-05-23 Evalve, Inc. Suture fasteners and methods of use
US7758582B2 (en) * 2002-06-14 2010-07-20 Smith & Nephew, Inc. Device and methods for placing external fixation elements
US20040133243A1 (en) * 2002-07-26 2004-07-08 Santamore William P. Cardiac rhythm management system with intramural myocardial pacing leads and electrodes
US8172856B2 (en) 2002-08-02 2012-05-08 Cedars-Sinai Medical Center Methods and apparatus for atrioventricular valve repair
US20040044364A1 (en) * 2002-08-29 2004-03-04 Devries Robert Tissue fasteners and related deployment systems and methods
US7083630B2 (en) 2002-08-29 2006-08-01 Scimed Life Systems, Inc. Devices and methods for fastening tissue layers
AU2003277115A1 (en) * 2002-10-01 2004-04-23 Ample Medical, Inc. Device and method for repairing a native heart valve leaflet
US7112219B2 (en) 2002-11-12 2006-09-26 Myocor, Inc. Devices and methods for heart valve treatment
US7481821B2 (en) 2002-11-12 2009-01-27 Thomas J. Fogarty Embolization device and a method of using the same
US6984242B2 (en) * 2002-12-20 2006-01-10 Gore Enterprise Holdings, Inc. Implantable medical device assembly
US20040260382A1 (en) 2003-02-12 2004-12-23 Fogarty Thomas J. Intravascular implants and methods of using the same
EP1608297A2 (en) * 2003-03-18 2005-12-28 St. Jude Medical, Inc. Body tissue remodeling apparatus
US10646229B2 (en) 2003-05-19 2020-05-12 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US20050027309A1 (en) * 2003-06-17 2005-02-03 Samuel Shiber Guidewire system
US20050143768A1 (en) * 2003-06-17 2005-06-30 Samuel Shiber Sleeved guidewire system method of use
US20050177073A1 (en) * 2003-06-17 2005-08-11 Samuel Shiber Guidewire system with a deflectable distal tip
US20050015110A1 (en) 2003-07-18 2005-01-20 Fogarty Thomas J. Embolization device and a method of using the same
US7174222B2 (en) * 2003-09-30 2007-02-06 Cardiac Pacemakers, Inc. Guide wire stylet
US20060276684A1 (en) * 2003-11-07 2006-12-07 Giovanni Speziali Device and method for treating congestive heart failure
US7056286B2 (en) 2003-11-12 2006-06-06 Adrian Ravenscroft Medical device anchor and delivery system
US7976539B2 (en) 2004-03-05 2011-07-12 Hansen Medical, Inc. System and method for denaturing and fixing collagenous tissue
EP1734903B2 (en) * 2004-03-11 2022-01-19 Percutaneous Cardiovascular Solutions Pty Limited Percutaneous heart valve prosthesis
US7942927B2 (en) 2004-03-15 2011-05-17 Baker Medical Research Institute Treating valve failure
US20080091059A1 (en) * 2004-05-14 2008-04-17 Ample Medical, Inc. Devices, systems, and methods for reshaping a heart valve annulus, including the use of a bridge implant having an adjustable bridge stop
JP4774048B2 (en) 2004-05-14 2011-09-14 エヴァルヴ インコーポレイテッド Locking mechanism of fixing device engaged with tissue and tissue engaging method
EP1781179A1 (en) * 2004-07-06 2007-05-09 Baker Medical Research Institute Treating valvular insufficiency
US8052592B2 (en) 2005-09-27 2011-11-08 Evalve, Inc. Methods and devices for tissue grasping and assessment
WO2006037073A2 (en) 2004-09-27 2006-04-06 Evalve, Inc. Methods and devices for tissue grasping and assessment
US20060106420A1 (en) * 2004-11-12 2006-05-18 Medtronic Vascular, Inc. Patch for treating a septal defect
EP3967269A3 (en) * 2005-02-07 2022-07-13 Evalve, Inc. Systems and devices for cardiac valve repair
US8128640B2 (en) 2005-02-07 2012-03-06 Ivy Sports Medicine LLC System and method for all-inside suture fixation for implant attachment and soft tissue repair
CA2595630C (en) 2005-02-07 2016-04-12 Regen Biologics, Inc. System and method for all-inside suture fixation for implant attachment and soft tissue repair
WO2011034628A1 (en) 2005-02-07 2011-03-24 Evalve, Inc. Methods, systems and devices for cardiac valve repair
US7993362B2 (en) * 2005-02-16 2011-08-09 Boston Scientific Scimed, Inc. Filter with positioning and retrieval devices and methods
JP2008534084A (en) * 2005-03-25 2008-08-28 アンプル メディカル, インコーポレイテッド Apparatus, system, and method for reshaping a heart valve annulus
US10219902B2 (en) 2005-03-25 2019-03-05 Mvrx, Inc. Devices, systems, and methods for reshaping a heart valve anulus, including the use of a bridge implant having an adjustable bridge stop
US20060247672A1 (en) * 2005-04-27 2006-11-02 Vidlund Robert M Devices and methods for pericardial access
US9149266B2 (en) 2005-05-20 2015-10-06 Neotract, Inc. Deforming anchor device
US8834492B2 (en) 2005-05-20 2014-09-16 Neotract, Inc. Continuous indentation lateral lobe apparatus and method
US10195014B2 (en) 2005-05-20 2019-02-05 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US7896891B2 (en) 2005-05-20 2011-03-01 Neotract, Inc. Apparatus and method for manipulating or retracting tissue and anatomical structure
US9549739B2 (en) 2005-05-20 2017-01-24 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US10925587B2 (en) 2005-05-20 2021-02-23 Neotract, Inc. Anchor delivery system
US7645286B2 (en) 2005-05-20 2010-01-12 Neotract, Inc. Devices, systems and methods for retracting, lifting, compressing, supporting or repositioning tissues or anatomical structures
US9364212B2 (en) 2005-05-20 2016-06-14 Neotract, Inc. Suture anchoring devices and methods for use
US7758594B2 (en) 2005-05-20 2010-07-20 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US8529584B2 (en) 2005-05-20 2013-09-10 Neotract, Inc. Median lobe band implant apparatus and method
US8603106B2 (en) 2005-05-20 2013-12-10 Neotract, Inc. Integrated handle assembly for anchor delivery system
US9504461B2 (en) 2005-05-20 2016-11-29 Neotract, Inc. Anchor delivery system
US8394113B2 (en) 2005-05-20 2013-03-12 Neotract, Inc. Coiled anchor device
US9034001B2 (en) 2005-05-20 2015-05-19 Neotract, Inc. Slotted anchor device
US8333776B2 (en) 2005-05-20 2012-12-18 Neotract, Inc. Anchor delivery system
US8628542B2 (en) 2005-05-20 2014-01-14 Neotract, Inc. Median lobe destruction apparatus and method
US8425535B2 (en) 2005-05-20 2013-04-23 Neotract, Inc. Multi-actuating trigger anchor delivery system
US8945152B2 (en) 2005-05-20 2015-02-03 Neotract, Inc. Multi-actuating trigger anchor delivery system
US8668705B2 (en) 2005-05-20 2014-03-11 Neotract, Inc. Latching anchor device
US7621866B2 (en) * 2005-05-31 2009-11-24 Ethicon, Inc. Method and device for deployment of a sub-pericardial sack
EP1887981A2 (en) * 2005-06-09 2008-02-20 The University Of Miami Papillary muscle attachement for left ventricular reduction
CA2612130C (en) * 2005-06-30 2014-05-06 Rox Medical, Inc. Devices, systems, and methods for creation of a peripherally located fistula
US8951285B2 (en) 2005-07-05 2015-02-10 Mitralign, Inc. Tissue anchor, anchoring system and methods of using the same
US9492277B2 (en) 2005-08-30 2016-11-15 Mayo Foundation For Medical Education And Research Soft body tissue remodeling methods and apparatus
WO2007028092A1 (en) 2005-09-01 2007-03-08 Cordis Corporation Patent foramen ovale closure method
CN101466316B (en) 2005-10-20 2012-06-27 阿普特斯内系统公司 Devices systems and methods for prosthesis delivery and implantation including the use of a fastener tool
US7632308B2 (en) 2005-11-23 2009-12-15 Didier Loulmet Methods, devices, and kits for treating mitral valve prolapse
US8430863B2 (en) * 2005-12-02 2013-04-30 Abbott Cardiovascular Systems Inc. Visualization of a catheter viewed under ultrasound imaging
US7867169B2 (en) * 2005-12-02 2011-01-11 Abbott Cardiovascular Systems Inc. Echogenic needle catheter configured to produce an improved ultrasound image
US20070265702A1 (en) * 2006-01-27 2007-11-15 Lattouf Omar M Percutaneous treatment for heart valves
US20070225681A1 (en) * 2006-03-21 2007-09-27 Medtronic Vascular Catheter Having a Selectively Formable Distal Section
US20070225759A1 (en) * 2006-03-22 2007-09-27 Daniel Thommen Method for delivering a medical device to the heart of a patient
WO2007136532A2 (en) * 2006-05-03 2007-11-29 St. Jude Medical, Inc. Soft body tissue remodeling methods and apparatus
US7794402B2 (en) * 2006-05-15 2010-09-14 Advanced Cardiovascular Systems, Inc. Echogenic needle catheter configured to produce an improved ultrasound image
US11389232B2 (en) 2006-06-28 2022-07-19 Kardium Inc. Apparatus and method for intra-cardiac mapping and ablation
US10028783B2 (en) 2006-06-28 2018-07-24 Kardium Inc. Apparatus and method for intra-cardiac mapping and ablation
US9119633B2 (en) 2006-06-28 2015-09-01 Kardium Inc. Apparatus and method for intra-cardiac mapping and ablation
US8470025B2 (en) * 2006-11-09 2013-06-25 Contract Medical International Gmbh Cardiovascular procedures
US20080195126A1 (en) * 2007-02-14 2008-08-14 Jan Otto Solem Suture and method for repairing a heart
US11660190B2 (en) 2007-03-13 2023-05-30 Edwards Lifesciences Corporation Tissue anchors, systems and methods, and devices
US8845723B2 (en) 2007-03-13 2014-09-30 Mitralign, Inc. Systems and methods for introducing elements into tissue
US8911461B2 (en) * 2007-03-13 2014-12-16 Mitralign, Inc. Suture cutter and method of cutting suture
US20080228199A1 (en) * 2007-03-16 2008-09-18 Ethicon Endo-Surgery, Inc. Endoscopic tissue approximation method
DE102007043830A1 (en) 2007-09-13 2009-04-02 Lozonschi, Lucian, Madison Heart valve stent
US9125632B2 (en) * 2007-10-19 2015-09-08 Guided Delivery Systems, Inc. Systems and methods for cardiac remodeling
US8906011B2 (en) 2007-11-16 2014-12-09 Kardium Inc. Medical device for use in bodily lumens, for example an atrium
CA2713865C (en) 2008-02-08 2017-06-20 Heartware, Inc. Ventricular assist device for intraventricular placement
WO2009140298A2 (en) * 2008-05-12 2009-11-19 Wright John T M Device and method for the surgical treatment of ischemic mitral regurgitation
US8945211B2 (en) * 2008-09-12 2015-02-03 Mitralign, Inc. Tissue plication device and method for its use
CA2740867C (en) 2008-10-16 2018-06-12 Aptus Endosystems, Inc. Devices, systems, and methods for endovascular staple and/or prosthesis delivery and implantation
EP2358297B1 (en) 2008-11-21 2019-09-11 Percutaneous Cardiovascular Solutions Pty Limited Heart valve prosthesis
EP2633821B1 (en) 2009-09-15 2016-04-06 Evalve, Inc. Device for cardiac valve repair
WO2011056578A2 (en) 2009-10-26 2011-05-12 Cardiokinetix, Inc. Ventricular volume reduction
EP2496189A4 (en) 2009-11-04 2016-05-11 Nitinol Devices And Components Inc Alternating circumferential bridge stent design and methods for use thereof
US9649211B2 (en) 2009-11-04 2017-05-16 Confluent Medical Technologies, Inc. Alternating circumferential bridge stent design and methods for use thereof
EP3649985B8 (en) 2009-12-08 2021-04-21 Avalon Medical Ltd. Device and system for transcatheter mitral valve replacement
US10058323B2 (en) 2010-01-22 2018-08-28 4 Tech Inc. Tricuspid valve repair using tension
US8961596B2 (en) 2010-01-22 2015-02-24 4Tech Inc. Method and apparatus for tricuspid valve repair using tension
US8475525B2 (en) 2010-01-22 2013-07-02 4Tech Inc. Tricuspid valve repair using tension
US9307980B2 (en) 2010-01-22 2016-04-12 4Tech Inc. Tricuspid valve repair using tension
US9107749B2 (en) 2010-02-03 2015-08-18 Edwards Lifesciences Corporation Methods for treating a heart
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
DE102010049455A1 (en) * 2010-10-22 2012-04-26 Igor Nikiforov Instrument for minimally invasive surgery in the field of spinal fusion on the human or animal body
EP2632342B1 (en) * 2010-10-25 2016-10-05 Boston Scientific Scimed, Inc. Fibrous containment for hemostasis plug
US10398445B2 (en) 2011-01-11 2019-09-03 Amsel Medical Corporation Method and apparatus for clamping tissue layers and occluding tubular body structures
US10820895B2 (en) 2011-01-11 2020-11-03 Amsel Medical Corporation Methods and apparatus for fastening and clamping tissue
US11259867B2 (en) 2011-01-21 2022-03-01 Kardium Inc. High-density electrode-based medical device system
US9452016B2 (en) 2011-01-21 2016-09-27 Kardium Inc. Catheter system
CA2764494A1 (en) 2011-01-21 2012-07-21 Kardium Inc. Enhanced medical device for use in bodily cavities, for example an atrium
US9480525B2 (en) 2011-01-21 2016-11-01 Kardium, Inc. High-density electrode-based medical device system
US9161749B2 (en) 2011-04-14 2015-10-20 Neotract, Inc. Method and apparatus for treating sexual dysfunction
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
EP3424468A1 (en) 2011-07-21 2019-01-09 4Tech Inc. Apparatus for tricuspid valve repair using tension
US9480559B2 (en) 2011-08-11 2016-11-01 Tendyne Holdings, Inc. Prosthetic valves and related inventions
US8945177B2 (en) 2011-09-13 2015-02-03 Abbott Cardiovascular Systems Inc. Gripper pusher mechanism for tissue apposition systems
US9827092B2 (en) 2011-12-16 2017-11-28 Tendyne Holdings, Inc. Tethers for prosthetic mitral valve
USD777926S1 (en) * 2012-01-20 2017-01-31 Kardium Inc. Intra-cardiac procedure device
USD777925S1 (en) * 2012-01-20 2017-01-31 Kardium Inc. Intra-cardiac procedure device
US10292801B2 (en) 2012-03-29 2019-05-21 Neotract, Inc. System for delivering anchors for treating incontinence
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
US8961594B2 (en) 2012-05-31 2015-02-24 4Tech Inc. Heart valve repair system
US10130353B2 (en) 2012-06-29 2018-11-20 Neotract, Inc. Flexible system for delivering an anchor
WO2014022124A1 (en) 2012-07-28 2014-02-06 Tendyne Holdings, Inc. Improved multi-component designs for heart valve retrieval device, sealing structures and stent assembly
US9675454B2 (en) 2012-07-30 2017-06-13 Tendyne Holdings, Inc. Delivery systems and methods for transcatheter prosthetic valves
US9788948B2 (en) 2013-01-09 2017-10-17 4 Tech Inc. Soft tissue anchors and implantation techniques
WO2014138482A1 (en) 2013-03-07 2014-09-12 Cedars-Sinai Medical Center Method and apparatus for percutaneous delivery and deployment of a cardiovascular prosthesis
WO2014138284A1 (en) * 2013-03-07 2014-09-12 Cedars-Sinai Medical Center Catheter based apical approach heart prostheses delivery system
US9907681B2 (en) 2013-03-14 2018-03-06 4Tech Inc. Stent with tether interface
US11224510B2 (en) 2013-04-02 2022-01-18 Tendyne Holdings, Inc. Prosthetic heart valve and systems and methods for delivering the same
US9486306B2 (en) 2013-04-02 2016-11-08 Tendyne Holdings, Inc. Inflatable annular sealing device for prosthetic mitral valve
US10463489B2 (en) 2013-04-02 2019-11-05 Tendyne Holdings, Inc. Prosthetic heart valve and systems and methods for delivering the same
US10478293B2 (en) 2013-04-04 2019-11-19 Tendyne Holdings, Inc. Retrieval and repositioning system for prosthetic heart valve
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
CN105358074A (en) 2013-05-07 2016-02-24 阿姆泽尔医药公司 Method and apparatus for occluding a blood vessel and/or securing two objects together
US9610159B2 (en) 2013-05-30 2017-04-04 Tendyne Holdings, Inc. Structural members for prosthetic mitral valves
WO2014210124A1 (en) 2013-06-25 2014-12-31 Mark Christianson Thrombus management and structural compliance features for prosthetic heart valves
JP6465883B2 (en) 2013-08-01 2019-02-06 テンダイン ホールディングス,インコーポレイテッド Epicardial anchor device and method
US10070857B2 (en) 2013-08-31 2018-09-11 Mitralign, Inc. Devices and methods for locating and implanting tissue anchors at mitral valve commissure
WO2015058039A1 (en) 2013-10-17 2015-04-23 Robert Vidlund Apparatus and methods for alignment and deployment of intracardiac devices
ES2773255T3 (en) 2013-10-28 2020-07-10 Tendyne Holdings Inc Prosthetic heart valve and systems to supply it
US9526611B2 (en) 2013-10-29 2016-12-27 Tendyne Holdings, Inc. Apparatus and methods for delivery of transcatheter prosthetic valves
US10052095B2 (en) 2013-10-30 2018-08-21 4Tech Inc. Multiple anchoring-point tension system
EP3062709A2 (en) 2013-10-30 2016-09-07 4Tech Inc. Multiple anchoring-point tension system
US10022114B2 (en) 2013-10-30 2018-07-17 4Tech Inc. Percutaneous tether locking
WO2015120122A2 (en) 2014-02-05 2015-08-13 Robert Vidlund Apparatus and methods for transfemoral delivery of prosthetic mitral valve
US9986993B2 (en) 2014-02-11 2018-06-05 Tendyne Holdings, Inc. Adjustable tether and epicardial pad system for prosthetic heart valve
CA2937566C (en) 2014-03-10 2023-09-05 Tendyne Holdings, Inc. Devices and methods for positioning and monitoring tether load for prosthetic mitral valve
US10390943B2 (en) 2014-03-17 2019-08-27 Evalve, Inc. Double orifice device for transcatheter mitral valve replacement
US9572666B2 (en) 2014-03-17 2017-02-21 Evalve, Inc. Mitral valve fixation device removal devices and methods
JP6559161B2 (en) * 2014-06-19 2019-08-14 4テック インコーポレイテッド Tightening heart tissue
US10799359B2 (en) 2014-09-10 2020-10-13 Cedars-Sinai Medical Center Method and apparatus for percutaneous delivery and deployment of a cardiac valve prosthesis
US10751183B2 (en) 2014-09-28 2020-08-25 Edwards Lifesciences Corporation Apparatuses for treating cardiac dysfunction
US10758265B2 (en) 2014-11-14 2020-09-01 Cedars-Sinai Medical Center Cardiovascular access and device delivery system
US9907547B2 (en) 2014-12-02 2018-03-06 4Tech Inc. Off-center tissue anchors
US10188392B2 (en) 2014-12-19 2019-01-29 Abbott Cardiovascular Systems, Inc. Grasping for tissue repair
EP3242630A2 (en) 2015-01-07 2017-11-15 Tendyne Holdings, Inc. Prosthetic mitral valves and apparatus and methods for delivery of same
EP3884906A1 (en) 2015-02-05 2021-09-29 Tendyne Holdings, Inc. Expandable epicardial pads and devices and methods for delivery of same
WO2016144391A1 (en) 2015-03-11 2016-09-15 Mvrx, Inc. Devices, systems, and methods for reshaping a heart valve annulus
US10524912B2 (en) 2015-04-02 2020-01-07 Abbott Cardiovascular Systems, Inc. Tissue fixation devices and methods
AU2016248314B2 (en) 2015-04-16 2020-05-21 Tendyne Holdings, Inc. Apparatus and methods for delivery, repositioning, and retrieval of transcatheter prosthetic valves
US10376673B2 (en) 2015-06-19 2019-08-13 Evalve, Inc. Catheter guiding system and methods
US10238494B2 (en) 2015-06-29 2019-03-26 Evalve, Inc. Self-aligning radiopaque ring
US10667815B2 (en) 2015-07-21 2020-06-02 Evalve, Inc. Tissue grasping devices and related methods
EP3324855B1 (en) 2015-07-23 2024-03-20 Cedars-Sinai Medical Center Device for securing heart valve leaflets
US10413408B2 (en) 2015-08-06 2019-09-17 Evalve, Inc. Delivery catheter systems, methods, and devices
US10327894B2 (en) 2015-09-18 2019-06-25 Tendyne Holdings, Inc. Methods for delivery of prosthetic mitral valves
US10238495B2 (en) 2015-10-09 2019-03-26 Evalve, Inc. Delivery catheter handle and methods of use
US10463492B2 (en) 2015-11-17 2019-11-05 Edwards Lifesciences Corporation Systems and devices for setting an anchor
JP2018535754A (en) 2015-12-03 2018-12-06 テンダイン ホールディングス,インコーポレイテッド Frame features for artificial mitral valves
CA3006662C (en) 2015-12-10 2023-12-19 Mvrx, Inc. Devices, systems, and methods for reshaping a heart valve annulus
JP7002451B2 (en) 2015-12-15 2022-01-20 ニオバスク ティアラ インコーポレイテッド Transseptal delivery system
JP6795591B2 (en) 2015-12-28 2020-12-02 テンダイン ホールディングス,インコーポレイテッド Atrial pocket closure for artificial heart valve
WO2017127939A1 (en) 2016-01-29 2017-08-03 Neovasc Tiara Inc. Prosthetic valve for avoiding obstruction of outflow
US10470877B2 (en) 2016-05-03 2019-11-12 Tendyne Holdings, Inc. Apparatus and methods for anterior valve leaflet management
US10932769B2 (en) 2016-05-26 2021-03-02 Ivy Sports Medicine, Llc System and method for all-inside suture fixation for implant attachment and soft tissue repair
WO2017218375A1 (en) 2016-06-13 2017-12-21 Tendyne Holdings, Inc. Sequential delivery of two-part prosthetic mitral valve
US11090157B2 (en) 2016-06-30 2021-08-17 Tendyne Holdings, Inc. Prosthetic heart valves and apparatus and methods for delivery of same
US10736632B2 (en) 2016-07-06 2020-08-11 Evalve, Inc. Methods and devices for valve clip excision
EP3484411A1 (en) 2016-07-12 2019-05-22 Tendyne Holdings, Inc. Apparatus and methods for trans-septal retrieval of prosthetic heart valves
US11071564B2 (en) 2016-10-05 2021-07-27 Evalve, Inc. Cardiac valve cutting device
US10363138B2 (en) 2016-11-09 2019-07-30 Evalve, Inc. Devices for adjusting the curvature of cardiac valve structures
US10398553B2 (en) 2016-11-11 2019-09-03 Evalve, Inc. Opposing disk device for grasping cardiac valve tissue
US10426616B2 (en) 2016-11-17 2019-10-01 Evalve, Inc. Cardiac implant delivery system
CN113893064A (en) 2016-11-21 2022-01-07 内奥瓦斯克迪亚拉公司 Methods and systems for rapid retrieval of transcatheter heart valve delivery systems
US10779837B2 (en) 2016-12-08 2020-09-22 Evalve, Inc. Adjustable arm device for grasping tissues
US10314586B2 (en) 2016-12-13 2019-06-11 Evalve, Inc. Rotatable device and method for fixing tricuspid valve tissue
JP7280194B2 (en) 2017-01-25 2023-05-23 セダーズ-シナイ メディカル センター A device that secures the heart valve leaflets
US10898330B2 (en) 2017-03-28 2021-01-26 Edwards Lifesciences Corporation Positioning, deploying, and retrieving implantable devices
US11065119B2 (en) 2017-05-12 2021-07-20 Evalve, Inc. Long arm valve repair clip
US10542941B2 (en) * 2017-06-05 2020-01-28 Biosense Webster (Israel) Ltd. Integrated assessment of electrical activation and myocardial strain
US11154399B2 (en) 2017-07-13 2021-10-26 Tendyne Holdings, Inc. Prosthetic heart valves and apparatus and methods for delivery of same
US10856984B2 (en) 2017-08-25 2020-12-08 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
EP3675774B1 (en) 2017-08-28 2023-06-21 Tendyne Holdings, Inc. Prosthetic heart valves with tether coupling features
US10806579B2 (en) 2017-10-20 2020-10-20 Boston Scientific Scimed, Inc. Heart valve repair implant for treating tricuspid regurgitation
CN109745149B (en) * 2017-11-07 2024-09-20 深圳市健心医疗科技有限公司 Heart valve anchoring device and heart valve
US11135062B2 (en) 2017-11-20 2021-10-05 Valtech Cardio Ltd. Cinching of dilated heart muscle
WO2019126718A1 (en) 2017-12-23 2019-06-27 Neotract, Inc. Expandable tissue engagement apparatus and method
WO2019152598A2 (en) 2018-02-02 2019-08-08 Cedars-Sinai Medical Center Delivery platforms, devices, and methods for tricuspid valve repair
US12102531B2 (en) 2018-10-22 2024-10-01 Evalve, Inc. Tissue cutting systems, devices and methods
CN113271890B (en) 2018-11-08 2024-08-30 内奥瓦斯克迪亚拉公司 Ventricular deployment of transcatheter mitral valve prosthesis
AU2020233892A1 (en) 2019-03-08 2021-11-04 Neovasc Tiara Inc. Retrievable prosthesis delivery system
WO2020206012A1 (en) 2019-04-01 2020-10-08 Neovasc Tiara Inc. Controllably deployable prosthetic valve
WO2020210652A1 (en) 2019-04-10 2020-10-15 Neovasc Tiara Inc. Prosthetic valve with natural blood flow
CN114025813B (en) 2019-05-20 2024-05-14 内奥瓦斯克迪亚拉公司 Introducer with hemostatic mechanism
WO2020257643A1 (en) 2019-06-20 2020-12-24 Neovasc Tiara Inc. Low profile prosthetic mitral valve
JP7543391B2 (en) 2019-07-15 2024-09-02 エバルブ,インコーポレイティド Method of Actuating Individual Proximal Elements
EP3831343B1 (en) 2019-12-05 2024-01-31 Tendyne Holdings, Inc. Braided anchor for mitral valve
US11648114B2 (en) 2019-12-20 2023-05-16 Tendyne Holdings, Inc. Distally loaded sheath and loading funnel
US11951002B2 (en) 2020-03-30 2024-04-09 Tendyne Holdings, Inc. Apparatus and methods for valve and tether fixation
US12048448B2 (en) 2020-05-06 2024-07-30 Evalve, Inc. Leaflet grasping and cutting device
US20220031358A1 (en) 2020-08-03 2022-02-03 Neotract, Inc. Handle and cartridge system for medical interventions
US11857417B2 (en) 2020-08-16 2024-01-02 Trilio Medical Ltd. Leaflet support
US11678980B2 (en) 2020-08-19 2023-06-20 Tendyne Holdings, Inc. Fully-transseptal apical pad with pulley for tensioning
US11129701B1 (en) * 2021-03-11 2021-09-28 Steve A. Haworth Lip implant and associated surgical method
WO2023009368A1 (en) * 2021-07-28 2023-02-02 Edwards Lifesciences Corporation Balloon epicardial anchor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5634936A (en) * 1995-02-06 1997-06-03 Scimed Life Systems, Inc. Device for closing a septal defect
US5855614A (en) * 1993-02-22 1999-01-05 Heartport, Inc. Method and apparatus for thoracoscopic intracardiac procedures

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3019790A (en) * 1960-07-15 1962-02-06 Robert J Militana Combination hemostat and intravenous needle
NL143127B (en) * 1969-02-04 1974-09-16 Rhone Poulenc Sa REINFORCEMENT DEVICE FOR A DEFECTIVE HEART VALVE.
US4192293A (en) * 1978-09-05 1980-03-11 Manfred Asrican Cardiac assist device
ES474582A1 (en) * 1978-10-26 1979-11-01 Aranguren Duo Iker Process for installing mitral valves in their anatomical space by attaching cords to an artificial stent
US4372293A (en) * 1980-12-24 1983-02-08 Vijil Rosales Cesar A Apparatus and method for surgical correction of ptotic breasts
US4579120A (en) * 1982-09-30 1986-04-01 Cordis Corporation Strain relief for percutaneous lead
US4592342A (en) * 1983-05-02 1986-06-03 Salmasian Samuel S Method for appetite suppression and weight loss maintenance and device
US5104392A (en) * 1985-03-22 1992-04-14 Massachusetts Institute Of Technology Laser spectro-optic imaging for diagnosis and treatment of diseased tissue
US4690134A (en) 1985-07-01 1987-09-01 Snyders Robert V Ventricular assist device
US4705040A (en) 1985-11-18 1987-11-10 Medi-Tech, Incorporated Percutaneous fixation of hollow organs
SU1604377A1 (en) * 1987-02-23 1990-11-07 Благовещенский государственный медицинский институт Artificial pericardium
CA2330419C (en) 1989-02-13 2001-11-27 Baxter International Inc. Selectively flexible annuloplasty ring
US4991578A (en) * 1989-04-04 1991-02-12 Siemens-Pacesetter, Inc. Method and system for implanting self-anchoring epicardial defibrillation electrodes
US5290300A (en) 1989-07-31 1994-03-01 Baxter International Inc. Flexible suture guide and holder
US4997431A (en) * 1989-08-30 1991-03-05 Angeion Corporation Catheter
US5389096A (en) * 1990-12-18 1995-02-14 Advanced Cardiovascular Systems System and method for percutaneous myocardial revascularization
CA2059245C (en) * 1991-02-08 2004-07-06 Michael P. Chesterfield Method and apparatus for calendering and coating/filling sutures
US5300087A (en) * 1991-03-22 1994-04-05 Knoepfler Dennis J Multiple purpose forceps
DK168419B1 (en) * 1991-11-25 1994-03-28 Cook Inc A Cook Group Company Abdominal wall support device and apparatus for insertion thereof
US5192314A (en) * 1991-12-12 1993-03-09 Daskalakis Michael K Synthetic intraventricular implants and method of inserting
US5758663A (en) 1992-04-10 1998-06-02 Wilk; Peter J. Coronary artery by-pass method
US5383840A (en) * 1992-07-28 1995-01-24 Vascor, Inc. Biocompatible ventricular assist and arrhythmia control device including cardiac compression band-stay-pad assembly
US5718725A (en) * 1992-12-03 1998-02-17 Heartport, Inc. Devices and methods for intracardiac procedures
US5284488A (en) * 1992-12-23 1994-02-08 Sideris Eleftherios B Adjustable devices for the occlusion of cardiac defects
US5522884A (en) * 1993-02-19 1996-06-04 Medtronic, Inc. Holder for adjustable mitral & tricuspid annuloplasty rings
US5972030A (en) 1993-02-22 1999-10-26 Heartport, Inc. Less-invasive devices and methods for treatment of cardiac valves
DE4306277C2 (en) 1993-03-01 2000-11-02 Leibinger Gmbh Operation marking tool
US5385528A (en) * 1993-06-17 1995-01-31 Wilk; Peter J. Intrapericardial assist device and associated method
US5971911A (en) 1993-06-17 1999-10-26 Wilk; Peter J. Intrapericardial assist device and associated method
US6572529B2 (en) 1993-06-17 2003-06-03 Wilk Patent Development Corporation Intrapericardial assist method
US6258021B1 (en) 1993-06-17 2001-07-10 Peter J. Wilk Intrapericardial assist method
FR2708458B1 (en) * 1993-08-03 1995-09-15 Seguin Jacques Prosthetic ring for cardiac surgery.
US5480424A (en) 1993-11-01 1996-01-02 Cox; James L. Heart valve replacement using flexible tubes
WO1997024083A1 (en) 1993-11-01 1997-07-10 Cox James L Method of replacing heart valves using flexible tubes
US5417709A (en) * 1994-04-12 1995-05-23 Symbiosis Corporation Endoscopic instrument with end effectors forming suction and/or irrigation lumens
US5509428A (en) * 1994-05-31 1996-04-23 Dunlop; Richard W. Method and apparatus for the creation of tricuspid regurgitation
US5695457A (en) * 1994-07-28 1997-12-09 Heartport, Inc. Cardioplegia catheter system
US5593435A (en) * 1994-07-29 1997-01-14 Baxter International Inc. Distensible annuloplasty ring for surgical remodelling of an atrioventricular valve and nonsurgical method for post-implantation distension thereof to accommodate patient growth
US6217610B1 (en) 1994-07-29 2001-04-17 Edwards Lifesciences Corporation Expandable annuloplasty ring
US5593424A (en) * 1994-08-10 1997-01-14 Segmed, Inc. Apparatus and method for reducing and stabilizing the circumference of a vascular structure
JPH08196538A (en) 1994-09-26 1996-08-06 Ethicon Inc Tissue sticking apparatus for surgery with elastomer component and method of attaching mesh for surgery to said tissue
IL115680A (en) * 1994-10-21 1999-03-12 St Jude Medical Rotatable cuff assembly for a heart valve prosthesis
US6132438A (en) * 1995-06-07 2000-10-17 Ep Technologies, Inc. Devices for installing stasis reducing means in body tissue
US5800528A (en) * 1995-06-13 1998-09-01 Abiomed R & D, Inc. Passive girdle for heart ventricle for therapeutic aid to patients having ventricular dilatation
US5713954A (en) * 1995-06-13 1998-02-03 Abiomed R&D, Inc. Extra cardiac ventricular assist device
DE19538796C2 (en) 1995-10-18 1999-09-23 Fraunhofer Ges Forschung Device for supporting the heart function with elastic filling chambers
US5957977A (en) * 1996-01-02 1999-09-28 University Of Cincinnati Activation device for the natural heart including internal and external support structures
US6592619B2 (en) 1996-01-02 2003-07-15 University Of Cincinnati Heart wall actuation device for the natural heart
US6520904B1 (en) * 1996-01-02 2003-02-18 The University Of Cincinnati Device and method for restructuring heart chamber geometry
US6182664B1 (en) 1996-02-19 2001-02-06 Edwards Lifesciences Corporation Minimally invasive cardiac valve surgery procedure
US5800478A (en) * 1996-03-07 1998-09-01 Light Sciences Limited Partnership Flexible microcircuits for internal light therapy
US5853422A (en) * 1996-03-22 1998-12-29 Scimed Life Systems, Inc. Apparatus and method for closing a septal defect
US5738649A (en) * 1996-04-16 1998-04-14 Cardeon Corporation Peripheral entry biventricular catheter system for providing access to the heart for cardiopulmonary surgery or for prolonged circulatory support of the heart
SE510577C2 (en) * 1996-05-08 1999-06-07 Carag Ag Device for implants
US5855601A (en) 1996-06-21 1999-01-05 The Trustees Of Columbia University In The City Of New York Artificial heart valve and method and device for implanting the same
US5972019A (en) * 1996-07-25 1999-10-26 Target Therapeutics, Inc. Mechanical clot treatment device
US5755783A (en) 1996-07-29 1998-05-26 Stobie; Robert Suture rings for rotatable artificial heart valves
US5800531A (en) 1996-09-30 1998-09-01 Baxter International Inc. Bioprosthetic heart valve implantation device
US5702343A (en) * 1996-10-02 1997-12-30 Acorn Medical, Inc. Cardiac reinforcement device
US6123662A (en) * 1998-07-13 2000-09-26 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
BR9712239A (en) 1996-10-18 2000-01-25 Cardio Tech Inc Method and apparatus to assist a heart to pump blood by applying substantially uniform pressure to at least a portion of the ventricles.
EP0839497A1 (en) * 1996-11-01 1998-05-06 EndoSonics Corporation A method for measuring volumetric fluid flow and its velocity profile in a lumen or other body cavity
US6102926A (en) * 1996-12-02 2000-08-15 Angiotrax, Inc. Apparatus for percutaneously performing myocardial revascularization having means for sensing tissue parameters and methods of use
US6206004B1 (en) * 1996-12-06 2001-03-27 Comedicus Incorporated Treatment method via the pericardial space
US6071303A (en) * 1996-12-08 2000-06-06 Hearten Medical, Inc. Device for the treatment of infarcted tissue and method of treating infarcted tissue
US5961440A (en) 1997-01-02 1999-10-05 Myocor, Inc. Heart wall tension reduction apparatus and method
US6406420B1 (en) 1997-01-02 2002-06-18 Myocor, Inc. Methods and devices for improving cardiac function in hearts
US6183411B1 (en) 1998-09-21 2001-02-06 Myocor, Inc. External stress reduction device and method
US6077214A (en) * 1998-07-29 2000-06-20 Myocor, Inc. Stress reduction apparatus and method
US6050936A (en) * 1997-01-02 2000-04-18 Myocor, Inc. Heart wall tension reduction apparatus
US6045497A (en) 1997-01-02 2000-04-04 Myocor, Inc. Heart wall tension reduction apparatus and method
US5928281A (en) 1997-03-27 1999-07-27 Baxter International Inc. Tissue heart valves
US5961549A (en) 1997-04-03 1999-10-05 Baxter International Inc. Multi-leaflet bioprosthetic heart valve
US6245102B1 (en) * 1997-05-07 2001-06-12 Iowa-India Investments Company Ltd. Stent, stent graft and stent valve
US6269819B1 (en) * 1997-06-27 2001-08-07 The Trustees Of Columbia University In The City Of New York Method and apparatus for circulatory valve repair
US6338712B2 (en) * 1997-09-17 2002-01-15 Origin Medsystems, Inc. Device to permit offpump beating heart coronary bypass surgery
US6019722A (en) * 1997-09-17 2000-02-01 Guidant Corporation Device to permit offpump beating heart coronary bypass surgery
US6361545B1 (en) * 1997-09-26 2002-03-26 Cardeon Corporation Perfusion filter catheter
US6086532A (en) * 1997-09-26 2000-07-11 Ep Technologies, Inc. Systems for recording use of structures deployed in association with heart tissue
JP2001521790A (en) 1997-11-03 2001-11-13 カーディオ・テクノロジーズ・インコーポレーテッド Method and apparatus for assisting the blood pumping function of the heart
US6174332B1 (en) * 1997-12-05 2001-01-16 St. Jude Medical, Inc. Annuloplasty ring with cut zone
US6332893B1 (en) 1997-12-17 2001-12-25 Myocor, Inc. Valve to myocardium tension members device and method
US6001126A (en) 1997-12-24 1999-12-14 Baxter International Inc. Stentless bioprosthetic heart valve with coronary protuberances and related methods for surgical repair of defective heart valves
US5944738A (en) * 1998-02-06 1999-08-31 Aga Medical Corporation Percutaneous catheter directed constricting occlusion device
US6314322B1 (en) 1998-03-02 2001-11-06 Abiomed, Inc. System and method for treating dilated cardiomyopathy using end diastolic volume (EDV) sensing
US6190408B1 (en) 1998-03-05 2001-02-20 The University Of Cincinnati Device and method for restructuring the heart chamber geometry
US5902229A (en) 1998-03-30 1999-05-11 Cardio Technologies, Inc. Drive system for controlling cardiac compression
US6095968A (en) 1998-04-10 2000-08-01 Cardio Technologies, Inc. Reinforcement device
US6221104B1 (en) 1998-05-01 2001-04-24 Cor Restore, Inc. Anterior and interior segment cardiac restoration apparatus and method
US6024096A (en) * 1998-05-01 2000-02-15 Correstore Inc Anterior segment ventricular restoration apparatus and method
US6544167B2 (en) * 1998-05-01 2003-04-08 Correstore, Inc. Ventricular restoration patch
US6231518B1 (en) * 1998-05-26 2001-05-15 Comedicus Incorporated Intrapericardial electrophysiological procedures
US6511426B1 (en) * 1998-06-02 2003-01-28 Acuson Corporation Medical diagnostic ultrasound system and method for versatile processing
US6250308B1 (en) 1998-06-16 2001-06-26 Cardiac Concepts, Inc. Mitral valve annuloplasty ring and method of implanting
US6165183A (en) 1998-07-15 2000-12-26 St. Jude Medical, Inc. Mitral and tricuspid valve repair
US6260552B1 (en) 1998-07-29 2001-07-17 Myocor, Inc. Transventricular implant tools and devices
US6251061B1 (en) * 1998-09-09 2001-06-26 Scimed Life Systems, Inc. Cardiac assist device using field controlled fluid
DE19947885B4 (en) 1998-10-05 2009-04-09 Cardiothoracic Systems, Inc., Cupertino Device for positioning the heart during cardiac surgery while maintaining cardiac output
US6685627B2 (en) * 1998-10-09 2004-02-03 Swaminathan Jayaraman Modification of properties and geometry of heart tissue to influence heart function
US6360749B1 (en) * 1998-10-09 2002-03-26 Swaminathan Jayaraman Modification of properties and geometry of heart tissue to influence heart function
FR2785521B1 (en) 1998-11-10 2001-01-05 Sofradim Production SUSPENSION DEVICE FOR THE TREATMENT OF PROLAPSUS AND URINARY INCONTINENCES
US6230714B1 (en) 1998-11-18 2001-05-15 Acorn Cardiovascular, Inc. Cardiac constraint with prior venus occlusion methods
US6169922B1 (en) * 1998-11-18 2001-01-02 Acorn Cardiovascular, Inc. Defibrillating cardiac jacket with interwoven electrode grids
US6338740B1 (en) 1999-01-26 2002-01-15 Edwards Lifesciences Corporation Flexible heart valve leaflets
WO2000042951A1 (en) 1999-01-26 2000-07-27 Edwards Lifesciences Corporation Anatomical orifice sizers and methods of orifice sizing
US6701929B2 (en) 1999-03-03 2004-03-09 Hany Hussein Device and method for treatment of congestive heart failure
US6695768B1 (en) * 1999-03-30 2004-02-24 Robert A. Levine Adjustable periventricular ring/ring like device/method for control of ischemic mitral regurgitation and congestive heart disease
FR2791883B1 (en) 1999-04-08 2001-08-10 Ethicon Inc FLEXIBLE PROSTHESIS IN PARTICULAR FOR CELIOSCOPIC HERNIA TREATMENT
US6752813B2 (en) 1999-04-09 2004-06-22 Evalve, Inc. Methods and devices for capturing and fixing leaflets in valve repair
WO2000060995A2 (en) * 1999-04-09 2000-10-19 Evalve, Inc. Methods and apparatus for cardiac valve repair
US6183512B1 (en) 1999-04-16 2001-02-06 Edwards Lifesciences Corporation Flexible annuloplasty system
US6231602B1 (en) 1999-04-16 2001-05-15 Edwards Lifesciences Corporation Aortic annuloplasty ring
SE514718C2 (en) * 1999-06-29 2001-04-09 Jan Otto Solem Apparatus for treating defective closure of the mitral valve apparatus
US7192442B2 (en) 1999-06-30 2007-03-20 Edwards Lifesciences Ag Method and device for treatment of mitral insufficiency
US6997951B2 (en) * 1999-06-30 2006-02-14 Edwards Lifesciences Ag Method and device for treatment of mitral insufficiency
US6241654B1 (en) 1999-07-07 2001-06-05 Acorn Cardiovasculr, Inc. Cardiac reinforcement devices and methods
US6258023B1 (en) * 1999-07-08 2001-07-10 Chase Medical, Inc. Device and method for isolating a surface of a beating heart during surgery
US6350281B1 (en) 1999-09-14 2002-02-26 Edwards Lifesciences Corp. Methods and apparatus for measuring valve annuluses during heart valve-replacement surgery
US6231561B1 (en) * 1999-09-20 2001-05-15 Appriva Medical, Inc. Method and apparatus for closing a body lumen
US6179791B1 (en) 1999-09-21 2001-01-30 Acorn Cardiovascular, Inc. Device for heart measurement
US6174279B1 (en) 1999-09-21 2001-01-16 Acorn Cardiovascular, Inc. Cardiac constraint with tension indicator
US6193648B1 (en) 1999-09-21 2001-02-27 Acorn Cardiovascular, Inc. Cardiac constraint with draw string tensioning
US6312447B1 (en) 1999-10-13 2001-11-06 The General Hospital Corporation Devices and methods for percutaneous mitral valve repair
US6626930B1 (en) 1999-10-21 2003-09-30 Edwards Lifesciences Corporation Minimally invasive mitral valve repair method and apparatus
US6409759B1 (en) * 1999-12-30 2002-06-25 St. Jude Medical, Inc. Harvested tissue heart valve with sewing rim
US6293906B1 (en) 2000-01-14 2001-09-25 Acorn Cardiovascular, Inc. Delivery of cardiac constraint jacket
ATE431165T1 (en) 2000-01-25 2009-05-15 Edwards Lifesciences Corp BIOACTIVE COATINGS TO PREVENT TISSUE GROWTH ON ARTIFICIAL HEART VALVES
US6402781B1 (en) * 2000-01-31 2002-06-11 Mitralife Percutaneous mitral annuloplasty and cardiac reinforcement
US6989028B2 (en) * 2000-01-31 2006-01-24 Edwards Lifesciences Ag Medical system and method for remodeling an extravascular tissue structure
US6797002B2 (en) * 2000-02-02 2004-09-28 Paul A. Spence Heart valve repair apparatus and methods
US6406422B1 (en) * 2000-03-02 2002-06-18 Levram Medical Devices, Ltd. Ventricular-assist method and apparatus
JP2003526448A (en) 2000-03-10 2003-09-09 パラコー サージカル インコーポレイテッド Inflatable cardiac harness for treating congestive heart failure
US6537198B1 (en) * 2000-03-21 2003-03-25 Myocor, Inc. Splint assembly for improving cardiac function in hearts, and method for implanting the splint assembly
US6425856B1 (en) 2000-05-10 2002-07-30 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US20030023132A1 (en) * 2000-05-31 2003-01-30 Melvin David B. Cyclic device for restructuring heart chamber geometry
WO2001091667A2 (en) 2000-05-31 2001-12-06 Cardioclasp, Inc. Devices and methods for assisting natural heart function
US6902522B1 (en) 2000-06-12 2005-06-07 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6730016B1 (en) * 2000-06-12 2004-05-04 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6482146B1 (en) 2000-06-13 2002-11-19 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6343605B1 (en) 2000-08-08 2002-02-05 Scimed Life Systems, Inc. Percutaneous transluminal myocardial implantation device and method
US6572533B1 (en) * 2000-08-17 2003-06-03 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6846296B1 (en) * 2000-09-14 2005-01-25 Abiomed, Inc. Apparatus and method for detachably securing a device to a natural heart
US6723038B1 (en) 2000-10-06 2004-04-20 Myocor, Inc. Methods and devices for improving mitral valve function
US6673009B1 (en) * 2000-11-08 2004-01-06 Acorn Cardiovascular, Inc. Adjustment clamp
US6702763B2 (en) * 2001-02-28 2004-03-09 Chase Medical, L.P. Sizing apparatus and method for use during ventricular restoration
US6786924B2 (en) * 2001-03-15 2004-09-07 Medtronic, Inc. Annuloplasty band and method
US6619291B2 (en) * 2001-04-24 2003-09-16 Edwin J. Hlavka Method and apparatus for catheter-based annuloplasty
US6800090B2 (en) * 2001-05-14 2004-10-05 Cardiac Dimensions, Inc. Mitral valve therapy device, system and method
US6676702B2 (en) * 2001-05-14 2004-01-13 Cardiac Dimensions, Inc. Mitral valve therapy assembly and method
ITMI20011012A1 (en) * 2001-05-17 2002-11-17 Ottavio Alfieri ANNULAR PROSTHESIS FOR MITRAL VALVE
US6858039B2 (en) * 2002-07-08 2005-02-22 Edwards Lifesciences Corporation Mitral valve annuloplasty ring having a posterior bow
US6685620B2 (en) * 2001-09-25 2004-02-03 The Foundry Inc. Ventricular infarct assist device and methods for using it
US7052487B2 (en) * 2001-10-26 2006-05-30 Cohn William E Method and apparatus for reducing mitral regurgitation
US7635387B2 (en) * 2001-11-01 2009-12-22 Cardiac Dimensions, Inc. Adjustable height focal tissue deflector
US7179282B2 (en) * 2001-12-05 2007-02-20 Cardiac Dimensions, Inc. Device and method for modifying the shape of a body organ
US7011688B2 (en) * 2002-05-10 2006-03-14 C.R. Bard, Inc. Prosthetic repair fabric
US6682475B2 (en) * 2002-06-11 2004-01-27 Acorn Cardiovascular, Inc. Tension indicator for cardiac support device and method therefore
US7081084B2 (en) * 2002-07-16 2006-07-25 University Of Cincinnati Modular power system and method for a heart wall actuation system for the natural heart
US20040015041A1 (en) * 2002-07-18 2004-01-22 The University Of Cincinnati Protective sheath apparatus and method for use with a heart wall actuation system for the natural heart
US20040015040A1 (en) * 2002-07-18 2004-01-22 The University Of Cincinnati Flexible, torsionable cardiac framework for heart wall actuation of the natural heart
US6988982B2 (en) * 2002-08-19 2006-01-24 Cardioenergetics Heart wall actuation system for the natural heart with shape limiting elements
US7485143B2 (en) * 2002-11-15 2009-02-03 Abbott Cardiovascular Systems Inc. Apparatuses and methods for heart valve repair
US7351259B2 (en) * 2003-06-05 2008-04-01 Cardiac Dimensions, Inc. Device, system and method to affect the mitral valve annulus of a heart
US7887582B2 (en) * 2003-06-05 2011-02-15 Cardiac Dimensions, Inc. Device and method for modifying the shape of a body organ
US8052751B2 (en) * 2003-07-02 2011-11-08 Flexcor, Inc. Annuloplasty rings for repairing cardiac valves
US20050004665A1 (en) * 2003-07-02 2005-01-06 Lishan Aklog Annuloplasty rings and methods for repairing cardiac valves
US20050010286A1 (en) * 2003-07-11 2005-01-13 Vedic Biotechnology, Inc. Heart failure mitral annuloplasty ring with removable central posterior portion
US20050010283A1 (en) * 2003-07-11 2005-01-13 Vedic Biotechnology, Inc. Heart failure mitral annuloplasty ring with multiple sets of suture placement indicia
US20050038509A1 (en) * 2003-08-14 2005-02-17 Ashe Kassem Ali Valve prosthesis including a prosthetic leaflet

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855614A (en) * 1993-02-22 1999-01-05 Heartport, Inc. Method and apparatus for thoracoscopic intracardiac procedures
US5634936A (en) * 1995-02-06 1997-06-03 Scimed Life Systems, Inc. Device for closing a septal defect

Cited By (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10292821B2 (en) 2001-09-07 2019-05-21 Phoenix Cardiac Devices, Inc. Method and apparatus for external stabilization of the heart
US8715160B2 (en) 2001-09-07 2014-05-06 Mardil, Inc. Method and apparatus for external stabilization of the heart
US8128553B2 (en) 2001-09-07 2012-03-06 Mardil, Inc. Method and apparatus for external stabilization of the heart
US8092367B2 (en) 2001-09-07 2012-01-10 Mardil, Inc. Method for external stabilization of the base of the heart
US9289298B2 (en) 2001-09-07 2016-03-22 Mardil, Inc. Method and apparatus for external stabilization of the heart
US20040260317A1 (en) * 2003-06-20 2004-12-23 Elliot Bloom Tensioning device, system, and method for treating mitral valve regurgitation
US7316706B2 (en) 2003-06-20 2008-01-08 Medtronic Vascular, Inc. Tensioning device, system, and method for treating mitral valve regurgitation
US7288104B2 (en) * 2004-06-25 2007-10-30 Cardiac Pacemakers, Inc. Endocardial splint and method therefor
US20050288613A1 (en) * 2004-06-25 2005-12-29 Cardiac Pacemakers, Inc. Endocardial splint and method therefor
US7530989B2 (en) 2004-06-25 2009-05-12 Cardiac Pacemakers, Inc. Endocardial splint and method therefor
US20080033236A1 (en) * 2004-06-25 2008-02-07 Cardiac Pacemakers, Inc. Endocardial splint and method therefor
US10398557B2 (en) 2004-10-13 2019-09-03 Bioventrix, Inc. Method and device for percutaneous left ventricular reconstruction
US9526618B2 (en) 2004-10-13 2016-12-27 Bioventrix, Inc. Method and device for percutaneous left ventricular reconstruction
US8449442B2 (en) 2004-10-13 2013-05-28 Bioventrix, Inc. Method and device for percutaneous left ventricular reconstruction
US11273040B2 (en) 2004-10-13 2022-03-15 Bioventrix, Inc. Method and device for percutaneous left ventricular reconstruction
US9119720B2 (en) 2004-10-13 2015-09-01 Bioventrix, Inc. Method and device for percutaneous left ventricular reconstruction
US20080097148A1 (en) * 2004-10-13 2008-04-24 Chf Technologies, Inc. Method and device for percutaneous left ventricular reconstruction
US20060089711A1 (en) * 2004-10-27 2006-04-27 Medtronic Vascular, Inc. Multifilament anchor for reducing a compass of a lumen or structure in mammalian body
US20060106403A1 (en) * 2004-11-15 2006-05-18 Laurent Schaller Catheter-based tissue remodeling devices and methods
US8391996B2 (en) 2004-11-15 2013-03-05 Benvenue Medical, Inc. Catheter-based tissue remodeling devices and methods
US7452325B2 (en) 2004-11-15 2008-11-18 Benvenue Medical Inc. Catheter-based tissue remodeling devices and methods
US7374530B2 (en) 2004-11-15 2008-05-20 Benvenue Medical Inc. Catheter-based tissue remodeling devices and methods
US20060135970A1 (en) * 2004-11-15 2006-06-22 Laurent Schaller Catheter-based tissue remodeling devices and methods
US20060135968A1 (en) * 2004-11-15 2006-06-22 Laurent Schaller Catheter-based tissue remodeling devices and methods
US20060135966A1 (en) * 2004-11-15 2006-06-22 Laurent Schaller Catheter-based tissue remodeling devices and methods
US8968338B2 (en) 2005-01-21 2015-03-03 Mayo Foundation For Medical Education And Research Thorascopic heart valve repair method and apparatus
US10582924B2 (en) 2005-01-21 2020-03-10 Mayo Foundation For Medical Education And Research Thorascopic heart valve repair method
US20060167494A1 (en) * 2005-01-21 2006-07-27 Loubert Suddaby Aneurysm repair method and apparatus
US8465500B2 (en) 2005-01-21 2013-06-18 Mayo Foundation For Medical Education And Research Thorascopic heart valve repair method and apparatus
US9700300B2 (en) 2005-01-21 2017-07-11 Mayo Foundation For Medical Education And Research Thorascopic heart valve repair apparatus
US9364213B2 (en) 2005-01-21 2016-06-14 Mayo Foundation For Medical Education And Research Thorascopic heart valve repair method
US11534156B2 (en) 2005-01-21 2022-12-27 Mayo Foundation For Medical Education And Research Thorascopic heart valve repair method and apparatus
US9107658B2 (en) 2005-04-22 2015-08-18 Benvenue Medical, Inc. Catheter-based tissue remodeling devices and methods
US10966696B2 (en) 2005-04-22 2021-04-06 Laurent Schaller Catheter-based tissue remodeling devices and methods
US10912546B2 (en) 2005-04-22 2021-02-09 Laurent Schaller Catheter-based tissue remodeling devices and methods
US8333777B2 (en) 2005-04-22 2012-12-18 Benvenue Medical, Inc. Catheter-based tissue remodeling devices and methods
US8986189B2 (en) 2005-06-09 2015-03-24 Bioventrix, Inc. Method and apparatus for closing off a portion of a heart ventricle
US10624745B2 (en) 2005-06-09 2020-04-21 Bioventrix, Inc. Method and apparatus for closing off a portion of a heart ventricle
US11793643B2 (en) 2005-06-09 2023-10-24 Bioventrix, Inc. Method and apparatus for closing off a portion of a heart ventricle
US20070049971A1 (en) * 2005-06-09 2007-03-01 Sing-Fatt Chin Method and apparatus for closing off a portion of a heart ventricle
US10022226B2 (en) 2005-06-09 2018-07-17 Bioventrix, Inc. Method and apparatus for closing off a portion of a heart ventricle
US20100268020A1 (en) * 2005-06-09 2010-10-21 Bioventrix (A Chf Technologies, Inc.) Method and Apparatus For Closing Off a Portion of a Heart Ventricle
US7766816B2 (en) 2005-06-09 2010-08-03 Chf Technologies, Inc. Method and apparatus for closing off a portion of a heart ventricle
US20070025009A1 (en) * 2005-07-29 2007-02-01 Fuji Photo Film Co., Ltd. Magnetic recorder
US8506474B2 (en) 2005-08-19 2013-08-13 Bioventrix, Inc. Method and device for treating dysfunctional cardiac tissue
US9044231B2 (en) 2005-08-19 2015-06-02 Bioventrix, Inc. Steerable lesion excluding heart implants for congestive heart failure
US10335279B2 (en) 2005-08-19 2019-07-02 Bioventrix, Inc. Method and device for treating dysfunctional cardiac tissue
US9259319B2 (en) 2005-08-19 2016-02-16 Bioventrix, Inc. Method and device for treating dysfunctional cardiac tissue
US20070073274A1 (en) * 2005-08-19 2007-03-29 Sing-Fatt Chin Method and device for treating dysfunctional cardiac tissue
US20110160750A1 (en) * 2005-08-19 2011-06-30 BioVentrix (a CHF Technologies Company) Steerable Lesion Excluding Heart Implants For Congestive Heart Failure
US10478305B2 (en) 2005-08-19 2019-11-19 Bioventrix, Inc. Steerable lesion excluding heart implants for congestive heart failure
US8394008B2 (en) 2005-08-19 2013-03-12 Bioventrix, Inc. Steerable lesion excluding heart implants for congestive heart failure
US9744040B2 (en) 2005-08-19 2017-08-29 Bioventrix, Inc. Steerable lesion excluding heart implants for congestive heart failure
US11331190B2 (en) 2005-08-19 2022-05-17 Bioventrix, Inc. Steerable lesion excluding heart implants for congestive heart failure
US11259929B2 (en) 2005-08-19 2022-03-01 Bioventrix, Inc. Method and device for treating dysfunctional cardiac tissue
US9402722B2 (en) 2005-08-19 2016-08-02 Bioventrix, Inc. Steerable lesion excluding heart implants for congestive heart failure
US20070066863A1 (en) * 2005-08-31 2007-03-22 Medtronic Vascular, Inc. Device for treating mitral valve regurgitation
US20070203391A1 (en) * 2006-02-24 2007-08-30 Medtronic Vascular, Inc. System for Treating Mitral Valve Regurgitation
US10806580B2 (en) 2006-03-03 2020-10-20 Mardil, Inc. Self-adjusting attachment structure for a cardiac support device
US9737403B2 (en) 2006-03-03 2017-08-22 Mardil, Inc. Self-adjusting attachment structure for a cardiac support device
US20070265658A1 (en) * 2006-05-12 2007-11-15 Aga Medical Corporation Anchoring and tethering system
US9039594B2 (en) 2006-09-28 2015-05-26 Bioventrix, Inc. Signal transmitting and lesion excluding heart implants for pacing, defibrillating, and/or sensing of heart beat
US20080294251A1 (en) * 2006-09-28 2008-11-27 Bioventrix (A Chf Technologies' Company) Location, time, and/or pressure determining devices, systems, and methods for deployment of lesion-excluding heart implants for treatment of cardiac heart failure and other disease states
US9211115B2 (en) 2006-09-28 2015-12-15 Bioventrix, Inc. Location, time, and/or pressure determining devices, systems, and methods for deployment of lesion-excluding heart implants for treatment of cardiac heart failure and other disease states
US9913719B2 (en) 2006-09-28 2018-03-13 Bioventrix, Inc. Location, time, and/or pressure determining devices, systems, and methods for deployment of lesion-excluding heart implants for treatment of cardiac heart failure and other disease states
US8636639B2 (en) 2006-09-28 2014-01-28 Bioventrix, Inc. Signal transmitting and lesion excluding heart implants for pacing, defibrillating, and/or sensing of heart beat
US20080243144A1 (en) * 2006-10-04 2008-10-02 Michael Laufer Methods and systems for manipulating tissue
US8166978B2 (en) 2006-10-04 2012-05-01 Ethicon Endo-Surgery, Inc. Methods and systems for manipulating tissue
US8882789B2 (en) 2006-10-04 2014-11-11 Ethicon Endo-Surgery, Inc. Methods and systems for tissue manipulation
US8926641B2 (en) * 2006-10-04 2015-01-06 Ethicon Endo-Surgery, Inc. Methods and devices for reconfiguring a body organ
US20090018558A1 (en) * 2006-10-04 2009-01-15 Michael Laufer Methods of organ reconfiguration
US8209037B2 (en) 2006-10-04 2012-06-26 Ethicon Endo-Surgery, Inc. Methods and devices for medical treatment
US20090018389A1 (en) * 2006-10-04 2009-01-15 Michael Laufer Methods and systems for tissue manipulation
US20080312750A1 (en) * 2006-10-04 2008-12-18 Michael Laufer Methods and devices for reconfiguring a body organ
US8469976B2 (en) 2006-10-04 2013-06-25 Ethicon Endo-Surgery, Inc. Methods of organ reconfiguration
US11419723B2 (en) 2007-05-21 2022-08-23 Bioventrix, Inc. Location, time, and/or pressure determining devices, systems, and methods for deployment of lesion-excluding heart implants for treatment of cardiac heart failure and other disease states
US10617525B2 (en) 2007-05-21 2020-04-14 Bioventrix, Inc. Location, time, and/or pressure determining devices, systems, and methods for deployment of lesion-excluding heart implants for treatment of cardiac heart failure and other disease states
USRE46927E1 (en) 2007-09-05 2018-07-03 Mardil, Inc. Heart band with fillable chambers to modify heart valve function
US8092363B2 (en) 2007-09-05 2012-01-10 Mardil, Inc. Heart band with fillable chambers to modify heart valve function
US9889008B2 (en) 2007-10-03 2018-02-13 Bioventrix, Inc. Treating dysfunctional cardiac tissue
US8968175B2 (en) 2007-10-03 2015-03-03 Bioventrix, Inc. Treating dysfunctional cardiac tissue
US8491455B2 (en) 2007-10-03 2013-07-23 Bioventrix, Inc. Treating dysfunctional cardiac tissue
US10624744B2 (en) 2007-10-03 2020-04-21 Bioventrix, Inc. Treating dysfunctional cardiac tissue
US9486206B2 (en) 2007-10-03 2016-11-08 Bioventrix, Inc. Treating dysfunctional cardiac tissue
US11399942B2 (en) 2007-10-03 2022-08-02 Bioventrix, Inc. Treating dysfunctional cardiac tissue
US20090093670A1 (en) * 2007-10-03 2009-04-09 Bioventrix (A Chf Technologies, Inc.) Treating Dysfunctional Cardiac Tissue
US8758393B2 (en) 2007-10-18 2014-06-24 Neochord, Inc. Minimally invasive repair of a valve leaflet in a beating heart
US11419602B2 (en) 2007-10-18 2022-08-23 Neochord, Inc. Minimally invasive repair of a valve leaflet in a beating heart
US10507018B2 (en) 2007-10-18 2019-12-17 Neochord, Inc. Minimally invasive repair of a valve leaflet in a beating heart
US9192374B2 (en) 2007-10-18 2015-11-24 Neochord, Inc. Minimally invasive repair of a valve leaflet in a beating heart
US20100016655A1 (en) * 2008-07-21 2010-01-21 Bio Ventrix (a CHF Technologies, Inc. Cardiac Anchor Structures, Methods, and Systems for Treatment of Congestive Heart Failure and Other Conditions
US8425402B2 (en) 2008-07-21 2013-04-23 Bioventrix, Inc. Cardiac anchor structures, methods, and systems for treatment of congestive heart failure and other conditions
US20120172931A1 (en) * 2009-06-21 2012-07-05 Aesthetics Point Ltd. implanted medical device useful for cosmetic surgery
US9050078B2 (en) * 2009-06-21 2015-06-09 Aesthetics Point Ltd. Implanted medical device useful for cosmetic surgery
US9044221B2 (en) 2010-12-29 2015-06-02 Neochord, Inc. Exchangeable system for minimally invasive beating heart repair of heart valve leaflets
US10080659B1 (en) 2010-12-29 2018-09-25 Neochord, Inc. Devices and methods for minimally invasive repair of heart valves
US10130474B2 (en) 2010-12-29 2018-11-20 Neochord, Inc. Exchangeable system for minimally invasive beating heart repair of heart valve leaflets
US11974920B2 (en) 2011-06-01 2024-05-07 Neochord, Inc. Minimally invasive repair of heart valve leaflets
US10695178B2 (en) 2011-06-01 2020-06-30 Neochord, Inc. Minimally invasive repair of heart valve leaflets
US20130090672A1 (en) * 2011-09-30 2013-04-11 Bioventrix, Inc. Cardiac implant migration inhibiting systems
US9320513B2 (en) 2011-09-30 2016-04-26 Bioventrix, Inc. Trans-catheter ventricular reconstruction structures, methods, and systems for treatment of congestive heart failure and other conditions
US10219904B2 (en) 2011-09-30 2019-03-05 Bioventrix, Inc. Cardiac implant migration inhibiting systems
US20130096579A1 (en) * 2011-09-30 2013-04-18 Bioventrix, Inc Over-the-wire cardiac implant delivery system for treatment of chf and other conditions
US10179049B2 (en) 2011-09-30 2019-01-15 Bioventrix, Inc. Trans-catheter ventricular reconstruction structures, methods, and systems for treatment of congestive heart failure and other conditions
US11051942B2 (en) 2011-09-30 2021-07-06 Bioventrix, Inc. Trans-catheter ventricular reconstruction structures, methods, and systems for treatment of congestive heart failure and other conditions
US9662212B2 (en) 2011-09-30 2017-05-30 Bioventrix, Inc. Trans-catheter ventricular reconstruction structures, methods, and systems for treatment of congestive heart failure and other conditions
US11051941B2 (en) 2011-09-30 2021-07-06 Bioventrix, Inc. Over-the-wire cardiac implant delivery system for treatment of CHF and other conditions
US9937043B2 (en) 2011-09-30 2018-04-10 Bioventrix, Inc. Remote pericardial hemostasis for ventricular access and reconstruction or other organ therapies
US9173711B2 (en) * 2011-09-30 2015-11-03 Bioventrix, Inc. Cardiac implant migration inhibiting systems
US9173712B2 (en) * 2011-09-30 2015-11-03 Bioventrix, Inc. Over-the-wire cardiac implant delivery system for treatment of CHF and other conditions
US9095363B2 (en) 2011-09-30 2015-08-04 Bioventrix, Inc. Remote pericardial hemostasis for ventricular access and reconstruction or other organ therapies
US8979750B2 (en) 2011-09-30 2015-03-17 Bioventrix, Inc. Trans-catheter ventricular reconstruction structures, methods, and systems for treatment of congestive heart failure and other conditions
US9370425B2 (en) 2012-10-12 2016-06-21 Mardil, Inc. Cardiac treatment system and method
US9421101B2 (en) 2012-10-12 2016-08-23 Mardil, Inc. Cardiac treatment system
US11517437B2 (en) 2012-10-12 2022-12-06 Diaxamed, Llc Cardiac treatment system
US9421102B2 (en) 2012-10-12 2016-08-23 Mardil, Inc. Cardiac treatment system and method
US9844437B2 (en) 2012-10-12 2017-12-19 Mardil, Inc. Cardiac treatment system and method
US10420644B2 (en) 2012-10-12 2019-09-24 Mardil, Inc. Cardiac treatment system and method
US11406500B2 (en) 2012-10-12 2022-08-09 Diaxamed, Llc Cardiac treatment system and method
US10064723B2 (en) 2012-10-12 2018-09-04 Mardil, Inc. Cardiac treatment system and method
US10405981B2 (en) 2012-10-12 2019-09-10 Mardil, Inc. Cardiac treatment system
US11540861B2 (en) 2013-04-15 2023-01-03 Transseptal Solutions Ltd. Fossa ovalis puncturing catheter
US9700351B2 (en) 2013-04-15 2017-07-11 Transseptal Solutions Ltd. Fossa ovalis penetration
US9545265B2 (en) 2013-04-15 2017-01-17 Transseptal Solutions Ltd. Fossa ovalis penetration using balloons
US10582950B2 (en) 2013-04-15 2020-03-10 Transseptal Solutions Ltd. Fossa ovalis penetration
US9788858B2 (en) 2013-04-15 2017-10-17 Transseptal Solutions Ltd. Fossa ovalis penetration using probing elements
US11559212B2 (en) 2013-05-24 2023-01-24 Bioventrix, Inc. Cardiac tissue penetrating devices, methods, and systems for treatment of congestive heart failure and other conditions
US10314498B2 (en) 2013-05-24 2019-06-11 Bioventrix, Inc. Cardiac tissue penetrating devices, methods, and systems for treatment of congestive heart failure and other conditions
US10575953B2 (en) 2013-08-30 2020-03-03 Bioventrix, Inc. Heart anchor positioning devices, methods, and systems for treatment of congestive heart failure and other conditions
US10588613B2 (en) 2013-08-30 2020-03-17 Bioventrix, Inc. Cardiac tissue anchoring devices, methods, and systems for treatment of congestive heart failure and other conditions
US11540822B2 (en) 2013-08-30 2023-01-03 Bioventrix, Inc. Cardiac tissue anchoring devices, methods, and systems for treatment of congestive heart failure and other conditions
US11903834B2 (en) 2013-08-30 2024-02-20 Bioventrix, Inc. Heart anchor positioning devices, methods, and systems for treatment of congestive heart failure and other conditions
USD717954S1 (en) 2013-10-14 2014-11-18 Mardil, Inc. Heart treatment device
EP3060172A4 (en) * 2013-10-23 2017-07-05 LC Therapeutics, Inc. Percutaneous or minimally invasive cardiac valve repair system and methods of using the same
US11324921B2 (en) 2014-10-14 2022-05-10 Transseptal Solutions Ltd. Catheter having partially-braided wall
WO2016059638A1 (en) * 2014-10-14 2016-04-21 Transseptal Solutions Ltd. Fossa ovalis penetration
US10500371B2 (en) 2014-10-14 2019-12-10 Transseptal Solutions Ltd. Fossa ovalis penetration
US11896206B2 (en) 2015-03-03 2024-02-13 Transseptal Solutions Ltd. Treatment of appendage openings
US9668674B2 (en) 2015-03-03 2017-06-06 Transseptal Solutions Ltd. Measurement of appendage openings
US10238371B2 (en) 2015-03-03 2019-03-26 Transseptal Solutions Ltd. Treatment of appendage openings
US9706982B2 (en) 2015-03-03 2017-07-18 Transseptal Solutions Ltd. Treatment of appendage openings
US10206779B2 (en) 2015-09-10 2019-02-19 Bioventrix, Inc. Systems and methods for deploying a cardiac anchor
US11185414B2 (en) 2015-09-10 2021-11-30 Bioventrix, Inc. Systems and methods for deploying a cardiac anchor
US10765517B2 (en) 2015-10-01 2020-09-08 Neochord, Inc. Ringless web for repair of heart valves
US11484409B2 (en) 2015-10-01 2022-11-01 Neochord, Inc. Ringless web for repair of heart valves
US11324549B2 (en) 2015-10-14 2022-05-10 Transseptal Solutions Ltd. Interatrial septum penetration
US10398503B2 (en) 2015-10-14 2019-09-03 Transseptal Soulutions Ltd. Fossa ovalis penetration
US11478353B2 (en) 2016-01-29 2022-10-25 Bioventrix, Inc. Percutaneous arterial access to position trans-myocardial implant devices and methods
US11058538B2 (en) 2016-03-10 2021-07-13 Charles Somers Living Trust Synthetic chord for cardiac valve repair applications
US10682229B2 (en) 2017-02-08 2020-06-16 4Tech Inc. Post-implantation tensioning in cardiac implants
US10441266B2 (en) 2017-03-01 2019-10-15 4Tech Inc. Post-implantation tension adjustment in cardiac implants
US11589989B2 (en) 2017-03-31 2023-02-28 Neochord, Inc. Minimally invasive heart valve repair in a beating heart
US10588620B2 (en) 2018-03-23 2020-03-17 Neochord, Inc. Device for suture attachment for minimally invasive heart valve repair
US11612389B2 (en) 2018-03-23 2023-03-28 Neochord, Inc. Device for suture attachment for minimally invasive heart valve repair
US11957584B2 (en) 2018-05-09 2024-04-16 Neochord, Inc. Suture length adjustment for minimally invasive heart valve repair
US11253360B2 (en) 2018-05-09 2022-02-22 Neochord, Inc. Low profile tissue anchor for minimally invasive heart valve repair
US11173030B2 (en) 2018-05-09 2021-11-16 Neochord, Inc. Suture length adjustment for minimally invasive heart valve repair
US10966709B2 (en) 2018-09-07 2021-04-06 Neochord, Inc. Device for suture attachment for minimally invasive heart valve repair
US11376126B2 (en) 2019-04-16 2022-07-05 Neochord, Inc. Transverse helical cardiac anchor for minimally invasive heart valve repair
US11918468B2 (en) 2019-04-16 2024-03-05 Neochord, Inc. Transverse helical cardiac anchor for minimally invasive heart valve repair
US12121292B2 (en) 2022-04-13 2024-10-22 Transseptal Solutions Ltd. Interatrial septum penetration

Also Published As

Publication number Publication date
EP1322259A2 (en) 2003-07-02
US6616684B1 (en) 2003-09-09
AU2001294921A1 (en) 2002-04-22
US20030181928A1 (en) 2003-09-25
ATE326921T1 (en) 2006-06-15
WO2002030335A3 (en) 2003-01-16
EP1322259B1 (en) 2006-05-24
EP2014242A2 (en) 2009-01-14
EP1695674A2 (en) 2006-08-30
DE60119944T2 (en) 2007-01-18
WO2002030335A2 (en) 2002-04-18
EP2014242A3 (en) 2009-08-05
EP1695674A3 (en) 2007-01-17
US20070055303A1 (en) 2007-03-08
DE60119944D1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
US6616684B1 (en) Endovascular splinting devices and methods
US9198757B2 (en) Methods and devices for improving mitral valve function
US11883294B2 (en) Systems and devices for setting an anchor
US9889008B2 (en) Treating dysfunctional cardiac tissue
US7316706B2 (en) Tensioning device, system, and method for treating mitral valve regurgitation
US6547821B1 (en) Surgical procedures and devices for increasing cardiac output of the heart
US20180250132A1 (en) Methods, systems and devices for cardiac valve repair
US8956407B2 (en) Methods for reshaping a heart valve annulus using a tensioning implant
US7189199B2 (en) Methods and devices for improving cardiac function in hearts
US20070203391A1 (en) System for Treating Mitral Valve Regurgitation
US20130226288A1 (en) Minimally invasive surgical techniques
US20110295059A1 (en) Devices, systems, and methods for reshaping a heart valve annulus, including the use of a bridge implant having an adjustable bridge stop
WO2001028455A1 (en) Methods and devices for improving cardiac function in hearts
CN112888375B (en) Preformed tissue anchors and needles for tissue anchor deployment
US10219902B2 (en) Devices, systems, and methods for reshaping a heart valve anulus, including the use of a bridge implant having an adjustable bridge stop
US20130197559A1 (en) Minimally invasive surgical techniques
US20130197571A1 (en) Minimally invasive surgical techniques
CN106572910B (en) Mitral valve implant for treating valvular regurgitation
US20230255616A1 (en) Intra-lumen suture knot deployment
JP2024500328A (en) Methods for crossing anatomical vessel walls
JP2023552437A (en) Devices, methods, and systems for reshaping heart valve annulus

Legal Events

Date Code Title Description
AS Assignment

Owner name: VENTURE LENDING & LEASING IV, INC., CALIFORNIA

Free format text: SECURITY AGREEMMENT;ASSIGNOR:MYOCOR, INC.;REEL/FRAME:019805/0072

Effective date: 20070820

Owner name: VENTURE LENDING & LEASING IV, INC.,CALIFORNIA

Free format text: SECURITY AGREEMMENT;ASSIGNOR:MYOCOR, INC.;REEL/FRAME:019805/0072

Effective date: 20070820

AS Assignment

Owner name: EDWARDS LIFESCIENCES LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MYOCOR, INC.;REEL/FRAME:022277/0011

Effective date: 20081029

Owner name: EDWARDS LIFESCIENCES LLC,CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MYOCOR, INC.;REEL/FRAME:022277/0011

Effective date: 20081029

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION